

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Does exercise dose matter in patients with long-term osteoarthritis of the knee? A study protocol of a randomized controlled trial in Sweden and Norway – the SWENOR study (NCT02024126)

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-018471
Article Type:	Protocol
Date Submitted by the Author:	06-Jul-2017
Complete List of Authors:	Torstensen, Tom Arild; Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Physiotherapy Grooten, Wilhelmus; Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Physiotherapy ; Karolinska University Hospital, Allied Health Professionals Function, Functional area Occupational Therapy and Physiotherapy Østerås, Håvard; Norwegian University of Science and Technology, Department of Neuromedicine and Movement Science Heijne, Annette; Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Physiotherapy ; Karolinska University Hospital, Allied Health Professionals Function, Functional area Occupational Therapy and Physiotherapy Harms-Ringdahl, Karin; Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Physiotherapy ; Karolinska University Hospital, Allied Health Professionals Function, Functional area Occupational Therapy and Physiotherapy Äng, Björn; Dalarna University, School of Education, Health and Social Sciences; Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Physiotherapy
Keywords:	Knee < ORTHOPAEDIC & TRAUMA SURGERY, Musculoskeletal disorders < ORTHOPAEDIC & TRAUMA SURGERY, PAIN MANAGEMENT, Clinical trials < THERAPEUTICS, REHABILITATION MEDICINE

SCHOLARONE™
Manuscripts

Words in text 5362
Words in abstract 296
References 99
Tables 2
Figures 3

Does exercise dose matter in patients with long-term osteoarthritis of the knee? A study protocol of a randomized controlled trial in Sweden and Norway – the SWENOR study (NCT02024126)

Torstensen TA (1), Grooten WJA (1,2), Østerås H (3), Heijne A (1,2), Harms-Ringdahl K (1,2), Äng BO (1,4,).

- 1) Department of Neurobiology, Care Sciences and Society, Division of Physiotherapy, Karolinska Institutet, Huddinge, Sweden
- 2) Allied Health Professionals Function, Functional area Occupational Therapy and Physiotherapy, Karolinska University Hospital, Stockholm, Sweden
- 3) Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway
- 4) School of Education, Health and Social Sciences, Dalarna University, Falun, Sweden

Corresponding author:

Tom Arild Torstensen

Department of Neurobiology, Care Sciences and Society, Division of Physiotherapy
Karolinska Institutet

Alfred Nobels Allé 23 23100
141 83 Huddinge, Sweden

Tel: +46 707344102

E-mail: tom.torstensen@ki.se

ABSTRACT

Introduction: Osteoarthritis (OA) of the knee is characterized by knee pain, disability, and degenerative changes, and places a burden on societies all over the world.

Medical exercise therapy (MET) is an often-used modality, but there is little evidence of what type of exercise dose is effective, indicating a need for controlled studies of the effect of different dosages. The aim of this study protocol was therefore to describe our planned study that is designed to evaluate the effects of high-dose versus low-dose MET in patients with knee OA.

Methods and analysis: This is a multicenter prospective randomized two arm trial with blinded evaluation. We are planning to include 200 patients aged 45-85 years with an X-ray verified diagnosis of knee OA . Those eligible for participation will be randomly allocated to either high-dose (n=100) or low-dose MET (n=100). All patients receive three supervised treatments each week for 12 weeks, giving a total of 36 MET sessions. The high-dose group receives a greater number of exercises, sets, and repetitions than the low-dose group, revealing an exercise dose of 80-90 min versus 20-30 min, respectively. Background and outcome variables are recorded at inclusion, and outcome measures are collected after every 6th treatment, at end of treatment, and at six- and 12-month follow-ups. Primary outcome is self-rated knee function and pain using the Knee Injury and Osteoarthritis Outcome Score (KOOS) and different visual analogue scales (VAS). The primary endpoint is at end of treatment – three months, and secondary endpoints are at 6 and 12 months after end of treatment.

Ethics and dissemination: This project has been approved by the Regional Research Ethics Committees in Stockholm, Sweden, and in Norway. Our results will be submitted to peer-reviewed journals and presented at national and international conferences.

Trial Registration number: (ClinicalTrials.gov NCT02024126)

Strengths and limitations of this study

- To the best of our knowledge, this is the first multicenter study prospectively comparing the effectiveness of two clearly defined doses of exercise therapy in patients with knee osteoarthritis.
- The proposed project includes a relatively large sample where primary outcomes are evaluated both during the 12-week intervention period, at the end of treatment, and at six and twelve months, respectively.
- The project uses both subjective and objective data, and includes analyses of cost-effectiveness and early predictors for a follow-up clinical outcome.
- Even though the different components of the exercise programmes are well described, one limitation could be possible confounders related to the exercise dose given.

MAIN TEXT

BACKGROUND

Osteoarthritis (OA) is the most common form of arthritis and is a major worldwide health problem causing illness and disability [1, 2]. Internationally, the burden to society, cost of the interventions and persistent clinical course of knee OA, is substantial [3]. The knee joint is most frequently affected, which commonly results in chronic joint pain, knee stiffness, decreased functioning, reduced quality of life, and sick leave [4]. The associated costs of

1
2
3
4 osteoarthritis are estimated to range between 1-2.5% of the gross national product as
5
6 calculated in six industrialized countries (Sweden, Australia, Canada, France, UK, and US) [5].
7
8
9

10
11 The prevalence of knee OA has increased during the last 20 years [1], and is expected to
12
13 continue to increase [6]. Murphy et al. [7] reported that almost half of US adults will have
14
15 symptomatic knee OA by the age of 85, with the highest risk being among obese individuals.
16
17 There is a sex difference, where the prevalence is estimated to be 40% in women and 30% in
18
19 men in people aged 65-75 years [8]. Although knee OA is known to be more common in
20
21 older age groups, the increasing global prevalence of obesity is anticipated to elevate the
22
23 prevalence of knee OA in younger people [9]. Currently, knee OA in younger people is most
24
25 often secondary to congenital disorders or sporting injuries and other traumas to the knee
26
27
28
29
30 [10, 11].
31
32
33

34 Traditionally, knee OA has been defined as a pathological condition characterized by focal
35
36 areas of loss of articular cartilage within the synovial joints, associated with hypertrophy of
37
38 the bone (osteophytes and sub-chondral bone sclerosis) and thickening of the capsule [12].
39
40 The mechanisms of knee OA-related pain are, however, complex [13], particularly in chronic
41
42 pain conditions where pain experience is nowadays believed to be more a result of changes
43
44 in the nervous system than in tissue structures [14], which somehow reflects a paradigm
45
46 shift in the understanding of the pathology of pain related to knee OA. Because of the
47
48 plasticity of the nervous system, pain lowers the threshold level of the nociceptive receptor
49
50 system [15], making it more sensitive to stimuli during normal movements like walking and
51
52 bending – so-called mechanical or loading allodynia. These changes occur in the peripheral
53
54
55
56
57
58
59
60

1
2
3
4 receptor system located in the knee and in the receptor system in the spinal cord resulting in
5
6 changes in the nervous system, i.e. peripheral and central sensitization [16]. The fact that
7
8 the problem lies more in the nervous system than in the knee makes it easier to understand
9
10 why there are poor correlations between structural degenerative changes of the knee, pain,
11
12 and functioning [17, 18].
13
14

15
16
17
18 The level of pain caused by these sensitization processes is also affected by psychological
19
20 factors such as anxiety and depression, which cause increased nociceptive input that
21
22 increases the pain experience [19, 20]. When pain becomes more persistent and does not
23
24 resolve, the person can develop negative attitudes and beliefs [20-22] that are closely linked
25
26 to catastrophizing and anxiety. This results in further sensitization with long-term pain [19,
27
28 23, 24]. Shifting our understanding of pain-related knee OA from exclusively involving
29
30 changes in tissue structures to involving changes in the nervous system is an important
31
32 paradigm shift for not only a better understanding of what knee OA is, but also for improved
33
34 optimal treatment designs including exercise therapy which is a frequently used modality in
35
36 treating knee OA.
37
38

39
40
41 In a systematic review, it was concluded that there exists high-level evidence that land-
42
43 based therapeutic exercise provides short-term effects of pain relief and function, and that
44
45 there is a moderate level of quality evidence regarding improvement in physical function
46
47 among patients with knee OA [25]. Despite this, several questions remain unanswered,
48
49 particularly regarding dose, intensity, and duration of the exercise therapy applied [26].
50
51

52
53 These unanswered questions may be one of the reasons why we see a large variation in
54
55 treatment effects observed across studies making it difficult to conclude what is the optimal
56
57

1
2
3
4 dose when delivering exercise therapy [25, 26]. The exercises vary from neuromuscular
5
6 exercise [27], knee joint stabilization exercises [28], strengthening exercises [29], and
7
8 endurance exercises. The theoretical basis for these different exercise programmes is not
9
10 always clear, especially when matching them to the cause of long-term knee pain; peripheral
11
12 and central sensitization. The knowledge that pain and swelling inhibits motor output,
13
14 decreases range of motion, and changes coordination [30], and that a traditional
15
16 strengthening exercise program can cause adverse effects [31], questions the use of
17
18 strengthening exercises. There is increasing evidence [32] that exercise therapy should focus
19
20 on treating the causality of pain-related knee OA such as peripheral and central sensitization
21
22 [14] and pain-related bodily and psychological changes [19] from a biopsychosocial
23
24 perspective [33, 34], rather than an impairment like muscle strength .
25
26
27
28
29
30
31

32 **Medical Exercise Therapy**

33
34 Medical Exercise Therapy (MET) was developed in Norway more that 50 years ago and is an
35
36 established treatment in the Nordic countries, other parts of Europe, and North America [33,
37
38 35, 36]. MET focuses on applying the optimal dose of exercise; i.e combining global aerobic
39
40 exercises with semiglobal and local joint exercises, where the goal is to apply 70 to 90
41
42 minutes of active dynamic exercise therapy [36-45]. The patient is to perform more than
43
44 1000 pain-free repetitions or close to pain-free repetitions per MET-session [36-45]. Even
45
46 though the optimal dose goal of MET is high, the treatment usually starts with a low dose
47
48 lasting 15 to 20 minutes mirroring the ability of the patient within a biopsychosocial context
49
50 [34], starting with an acceptable baseline where the patient manages the exercise therapy
51
52
53 [33, 36].
54
55
56
57
58
59
60

1
2
3
4
5
6
7 The theoretical basis for MET differs from most other forms of exercise therapy in that MET
8
9 focuses on treating the pain experience and the bodily and psychological reactions to the
10
11 pain experience [33] by applying an exercise dose lasting from 15 to 90 minutes [33]. The
12
13 goal is to reach 70 to 90 minutes of graded exercise resulting in a decrease of pain and
14
15 improvement of function. Possible physiological mechanisms for achieving this are believed
16
17 to activate the descending pain inhibiting system [46, 47], achieving spinal and cortical
18
19 control of nociceptive input and decreasing low inflammatory processes [48-50], which are
20
21 believed to contribute to sensitization [51, 52]. The goal of MET is hence to modulate the
22
23 pain experience and decrease sensitization like allodynia and hyperalgesia [32, 53], increase
24
25 range of motion, and improve functioning [43], resulting in improved muscle strength [43].
26
27 Expressions such as “exercise for the modulation of pain”, “exercise therapy as anti-
28
29 nociceptive therapy”, “exercise as anti allodyni therapy”, or “exercise as anti-inflammatory
30
31 therapy” [50] are used to better explain the goal of the exercise therapy when treating a
32
33 painful condition. For this purpose, exercises are adapted so that they can be performed
34
35 pain free or close to pain free. When a patient becomes pain free or close to pain free, the
36
37 exercise dose is increased with an aim to achieve neural changes in the central nervous
38
39 system and chemical changes in the muscle tissue, to achieve muscle strength, muscle
40
41 volume, and/or muscle endurance [33].
42
43
44
45
46
47
48
49

50 The practical application of MET protocols also differs from most other forms of exercise
51
52 therapies due to MET mixing global, semiglobal, and local exercises [33].
53
54
55
56
57
58
59
60

1
2
3
4 Global exercises are aerobic exercises activating large muscle groups of the body, semiglobal
5
6 exercises are exercises focusing on one extremity with movements in multiple joints, and
7
8 local exercises are exercises focusing on one isolated joint (e.g. knee joint) in an open chain
9
10 situation (Figure 1).
11
12

13 **[Figure 1 about here]**
14

15
16 Sessions of global exercises are performed several times during one treatment occasion,
17
18 where the goal is to substantially increase the heart rate activating the endocrine and pain
19
20 modulating systems of the body, i.e. the descending pain inhibiting system, achieving
21
22 cortical and spinal inhibition of nociceptive input. Semiglobal and local exercises are
23
24 performed for the same purpose, however, they are performed in sets of three where each
25
26 set consists of 30 repetitions. A local exercise can also be performed continuously for 3 to 5
27
28 minutes as one set, for example. The goals of local knee exercises are biological and
29
30 psychosocial. Biological goals include increasing local circulation stimulating
31
32 mechanoreceptors, activating muscles and collagen tissue in the knee resulting in pain
33
34 modulation having an anti-inflammatory effect. Psychosocial, where the local exercise is a
35
36 form of exposure therapy where the patient is exercising the part of the body, in this case
37
38 the knee, that is painful causing anxiety and fear of movement [54]. The goal of the local
39
40 exercise is for the person to “regain the knee” as a part of the body resulting in a decrease of
41
42 negative psychological factors.
43
44
45
46
47
48
49

50 Another element that differs between MET from many other exercise therapies is the focus
51
52 for the grade and dose of exercises to be pain free or close to pain free [33, 36]. From an
53
54 ethical point of view it may be questionable to push patients through painful exercises,
55
56
57

1
2
3
4 when simple doses and grades can make exercises basically pain free. Another theoretical
5
6 and practical argument for such doses is that it seems to be easier to motivate patients to
7
8 exercise when there is no or very little pain involved. By activating the pain-modulating
9
10 systems of the body [55, 56], negative psychological reactions can be avoided that may
11
12 inhibit the pain modulating systems [57, 58], and even decrease possible adverse effects
13
14 from the exercises [31]. However, when a person experiences pain as “meaningful”, as a
15
16 type of reward, it seems to be possible to activate the pain modulating systems [59, 60].
17
18 Thus, when it is not possible to grade and dose the MET exercises at a pain-free or close to
19
20 pain-free level, the patient may exercise with pain, but these painful exercises should be at
21
22 an acceptable level and not increase any negative psychological reactions. As summarized by
23
24 Lorås et al. [33], MET has been evaluated in several clinical trials, and has been shown to be
25
26 effective, both in the short and long term, in patients with long-term low back pain with or
27
28 without sciatica [35], subacromial pain [43-45], and long-term anterior knee pain [37, 38]. In
29
30 these latter studies, an exercise dose lasting 70 to 90 minutes has been been more
31
32 favourable when compared to an exercise dose lasting 20 to 30 minutes. High-dose MET was
33
34 also found to be more effective when compared to a hospital-based traditional exercise
35
36 program given after arthroscopic surgery after a degenerative meniscectomy [39, 40, 42].
37
38 One pilot study compared high-dose MET with arthroscopic surgery in patients with knee
39
40 pain [41] and found it to be associated with lower rates of depression.
41
42
43
44
45
46
47
48
49

50 In a narrative review, Lorås et al., 2015 [33], included four RCTs on the effectiveness of high-
51
52 dose MET, concluding that high-dose MET was positive and promising. However, to be able
53
54 to draw any firm conclusions about the efficacy of MET for patients with knee OA, rigorous
55
56
57
58
59

1
2
3
4 trials are needed on the effect of MET in this major patient group [61]. Effect trials of cost-
5
6 effectiveness are also needed as they are presently lacking in the scientific literature, and
7
8 the present project has the potential to fill this knowledge gap. It is also important to point
9
10 out that no exercise protocol is suited to all patients, and as knowledge of early predictors of
11
12 poor treatment outcomes obtained from longitudinal data is sparse, the development of
13
14 patient-customized treatments is hindered [62]. According to the Swedish Agency for Health
15
16 Technology Assessment and Assessment of Social Services (SBU) [63], as well as a recent
17
18 review [64], prediction studies are needed to be able to better individualize the treatment
19
20 and match the most promising treatment option to a certain patient profile in order to
21
22 maximize treatment outcomes and minimize costs. Therefore, we plan to conduct an RCT
23
24 post-hoc prediction study to gain insights into which patient characteristics predict
25
26 treatment outcome and which patients benefit more or less from exercise treatments.
27
28
29
30
31
32
33

34 **AIM OF THE STUDY**

35
36
37 The aim of this project is to prospectively evaluate short- and long-term effects of high-dose
38
39 MET compared to low-dose of MET in patients with X-ray verified knee OA regarding pain,
40
41 function, and cost-effectiveness. Another aim is to evaluate the effects on pain and function
42
43 during the intervention period after every sixth treatment. A further aim is to conduct a
44
45 post-hoc analysis on early prognostic factors that predict short- and long-term follow-up
46
47 outcomes, by targeting patients' early status and patient adherence to the intervention. The
48
49 long-term goal is to further develop and implement updated knowledge into knee OA
50
51 rehabilitation to meet the challenge of tomorrow's patients with knee OA pain.
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
1. What is the effect of high-dose MET compared to a low-dose exercise therapy (low-dose MET) with respect to self-rated pain, functional limitations, health-related quality of life, depression, and anxiety?
2. What is the effect of high-dose MET compared to low-dose MET on objective measures such as physical functioning of a 20-metre walk, sit to stand, and single knee bends, and pain threshold as determined by a pain-matcher instrument?
3. What is the cost-effectiveness of MET in patients with knee OA with respect to costs against potential effects (incremental cost-effectiveness ratio, ICER), and cost per quality-adjusted life year (QALY)?
4. Which patient characteristics (demographic or disease-related) predict long-term treatment outcomes with a focus on pain, functional limitation, and health-related quality of life? What important interaction effects between patient characteristics and exercise dose may predict treatment outcomes?

MATERIAL AND METHODS

Study design

This project is a double blinded randomized two-arm multicentre trial of a 12-week exercise intervention with a 12-month follow-up. Measurements will be taken at baseline, and follow-ups at two, four, six, eight, ten, 12, 26, and 52 weeks. Primary endpoint is after end of treatment at the 12-week follow-up. Secondary endpoints are at 26 weeks and at 52 weeks follow-up. The study will conform to CONSORT guidelines for reporting parallel randomised trials [65], figure 2.

[Figure 2 about here]

Participants

We are planning to include 200 patients with a diagnosis of symptomatic and radiographic knee OA who will be recruited from primary and secondary health care settings in Luleå and Västerвик in Sweden, and in Trondheim and Mosjøen in Norway, the SWENOR knee OA study.

Inclusion criteria:

Subjects aged 45-85 years, living in the defined geographic areas (Västerвик and Luleå municipalities in Sweden, and Trondheim and Mosjøen in Norway), who have had a diagnosis of symptomatic and radiographic osteoarthritis grade I-III according to Kellgren and Lawrence [66, 67], with pain (at least of three months duration), and decreased functioning.

Exclusion criteria:

Physiotherapy or other conservative therapy during the previous three months or a history of major knee trauma. Inflammatory joint disease, hip symptoms more aggravating than the knee symptoms, about to have knee replacement surgery within six months, and co-morbidities not allowing exercise such as cardiovascular, respiratory, systemic, or metabolic conditions limiting exercise tolerance.

Procedure

Before intervention starts, regular visits will be made to each intervention place by the first author (TAT), informing and communicating the local research team about the aims and run

1
2
3
4 of the study. Detailed description of the different stages of the study from recruitment,
5
6 treatment, and follow-up assessments after the end of the intervention period will be
7
8 instructed and discussed. Physiotherapists in charge of the objective clinical testing, not
9
10 otherwise involved in the treatment, will be educated theoretically and practically on how
11
12 these tests should be performed. The physiotherapists delivering the exercise intervention
13
14 will, in addition, have structured theoretical and practical sessions on how to apply and
15
16 grade the exercise therapies. A handbook will be made describing in detail all aspects of the
17
18 practical run of the study.
19
20
21
22
23
24

25 Recruitment will be achieved through referrals from medical doctors in primary and
26
27 secondary health care clinics. Patients will receive oral and written information about the
28
29 study, and after signing an informed consent form, patients will be assessed for eligibility by
30
31 physiotherapists at each intervention centre. Participants initially fill out questionnaires for
32
33 baseline data and perform the physical objective tests. Each patient is then randomized, as
34
35 described below, to either high or low dose medical exercise therapy.
36
37

38 *Data collection and management.*

39
40
41 Data from the questionnaires will be depersonalised at each intervention centre by the local
42
43 research assistant. In order to transfer data from Norway to Sweden, a data transfer
44
45 agreement between Norges Teknisk-Naturvitenskapelige Universitet (NTNU)/Norwegian
46
47 University of Science and Technology and Karolinska Institutet, NVS, has been set up.
48
49

50 *Post-recruitment retention and compliance strategies*

51
52
53 Our experiences of MET as an experimental intervention (HØ and TAT) [33, 37-43, 45, 68]
54
55 leads to the following retention and compliance strategies to be applied in this study.
56
57

- An independent research assistant at each intervention centre will always be available to answer questions when the patient is filling out the questionnaires. This is important to avoid any unnecessary misunderstandings regarding the content of the questionnaire and making sure that the patient understands that all information will be made depersonalized.
- During the interventions, the treating physiotherapist is present the whole time in the exercise room answering questions from the patient and re-grading the exercises according to changes in patients' exercise status and knee-OA symptoms.
- At the end of the 12-week intervention period the patient is again informed about the six- and 12-month follow-ups.
- During the post-intervention follow-ups, the patient will be contacted three weeks prior to the assessment and informed when to come to the intervention site for the planned post treatment evaluation.

During the intervention period, pain and functioning are assessed after every sixth treatment, giving a total of six assessments. The purpose of such repeated measurements is to obtain a reasonable measurement accuracy of both functioning status and pain during this period. The primary end-point will be on completion of the intervention after 36 treatments, which will take an average of three months. This is to obtain evaluation of effects on organized exercise therapy related with its direct implementation, while further follow-ups evaluate its retention effects. At this point primary and secondary outcomes are assessed.

Randomization procedure

1
2
3
4 In this individual randomized trial, a stratified allocation by age and intervention centre is
5
6 used, using a computerized program, where the goal is to get equal number of patients
7
8 between the ages of 45 and 64 years and 65 and 85 years at each of the four intervention
9
10 centres. The randomization key is concealed at each intervention place and kept under lock
11
12 by a research assistant not involved with the assessment or interventions.
13
14

15 16 17 18 **Blinding procedures**

19
20 Participants are not informed about the hypothesis of the study, thus being blinded
21
22 regarding the experimental intervention. In addition, the physiotherapists performing the
23
24 objective testing are blinded to allocation groups. Research assistants are also blinded to
25
26 groups when entering data to data-sheets, i.e. they do not know which patient has received
27
28 high-dose or low-dose MET. The group key will be opened after the analyses have been
29
30 finalised and the results have been written up in a manuscript (using intervention A and B
31
32 until results have been written).
33
34
35
36
37
38

39 **Interventions**

40
41 All participants receive an MET intervention, where they are treated in groups of four or five
42
43 in sessions lasting 20 to 90 minutes. During the sessions, they are supervised by an
44
45 experienced physiotherapist in an outpatient clinic. All participants are treated three times a
46
47 week for 12 weeks, totalling in 36 treatments. Each patient in the group has an
48
49 individualized exercise program tailored for their specific clinical symptoms and functional
50
51 level. As the treatment proceeds, exercises are adapted and new exercises are considered
52
53 according to changes in symptoms and functioning [33]. Specially designed exercise
54
55
56
57
58
59
60

equipment consisting of different forms of pulleys, exercise benches, dumbbells, and barbells, is used to grade and dose the exercises to be pain free or close to pain free, with the purpose of mitigating peripheral and central sensitization while exercising [33]. The difference between groups regarding exercise dose is outlined below in Table 1.

Table 1: Differences between the high-dose and low-dose MET regarding number of exercises-, sets-, and repetitions. Difference in time, performing global exercises and total time duration for each treatment.

	<i>Number of exercises</i>	<i>Number of sets</i>	<i>Number of repetitions</i>	<i>Time performing global exercise</i>	<i>Time duration of treatment</i>
High dose MET	9	3	30	20 min+10 min +10 min	70-90 min
Low dose MET	5	2	10	10 min	20-30 min

The grading of the exercises, including baseline settings, is based on the initial clinical assessment by the treating physiotherapist. From the patients' past and present histories and physical clinical assessments, information is gained about possible sensitization (local versus central sensitization), the ability to bear weights, range of motion of the knee, and tolerance for weight bearing within the available range of motion. From this information it is possible to have a clinical judgement about initial exercise grade, choosing a weight resistance that matches the desired number of repetitions and sets. It is hence possible for the patient to perform the exercise comfortably within the preferred active range of active motion (AROM). For example, if a part of the AROM in the knee joint is painful, the patient

1
2
3
4 starts to exercise within the pain-free or close to pain-free AROM. As the treatment
5
6 proceeds, the AROM is adjusted, making the patient exercising in a larger and more
7
8 functional AROM. If it is not possible to grade the exercise pain free or close to pain free, the
9
10 patient is allowed to exercise with pain. When exercising with pain it is important that the
11
12 pain experience does not cause any anxiety or fear. The pain has to be experienced as
13
14 meaningful for improvement [59]. If the exercise therapy results in an acute increase in pain,
15
16 the pain should have decreased to baseline before the next treatment session commences.
17
18 The group of 4-5 patients also contains patients with other diagnoses, who are not
19
20 participating in this study, making the delivery of the MET intervention pragmatically similar
21
22 to a real life situation. To be able to monitor the exercise dose, the treating physiotherapists
23
24 follow a structured progression plan of the exercises, and fill in a treatment log for each
25
26 patient at each treatment. The log contains information about number of exercises, length
27
28 of each global exercise, number of repetitions, and sets and weight resistance applied for
29
30 semiglobal and local exercises. Figure 3 show the two different exercise interventions
31
32 compared in this planned randomized trial, high dose MET versus low dose MET.
33
34
35
36
37
38
39
40

41 **[Figure 3 about here]**
42
43
44

45
46 To be able to reach a high number of repetitions despite ongoing pain, the principle of de-
47
48 loading is applied, facilitating a high number of repetitions that are nearly or entirely pain
49
50 free, see figure 1. For the high-dose MET, the deloaded knee extension is performed twice
51
52 during a treatment, each time for a five-minute duration. Later, as the patient improves and
53
54
55
56
57
58
59
60

1
2
3
4 can tolerate increased loading, the exercises are adapted to be more functional, using closed
5
6 chain exercises without deloading the body weight
7
8
9
10

11 **Baseline data**

12
13 The following data will be obtained by questionnaire; gender, age, height, weight, physical
14 activity and exercise levels, living arrangement, education level, employment status, possible
15 medication, co-morbidities, smoking habits, sleeping habits, pain and function of the knee,
16 catastrophizing thoughts, fear avoidance beliefs, level of anxiety and depression, life
17 satisfaction and quality of life, and beliefs about exercise. A schematic presentation of the
18 outcome measures recorded at baseline and at the follow-ups is presented in Table 2. Each
19 assessment, which involves filling out questionnaires, will take approximately one hour. The
20 objective testing of the knee and the testing with the PainMatcher apparatus will occur the
21 following day, and take approximately 30 minutes.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2 . Study measures to be collected

	Instrument for data collection	Collection points
PRIMARY OUTCOME MEASURE		
KOOS average score of five of the KOOS subscale scores	KOOS subscales; 1) pain, 2) other symptoms, 3) ADL, 4) Sport/Rec, and 5) QOL	0, 2, 4, 6, 8, 10, 12, 26 and 52 wks
<i>Knee pain to day/average last week</i>		
Knee pain	100 mm VAS	0, 2, 4, 6, 8, 10, 12, 26 and 52 wks
Knee pain not loading (sitting, lying)	100 mm VAS	0, 2, 4, 6, 8, 10, 12, 26 and 52 wks
Knee pain at weight bearing	100 mm VAS	
Knee pain at night	100 mm VAS	
SECONDARY OUTCOME MEASURES		
Quality of life (qol)		
Health related qol	EQ-5D-5L SF-36	0, 12, 26 and 52 wks 0, 12, 26 and 52 wks
Psychological outcomes		
Anxiety and Depression	HAD	0, 12, 26 and 52 wks
Catastrophizing	CSQ	0, 12, 26 and 52 wks
Fear Avoidance Beliefs	TSK	0, 12, 26 and 52 wks
Life Satisfaction	LISAT	0, 12, 26 and 52 wks
Beliefs of exercise		
Believes and attitudes to exercise	Self-efficacy for exercise (SEE) Outc.expec. for exercise (OEE)	0, 12, 26 and 52 wks 0, 12, 26 and 52 wks
Pain threshold and tolerance		
Objective functional performance		
Functional performance	Pain Matcher	0, 12 wks
	20 m walk test	0, 12 wks
	Chair stand test	0, 12 wks
	Unilateral knee bending	0, 12 wks
OTHER MEASURES		
Compliance with exercise	Treatment records, log-book	Continuously
Adverse events	Treatment records, log-book	Continuously
Satisfaction	A five-point Likert scale	52 wks

Primary outcome measures

In accordance with international consensus regarding the core set of outcome measures for clinical trials in OA [69], self-rated functioning and pain scoring (The Knee Injury and Osteoarthritis Outcome Score, KOOS) [70-73] are used as primary outcome measures. KOOS consists of 5 subscales; Pain, other Symptoms, Functioning in daily living (ADL), Functioning in sport and recreation (Sport/Rec), and knee-related Quality of life (QOL). Standardized answer options are given (5 Likert boxes) and each question is assigned a score from 0 to 4. A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is calculated for each subscale. For the purpose of an RCT, KOOS subscale scores can be aggregated and averaged as the primary outcome. We are planning to use KOOS at several time-points; at baseline, and during the intervention period until the final follow-up at 52 weeks, Table 2.

Other primary outcome measures are eight different pain measurements using a 100 mm visual analogue scale (VAS) [74], with terminal descriptors of “no pain” and “worst pain” asking about how painful a knee is, 1) today and 2) on average during the last week, related to the following four different life situations; 1) how painful is your knee, 2) how painful is your knee when loading your knee (e.g. walking, standing, 3) how painful is your knee when not loading your knee (e.g. sitting, lying), 4) how painful is your knee at night when you are sleeping (e.g. knee pain that disturbs your sleep).

Secondary outcome measures

Data on health related to quality of life are collected using the EQ 5-D questionnaire [75] and The SF-36 questionnaire [76]. These questionnaires will also be used to perform a health economic evaluation of the exercise interventions. Psychological factors such as anxiety, depression, catastrophizing, and fear-avoidance beliefs are believed to both predict outcome of an intervention [77] as well as influence the level of pain in patients with knee OA experience [78]. In this study, anxiety and depression are rated using the Hospital Anxiety and Depression Scale (HAD) [79], catastrophizing is rated using the Pain Catastrophizing Scale (PCS) [80], and fear avoidance beliefs [81] are rated using the Tampa Scale of Kinesiophobia (TSK) [82], see Table 2. Life satisfaction is assessed using the Life Satisfaction (LISAT) questionnaire by Fugl-Meyer [83]. Beliefs and attitudes towards exercise are rated using the Self-Efficacy for Exercise Scale (SEE) [84], and the patient's expectations of performing physical activity are rated using the Outcome Expectations for Exercise Scale (OEE) [85]. A PainMatcher apparatus [86] (Cefar Medical AB, Lund, Sweden) is used to record sensory level, pain level, and pain tolerance level. Pressing the thumb and first finger against a button on each side of the hand held PainMatcher apparatus; an electrode under each button activates an electrical current. As long as the pressure is kept against the buttons, the electrical current will slowly increase where the first sensation of the current is a measurement of sensory threshold. As the pressure is maintained, the electrical current slowly increases, and the sensation will turn into a pain sensation (pain threshold). Keeping the pressure on the buttons, the painful electrical current increases, and pain tolerance is recorded, i.e. the measure of how much painful electrical current the patient can endure.

Objective tests include the 20-meter walk test [87], first at a self-selected pace and then at maximum pace, 30-second maximum number of chair to standing test [88], and 30-second maximum number of repeated unilateral knee bends [87, 89]. Other measurements, logged by the supervising therapist, are recordings of compliance of the exercise treatments during the 12-week intervention also including a recording of exercise dose (weights, sets, repetitions, and treatment time) at each treatment occasion. Over the whole project period, from inclusion to end of the 52-week follow-up, any adverse effects are to be noted and reported.

Statistical analysis

In the statistical analyses of both primary and secondary outcomes, the principle of intention to treat will be used, comparing high-dose MET with low-dose MET. Within-group and inter-group statistical testing will be carried out using mixed model analyses where an alpha level of 0.05 will be used where appropriate. Significance of main or interaction effects will be explored using follow-up post hoc tests.

Analysis of cost-effectiveness will be performed using the incremental cost-effectiveness ratio (ICER), in order to provide a single measure for weighing costs against benefits of health care interventions. Cost per quality-adjusted life year (QALYs [90]), using data from EQ-5D and SF-36, will be added. In the predictive analyses, multivariable logistic regressions (e.g. GEE) will be used to estimate the association between potential predictors and outcomes. A purposeful selection procedure is planned resulting in a final model that

contains only significant independent variables, identified confounders and interactions. All final models will be examined for goodness-of-fit and accuracy according to established methods.

Sample size

The power calculation was based on proportions that can document a minimal clinical important change (MCIC). The primary outcome the Osteoarthritis Outcome Score (KOOS) is a numerical scale ranging from 0 (maximal problem) to 100 (no problem). A change of 10 points is evaluated as a clinical interesting change [71]. The hypothesis is that 40% of the patients receiving high-dose MET and 20% of the patients receiving low-dose MET will obtain a 10-point improvement after end of treatment at the three-month follow-up. The power calculation showed that 82 patients are needed in each arm to reach 80% between-group power. With a hypothetical drop out of the study of 20% the total sample is $82 \times 2 \times 1.2 = 197$ patients. We plan to include 200 patients giving each exercise intervention group a total of 100 participants.

ETHICS AND DISSEMINATION

The guidelines from the Helsinki declaration will be followed and the protocol has been reviewed by the Regional Ethics Review Board in Stockholm. Some relevant ethical considerations related to this study are mentioned below:

The infliction of pain

An often overlooked ethical issue is the infliction of pain when instructing patients to exercise [31]. Knee OA is commonly a painful condition and it is questionable if it is ethical to

1
2
3
4 push patients through the painful exercise regimens included in the approach that today is
5
6 recommended for treating knee OA. A worst-case scenario for this type of treatment is
7
8 pushing the patient into endurance behaviour which in itself may result in long-term pain
9
10 [91]. However, in this study, the focus on grading the exercises pain free or close to pain free
11
12 resolves, to some extent, this problem.
13
14

15 *The problem of large exercise dosage*

16
17 Asking patients to exercise for 70 to 90 minutes three times a week for 12 weeks may be
18
19 ethically questionable. However, such doses of exercise therapy have been shown to be
20
21 effective in patients with depression [41], and there is an argument today that both exercise
22
23 dose and exercise intensity should be increased for patients suffering from heart disease or a
24
25 metabolic syndrome, respectively [92]. The high compliance with a relatively extensive
26
27 exercise programme is possible because patients with chronic (or progressed) conditions
28
29 commonly prioritize rehabilitation to maintain (or improve) good functioning. Thus, it is a
30
31 need to investigate if a similar high dose of exercise therapy is effective for patients with
32
33 knee OA. It is also of high relevance to study whether a less time-consuming exercise
34
35 programme, such as the low-dose MET in the present study, results in similar effects
36
37 including effects on costs.
38
39
40
41
42
43
44

45 **DISCUSSION**

46
47 In an extensive review by Pedersen and Saltin [93], it was concluded that there is evidence
48
49 for prescribing exercise as a therapy for 26 different chronic diseases. In addition, there is
50
51 increasing evidence that a higher dose of exercise is more effective than a lower dose in
52
53 patients with long-term subacromial pain [44] and long-term anterior knee pain [37, 38],
54
55
56
57
58
59
60

1
2
3
4 patients suffering from depression [94], and patients suffering from a metabolic syndrome
5
6 [95]. A high dose of exercise has a greater effect on heart function [96] and a greater
7
8 positive impact on mood states and quality of life [97] in patients suffering from heart
9
10 failure.
11
12

13
14
15
16 In terms of knee OA, however, the evidence level of exercise dose is poor [93, 98]. [25, 26].
17
18 Juhl and colleagues [99] argue that an optimal exercise program for knee OA should focus on
19
20 improving quadriceps strength and aerobic capacity, as well as improving performance in
21
22 the lower extremities. Exercise programmes should be supervised and carried out three
23
24 times a week. They also argue that there is a great need to further investigate the effects of
25
26 differing exercise doses and that the interventions in such studies are described in detail
27
28 with regard to intensity, length of program, total number of supervised sessions, duration of
29
30 individual supervised sessions, and number of sessions per week.
31
32
33

34
35
36 To our knowledge, this study is the first to compare, in a controlled manner, if a higher dose
37
38 of exercise therapy is superior in terms of improvements in function and pain to a lower
39
40 dose of exercise therapy in patients with knee OA.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

CONTRIBUTOR SHIP STATEMENT.

Torstensen TA, Grooten WJA, Østerås H, Heijne A,-Harms-Ringdahl K and Äng B, have all actively been participating planning and designing the study as well as the writing of this manuscript describing the research protocol of the study.

COMPETING INTERESTS

I have read and understood the BMJ Group policy on declaration of interests and declare the following interests:

Name: Tom Arild Torstensen, Date: 2017-06-30

Declaration of interests: Teaches courses and seminars in medical exercise therapy

Name: Grooten WJA, Date: 2017-06-30

Declaration of interests: None

Name: Østerås H, Date: 2017-06-30

Declaration of interests: None

Name: Heijne A, Date: 2017-06-30

Declaration of interests: None

Name: Harms-Ringdahl K, Date: 2017-06-30

Declaration of interests: None

Name: Äng BO, Date: 2017-06-30

Declaration of interests: None

FUNDING STATEMENT:

This work is supported by the Swedish Rheumatology Association and Karolinska Institutet funds, which cover a part of the economical resources. None of the funders have had any influence in developing the protocol or any other part of the study, their role has been merely financial.

REFERENCES

1. Nguyen, U.S., et al., *Increasing prevalence of knee pain and symptomatic knee osteoarthritis: survey and cohort data*. Ann Intern Med, 2011. **155**(11): p. 725-32.
2. Johnson, V.L. and D.J. Hunter, *The epidemiology of osteoarthritis*. Best Pract Res Clin Rheumatol, 2014. **28**(1): p. 5-15.
3. Cross, M., et al., *The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study*. Ann Rheum Dis, 2014. **73**(7): p. 1323-30.
4. Dieppe, P.A. and L.S. Lohmander, *Pathogenesis and management of pain in osteoarthritis*. Lancet, 2005. **365**(9463): p. 965-73.
5. March, L.M. and C.J. Bachmeier, *Economics of osteoarthritis: a global perspective*. Baillieres Clin Rheumatol, 1997. **11**(4): p. 817-34.
6. Holt, H.L., et al., *Forecasting the burden of advanced knee osteoarthritis over a 10-year period in a cohort of 60-64 year-old US adults*. Osteoarthritis and Cartilage, 2011. **19**(1): p. 44-50.
7. Murphy, L., et al., *Lifetime risk of symptomatic knee osteoarthritis*. Arthritis Rheum, 2008. **59**(9): p. 1207-13.
8. Laxafoss, E., et al., *Case definitions of knee osteoarthritis in 4,151 unselected subjects: relevance for epidemiological studies: the Copenhagen Osteoarthritis Study*. Skeletal Radiol, 2010. **39**(9): p. 859-66.
9. Silverwood, V., et al., *Current evidence on risk factors for knee osteoarthritis in older adults: a systematic review and meta-analysis*. Osteoarthritis Cartilage, 2015. **23**(4): p. 507-15.
10. Risberg, M.A., et al., *Changes in Knee Osteoarthritis, Symptoms, and Function After Anterior Cruciate Ligament Reconstruction: A 20-Year Prospective Follow-up Study*. Am J Sports Med, 2016. **44**(5): p. 1215-24.
11. Roemer, F.W., et al., *Increased risk for radiographic osteoarthritis features in young active athletes: a cross-sectional matched case-control study*. Osteoarthritis Cartilage, 2015. **23**(2): p. 239-43.
12. Pereira, D., et al., *The effect of osteoarthritis definition on prevalence and incidence estimates: a systematic review*. Osteoarthritis Cartilage, 2011. **19**(11): p. 1270-85.

13. Iannetti, G.D. and A. Mouraux, *From the neuromatrix to the pain matrix (and back)*. *Exp Brain Res*, 2010. **205**(1): p. 1-12.
14. Arendt-Nielsen, L., *Joint pain: more to it than just structural damage?* *Pain*, 2017. **158 Suppl 1**: p. S66-S73.
15. Gold, M.S. and G.F. Gebhart, *Nociceptor sensitization in pain pathogenesis*. *Nat Med*, 2010. **16**(11): p. 1248-57.
16. Fingleton, C., et al., *Pain sensitization in people with knee osteoarthritis: a systematic review and meta-analysis*. *Osteoarthritis Cartilage*, 2015. **23**(7): p. 1043-56.
17. Tornbjerg, S.M., et al., *Structural pathology is not related to patient-reported pain and function in patients undergoing meniscal surgery*. *Br J Sports Med*, 2017. **51**(6): p. 525-530.
18. Thorstensson, C.A., et al., *Natural course of knee osteoarthritis in middle-aged subjects with knee pain: 12-year follow-up using clinical and radiographic criteria*. *Ann Rheum Dis*, 2009. **68**(12): p. 1890-3.
19. Campbell, C.M., et al., *Sleep, Pain Catastrophizing, and Central Sensitization in Knee Osteoarthritis Patients With and Without Insomnia*. *Arthritis Care Res (Hoboken)*, 2015. **67**(10): p. 1387-96.
20. Colloca, L. and F. Benedetti, *Nocebo hyperalgesia: how anxiety is turned into pain*. *Curr Opin Anaesthesiol*, 2007. **20**(5): p. 435-9.
21. Frisaldi, E., A. Piedimonte, and F. Benedetti, *Placebo and nocebo effects: a complex interplay between psychological factors and neurochemical networks*. *Am J Clin Hypn*, 2015. **57**(3): p. 267-84.
22. Benedetti, F., et al., *The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect*. *J Neurosci*, 2006. **26**(46): p. 12014-22.
23. Cruz-Almeida, Y., et al., *Psychological profiles and pain characteristics of older adults with knee osteoarthritis*. *Arthritis Care Res (Hoboken)*, 2013. **65**(11): p. 1786-94.
24. Herbert, M.S., et al., *Pain hypervigilance is associated with greater clinical pain severity and enhanced experimental pain sensitivity among adults with symptomatic knee osteoarthritis*. *Ann Behav Med*, 2014. **48**(1): p. 50-60.
25. Fransen, M., et al., *Exercise for osteoarthritis of the knee*. *Cochrane Database Syst Rev*, 2015. **1**: p. Cd004376.
26. Regnaud, J.P., et al., *High-intensity versus low-intensity physical activity or exercise in people with hip or knee osteoarthritis*. *Cochrane Database Syst Rev*, 2015(10): p. Cd010203.
27. Ageberg, E. and E.M. Roos, *Neuromuscular exercise as treatment of degenerative knee disease*. *Exerc Sport Sci Rev*, 2015. **43**(1): p. 14-22.
28. Knoop, J., et al., *Knee joint stabilization therapy in patients with osteoarthritis of the knee: a randomized, controlled trial*. *Osteoarthritis Cartilage*, 2013. **21**(8): p. 1025-34.
29. Latham, N. and C.J. Liu, *Strength training in older adults: the benefits for osteoarthritis*. *Clin Geriatr Med*, 2010. **26**(3): p. 445-59.
30. Henriksen, M., et al., *Experimental knee pain reduces muscle strength*. *J Pain*, 2011. **12**(4): p. 460-7.
31. Liu, C.J. and N. Latham, *Adverse events reported in progressive resistance strength training trials in older adults: 2 sides of a coin*. *Arch Phys Med Rehabil*, 2010. **91**(9): p. 1471-3.

32. Henriksen, M., et al., *Association of exercise therapy and reduction of pain sensitivity in patients with knee osteoarthritis: a randomized controlled trial*. *Arthritis Care Res (Hoboken)*, 2014. **66**(12): p. 1836-43.
33. Loras, H., et al., *Medical Exercise Therapy for Treating Musculoskeletal Pain: A Narrative Review of Results from Randomized Controlled Trials with a Theoretical Perspective*. *Physiother Res Int*, 2015. **20**(3): p. 182-90.
34. Hurley, M.V., H.L. Mitchell, and N. Walsh, *In osteoarthritis, the psychosocial benefits of exercise are as important as physiological improvements*. *Exerc Sport Sci Rev*, 2003. **31**(3): p. 138-43.
35. Torstensen, T.A., et al., *Efficiency and costs of medical exercise therapy, conventional physiotherapy, and self-exercise in patients with chronic low back pain. A pragmatic, randomized, single-blinded, controlled trial with 1-year follow-up*. *Spine (Phila Pa 1976)*, 1998. **23**(23): p. 2616-24.
36. Torstensen, T.A., H.D. Meen, and M. Stiris, *The effect of medical exercise therapy on a patient with chronic supraspinatus tendinitis. Diagnostic ultrasound--tissue regeneration: a case study*. *J Orthop Sports Phys Ther*, 1994. **20**(6): p. 319-27.
37. Osteras, B., H. Osteras, and T.A. Torstensen, *Long-term effects of medical exercise therapy in patients with patellofemoral pain syndrome: results from a single-blinded randomized controlled trial with 12 months follow-up*. *Physiotherapy*, 2013. **99**(4): p. 311-6.
38. Osteras, B., et al., *Dose-response effects of medical exercise therapy in patients with patellofemoral pain syndrome: a randomised controlled clinical trial*. *Physiotherapy*, 2013. **99**(2): p. 126-31.
39. Osteras, H., *A 12-week medical exercise therapy program leads to significant improvement in knee function after degenerative meniscectomy: a randomized controlled trial with one year follow-up*. *J Bodyw Mov Ther*, 2014. **18**(3): p. 374-82.
40. Osteras, H., B. Osteras, and T.A. Torstensen, *Medical Exercise Therapy is Effective After Arthroscopic Surgery of Degenerative Meniscus of the Knee: A Randomized Controlled Trial*. *J Clin Med Res*, 2012. **4**(6): p. 378-84.
41. Osteras, H., B. Osteras, and T.A. Torstensen, *Medical exercise therapy, and not arthroscopic surgery, resulted in decreased depression and anxiety in patients with degenerative meniscus injury*. *J Bodyw Mov Ther*, 2012. **16**(4): p. 456-63.
42. Osteras, H., B. Osteras, and T.A. Torstensen, *Is postoperative exercise therapy necessary in patients with degenerative meniscus? A randomized controlled trial with one year follow-up*. *Knee Surg Sports Traumatol Arthrosc*, 2014. **22**(1): p. 200-6.
43. Osteras, H. and T.A. Torstensen, *The dose-response effect of medical exercise therapy on impairment in patients with unilateral longstanding subacromial pain*. *Open Orthop J*, 2010. **4**: p. 1-6.
44. Osteras, H., T.A. Torstensen, and B. Osteras, *High-dosage medical exercise therapy in patients with long-term subacromial shoulder pain: a randomized controlled trial*. *Physiother Res Int*, 2010. **15**(4): p. 232-42.
45. Osteras, H., et al., *A comparison of work absence periods and the associated costs for two different modes of exercise therapies for patients with longstanding subacromial pain*. *J Med Econ*, 2008. **11**(3): p. 371-81.
46. Koltyn, K.F., et al., *Mechanisms of exercise-induced hypoalgesia*. *J Pain*, 2014. **15**(12): p. 1294-1304.

- 1
- 2
- 3
- 4
- 5 47. Fuentes, C.J., et al., *Effects of exercise therapy on endogenous pain-relieving*
- 6 *peptides in musculoskeletal pain: a systematic review*. Clin J Pain, 2011. **27**(4): p.
- 7 365-74.
- 8 48. Schnyder, S. and C. Handschin, *Skeletal muscle as an endocrine organ: PGC-1alpha,*
- 9 *myokines and exercise*. Bone, 2015. **80**: p. 115-25.
- 10 49. Pedersen, B.K., *Exercise-induced myokines and their role in chronic diseases*. Brain
- 11 Behav Immun, 2011. **25**(5): p. 811-6.
- 12 50. Pedersen, B.K., *Muscle as a secretory organ*. Compr Physiol, 2013. **3**(3): p. 1337-
- 13 62.
- 14 51. Scanzello, C.R., *Role of low-grade inflammation in osteoarthritis*. Curr Opin
- 15 Rheumatol, 2017. **29**(1): p. 79-85.
- 16 52. Schaible, H.G., *Nociceptive neurons detect cytokines in arthritis*. Arthritis Res Ther,
- 17 2014. **16**(5): p. 470.
- 18 53. Morgan, J.A., F. Corrigan, and B.T. Baune, *Effects of physical exercise on central*
- 19 *nervous system functions: a review of brain region specific adaptations*. J Mol
- 20 Psychiatry, 2015. **3**(1): p. 3.
- 21 54. Bailey, K.M., et al., *Treatments addressing pain-related fear and anxiety in patients*
- 22 *with chronic musculoskeletal pain: a preliminary review*. Cogn Behav Ther, 2010.
- 23 **39**(1): p. 46-63.
- 24 55. Brellenthin, A.G., et al., *Psychosocial Influences on Exercise-Induced Hypoalgesia*.
- 25 Pain Med, 2017. **18**(3): p. 538-550.
- 26 56. Fingleton, C., K.M. Smart, and C.M. Doody, *Exercise-induced Hypoalgesia in People*
- 27 *With Knee Osteoarthritis With Normal and Abnormal Conditioned Pain Modulation*.
- 28 Clin J Pain, 2017. **33**(5): p. 395-404.
- 29 57. Nahman-Averbuch, H., et al., *Psychological Factors and Conditioned Pain*
- 30 *Modulation: A Meta-Analysis*. Clin J Pain, 2016. **32**(6): p. 541-54.
- 31 58. Nahman-Averbuch, H., et al., *Relationship between Personality Traits and*
- 32 *Endogenous Analgesia: The Role of Harm Avoidance*. Pain Pract, 2016. **16**(1): p.
- 33 38-45.
- 34 59. Benedetti, F., et al., *Pain as a reward: changing the meaning of pain from negative*
- 35 *to positive co-activates opioid and cannabinoid systems*. Pain, 2013. **154**(3): p.
- 36 361-7.
- 37 60. Carlino, E. and F. Benedetti, *Different contexts, different pains, different*
- 38 *experiences*. Neuroscience, 2016. **338**: p. 19-26.
- 39 61. McAlindon, T.E., et al., *OARSI Clinical Trials Recommendations: Design, conduct,*
- 40 *and reporting of clinical trials for knee osteoarthritis*. Osteoarthritis Cartilage,
- 41 2015. **23**(5): p. 747-60.
- 42 62. Deyle, G.D., et al., *Knee OA: which patients are unlikely to benefit from manual PT*
- 43 *and exercise?* J Fam Pract, 2012. **61**(1): p. E1-8.
- 44 63. SBU, *Träning som behandling av smärta och funktionsnedsättning vid knäartros*.
- 45 2015. p. www.sbu.se/2015_10.
- 46 64. Laisne, F., C. Lecomte, and M. Corbiere, *Biopsychosocial predictors of prognosis in*
- 47 *musculoskeletal disorders: a systematic review of the literature (corrected and*
- 48 *republished) **. Disabil Rehabil, 2012. **34**(22): p. 1912-41.
- 49 65. Schulz, K.F., et al., *CONSORT 2010 statement: updated guidelines for reporting*
- 50 *parallel group randomised trials*. Int J Surg, 2011. **9**(8): p. 672-7.
- 51 66. Kellgren, J.H. and J.S. Lawrence, *Radiological assessment of osteo-arthrosis*. Ann
- 52 Rheum Dis, 1957. **16**(4): p. 494-502.
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

- 1
2
3
4
5 67. Schiphof, D., M. Boers, and S.M. Bierma-Zeinstra, *Differences in descriptions of Kellgren and Lawrence grades of knee osteoarthritis*. *Ann Rheum Dis*, 2008. **67**(7): p. 1034-6.
- 6
7
8 68. Osteras, H., et al., *Clinical and MRI findings after high dosage medical exercise therapy in patients with long lasting subacromial pain syndrome: a case series on six patients*. *J Bodyw Mov Ther*, 2010. **14**(4): p. 352-60.
- 9
10
11 69. Bellamy, N., et al., *Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III*. *J Rheumatol*, 1997. **24**(4): p. 799-802.
- 12
13
14 70. Roos, E.M., *Effectiveness and practice variation of rehabilitation after joint replacement*. *Curr Opin Rheumatol*, 2003. **15**(2): p. 160-2.
- 15
16
17 71. Roos, E.M. and L.S. Lohmander, *The Knee injury and Osteoarthritis Outcome Score (KOOS): from joint injury to osteoarthritis*. *Health Qual Life Outcomes*, 2003. **1**: p. 64.
- 18
19
20 72. Roos, E.M., et al., *Knee injury and Osteoarthritis Outcome Score (KOOS)--validation of a Swedish version*. *Scand J Med Sci Sports*, 1998. **8**(6): p. 439-48.
- 21
22
23 73. Roos, E.M., et al., *Knee Injury and Osteoarthritis Outcome Score (KOOS)--development of a self-administered outcome measure*. *J Orthop Sports Phys Ther*, 1998. **28**(2): p. 88-96.
- 24
25
26 74. Lundeberg, T., et al., *Reliability and responsiveness of three different pain assessments*. *J Rehabil Med*, 2001. **33**(6): p. 279-83.
- 27
28
29 75. Fransen, M. and J. Edmonds, *Reliability and validity of the EuroQol in patients with osteoarthritis of the knee*. *Rheumatology (Oxford)*, 1999. **38**(9): p. 807-13.
- 30
31
32 76. Sullivan, M., J. Karlsson, and J.E. Ware, Jr., *The Swedish SF-36 Health Survey--I. Evaluation of data quality, scaling assumptions, reliability and construct validity across general populations in Sweden*. *Soc Sci Med*, 1995. **41**(10): p. 1349-58.
- 33
34
35 77. Orenius, T., et al., *Anxiety and depression are independent predictors of quality of life of patients with chronic musculoskeletal pain*. *J Health Psychol*, 2013. **18**(2): p. 167-75.
- 36
37
38 78. Urquhart, D.M., et al., *Are cognitive and behavioural factors associated with knee pain? A systematic review*. *Semin Arthritis Rheum*, 2015. **44**(4): p. 445-55.
- 39
40
41 79. Bjelland, I., et al., *The validity of the Hospital Anxiety and Depression Scale. An updated literature review*. *J Psychosom Res*, 2002. **52**(2): p. 69-77.
- 42
43
44 80. Osman, A., et al., *Factor structure, reliability, and validity of the Pain Catastrophizing Scale*. *J Behav Med*, 1997. **20**(6): p. 589-605.
- 45
46
47 81. Holla, J.F., et al., *The avoidance model in knee and hip osteoarthritis: a systematic review of the evidence*. *J Behav Med*, 2014. **37**(6): p. 1226-41.
- 48
49
50 82. Lundberg, M., et al., *Pain-related fear: a critical review of the related measures*. *Pain Res Treat*, 2011. **2011**: p. 494196.
- 51
52
53 83. Fugl-Meyer, A.R., M. Eklund, and K.S. Fugl-Meyer, *Vocational rehabilitation in northern Sweden. III. Aspects of life satisfaction*. *Scand J Rehabil Med*, 1991. **23**(2): p. 83-7.
- 54
55
56 84. Resnick, B. and L.S. Jenkins, *Testing the reliability and validity of the Self-Efficacy for Exercise scale*. *Nurs Res*, 2000. **49**(3): p. 154-9.
- 57
58
59 85. Resnick, B., *Reliability and validity of the Outcome Expectations for Exercise Scale-2*. *J Aging Phys Act*, 2005. **13**(4): p. 382-94.
- 60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
86. Stener-Victorin, E., J. Kowalski, and T. Lundeberg, *A new highly reliable instrument for the assessment of pre- and postoperative gynecological pain*. *Anesth Analg*, 2002. **95**(1): p. 151-7,
 87. Villadsen, A., et al., *Agreement and reliability of functional performance and muscle power in patients with advanced osteoarthritis of the hip or knee*. *Am J Phys Med Rehabil*, 2012. **91**(5): p. 401-10.
 88. Dobson, F., et al., *Measurement properties of performance-based measures to assess physical function in hip and knee osteoarthritis: a systematic review*. *Osteoarthritis Cartilage*, 2012. **20**(12): p. 1548-62.
 89. Bremander, A.B., L.L. Dahl, and E.M. Roos, *Validity and reliability of functional performance tests in meniscectomized patients with or without knee osteoarthritis*. *Scand J Med Sci Sports*, 2007. **17**(2): p. 120-7.
 90. Prieto, L. and J.A. Sacristan, *Problems and solutions in calculating quality-adjusted life years (QALYs)*. *Health Qual Life Outcomes*, 2003. **1**: p. 80.
 91. Hasenbring, M.I., et al., *Fear and anxiety in the transition from acute to chronic pain: there is evidence for endurance besides avoidance*. *Pain Manag*, 2014. **4**(5): p. 363-74.
 92. Wisloff, U., J.S. Coombes, and O. Rognmo, *CrossTalk proposal: High intensity interval training does have a role in risk reduction or treatment of disease*. *J Physiol*, 2015. **593**(24): p. 5215-7.
 93. Pedersen, B.K. and B. Saltin, *Exercise as medicine - evidence for prescribing exercise as therapy in 26 different chronic diseases*. *Scand J Med Sci Sports*, 2015. **25 Suppl 3**: p. 1-72.
 94. Dunn, A.L., et al., *Exercise treatment for depression: efficacy and dose response*. *Am J Prev Med*, 2005. **28**(1): p. 1-8.
 95. Slentz, C.A., J.A. Houmard, and W.E. Kraus, *Exercise, abdominal obesity, skeletal muscle, and metabolic risk: evidence for a dose response*. *Obesity (Silver Spring)*, 2009. **17 Suppl 3**: p. S27-33.
 96. Wisloff, U., O. Ellingsen, and O.J. Kemi, *High-intensity interval training to maximize cardiac benefits of exercise training?* *Exerc Sport Sci Rev*, 2009. **37**(3): p. 139-46.
 97. Evangelista, L.S., et al., *Dose-Response Relationship Between Exercise Intensity, Mood States, and Quality of Life in Patients With Heart Failure*. *J Cardiovasc Nurs*, 2017.
 98. Hurley, M.V., *Muscle dysfunction and effective rehabilitation of knee osteoarthritis: what we know and what we need to find out*. *Arthritis Rheum*, 2003. **49**(3): p. 444-52.
 99. Juhl, C., et al., *Impact of exercise type and dose on pain and disability in knee osteoarthritis: a systematic review and meta-regression analysis of randomized controlled trials*. *Arthritis Rheumatol*, 2014. **66**(3): p. 622-36.

FIGURE CAPTIONS

Figure 1: The principle of de-loading: The theoretical basis for the principle of de-loading is that the weight from the pulley de-loads the weight of the lower leg with a decrease of the compressive forces between bony and cartilaginous structures. The de-loading also results in decreased pull and loading of muscles, tendons and other soft tissue, decreasing sensitization like mechanical/loading allodynia making it possible to exercise pain free or close to pain free.

Figure 2. Flow chart of the design and run of the study. HDMET= High-dose MET and LDMET= Low-dose MET.

Figure 3: Show the two different exercise interventions compared in this randomized trial, high dose MET (HDMET) versus low dose MET (LDMET).




Figure 1: The principle of de-loading: The theoretical basis for the principle of de-loading is that the weight from the pulley de-loads the weight of the lower leg with a decrease of the compressive forces between bony and cartilaginous structures. The de-loading also results in decreased pull and loading of muscles, tendons and other soft tissue, decreasing sensitization like mechanical/loading allodynia making it possible to exercise pain free or close to pain free.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2017-018471 on 5 May 2018. Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.




Figure 2. Flow chart of the design and run of the study. HDMET= High-dose MET and LDMET= Low-dose MET.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60






EXERCISE	HIGH DOSE MET (70-90 MIN)	DOSE	LOW DOSE MET (20-30 MIN)	DOSE
1		GLOBAL 20 min		GLOBAL 10 min
2		SEMI GLOBAL CLOSED CHAIN 3x30 reps		SEMI GLOBAL CLOSED CHAIN 2x10 reps
3		LOCAL OPEN CHAIN 5 min		SEMI GLOBAL CLOSED CHAIN 2x10 reps
4		SEMI GLOBAL CLOSED CHAIN 3x30 reps		SEMI GLOBAL CLOSED CHAIN 2x10 reps
5		GLOBAL 10 min		SEMI GLOBAL OPEN CHAIN 2x10 reps
6		SEMI GLOBAL CLOSED CHAIN 3x30 reps		
7		LOCAL OPEN CHAIN 5 min		
8		LOCAL OPEN CHAIN 3x30 reps		
9		GLOBAL 10 min		

Figure 3. Show the two different exercise interventions compared in this randomized trial, high dose MET (HDMET) versus low dose MET (LDMET).

BMJ Open

Does exercise dose affect benefits in patients with long-term osteoarthritis of the knee? A study protocol of a randomized controlled trial in Sweden and Norway – the SWENOR study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-018471.R1
Article Type:	Protocol
Date Submitted by the Author:	19-Nov-2017
Complete List of Authors:	Torstensen, Tom Arild; Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Physiotherapy Grooten, Wilhelmus; Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Physiotherapy ; Karolinska University Hospital, Allied Health Professionals Function, Functional area Occupational Therapy and Physiotherapy Østerås, Håvard; Norwegian University of Science and Technology, Department of Neuromedicine and Movement Science Heijne, Annette; Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Physiotherapy ; Karolinska University Hospital, Allied Health Professionals Function, Functional area Occupational Therapy and Physiotherapy Harms-Ringdahl, Karin; Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Physiotherapy ; Karolinska University Hospital, Allied Health Professionals Function, Functional area Occupational Therapy and Physiotherapy Äng, Björn; Dalarna University, School of Education, Health and Social Sciences; Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Physiotherapy
Primary Subject Heading:	Rehabilitation medicine
Secondary Subject Heading:	Rheumatology, Sports and exercise medicine
Keywords:	Knee < ORTHOPAEDIC & TRAUMA SURGERY, Musculoskeletal disorders < ORTHOPAEDIC & TRAUMA SURGERY, PAIN MANAGEMENT, Clinical trials < THERAPEUTICS, REHABILITATION MEDICINE

SCHOLARONE™
Manuscripts

Words in text 6828
 Words in abstract 299
 Tables 2
 Figures 3
 Appendixes 2

Does exercise dose affect benefits in patients with long-term osteoarthritis of the knee? A study protocol of a randomized controlled trial in Sweden and Norway – the SWENOR study

Torstensen TA (1), Grooten WJA (1,2), Østerås H (3), Heijne A (1,2), Harms-Ringdahl K (1,2), Äng BO (1,4,5).

- 1) Department of Neurobiology, Care Sciences and Society, Division of Physiotherapy, Karolinska Institutet, Huddinge, Sweden
- 2) Allied Health Professionals Function, Functional area Occupational Therapy and Physiotherapy, Karolinska University Hospital, Stockholm, Sweden
- 3) Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway
- 4) School of Education, Health and Social Sciences, Dalarna University, Falun, Sweden
- 5) Center for Clinical Research Dalarna, Falun, Sweden

Corresponding author:

Tom Arild Torstensen

Department of Neurobiology, Care Sciences and Society, Division of Physiotherapy, Karolinska Institutet

Alfred Nobels Allé 23 23100
 141 83 Huddinge, Sweden

Tel: +46 707344102

E-mail: tom.torstensen@ki.se

Version 2, review, 2017 -11-19

ABSTRACT

Introduction: Osteoarthritis (OA) of the knee is characterized by knee pain, disability, and degenerative changes, and places a burden on societies all over the world.

Exercise therapy is an often-used modality, but there is little evidence of what type of exercise dose is the most effective, indicating a need for controlled studies of the effect of different dosages. Thus, the aim of this study described in this protocol is to evaluate the effects of high-dose versus low-dose medical exercise therapy (MET) in patients with knee OA.

Methods and analysis: This is a multicentre prospective randomized two-arm trial with blinded assessment and data analysis. We are planning to include 200 patients aged 45-85 years with a diagnosis of symptomatic (pain and decreased functioning) and X-ray verified diagnosis of knee OA. Those eligible for participation will be randomly allocated to either high-dose (n=100) or low-dose (n=100) MET. All patients receive three supervised treatments each week for twelve weeks, giving a total of 36 MET sessions. The high-dose group exercises for 80-90 min compared to 20-30 min in the low-dose group. The high-dose group not only exercises for a longer time, but also receives a greater number of exercises with more repetitions and sets. Background and outcome variables are recorded at inclusion, and outcome measures are collected after every sixth treatment, at end of treatment, and at six- and twelve-month follow-ups. Primary outcome is self-rated knee functioning and pain using the Knee Injury and Osteoarthritis Outcome Score (KOOS). The primary endpoint is at the end of treatment after three months, and secondary endpoints are at six and twelve months after end of treatment.

Ethics and dissemination: This project has been approved by the Regional Research Ethics Committees in Stockholm, Sweden, and in Norway. Our results will be submitted to peer-reviewed journals and presented at national and international conferences.

Trial Registration number: (ClinicalTrials.gov NCT02024126)

Strengths and limitations of this study

- To the best of our knowledge, this is the first multicentre study, with a bio-psycho-social view of pain, prospectively, comparing the effectiveness of two defined doses of pain-free or close to pain-free exercise therapies in patients with symptomatic knee osteoarthritis.
- The proposed project includes a relatively large sample where outcomes are evaluated both during the twelve-week intervention period, at the end of treatment, and at six and twelve months, respectively.
- The project uses both subjective and objective data, and includes analyses of cost-effectiveness and early predictors for a follow-up clinical outcome.
- Even though the different components of the exercise programmes are well described, one limitation could be possible confounders related to the exercise dose given.

MAIN TEXT

BACKGROUND

Osteoarthritis (OA) is the most common form of arthritis and is a major worldwide health problem causing illness and disability [1, 2]. The burden to society caused by knee OA is substantial [3]. The knee joint is most frequently affected, which commonly results in chronic joint pain, knee stiffness, decreased functioning, reduced quality of life, and sick leave [4]. The associated costs of osteoarthritis are estimated to range between 1-2.5% of the gross national product as calculated in six industrialized countries (Sweden, Australia, Canada, France, UK, and US) [5].

1
2
3 1
4
5 2 The prevalence of knee OA has increased during the last 20 years [1] and is expected to
6
7 3 continue to increase [6]. Murphy et al. [7] reported that almost half of US adults will have
8
9 4 symptomatic knee OA by the age of 85, with the highest risk being among obese individuals.
10
11 5 There is a sex difference, where the prevalence is estimated to be 40% in women and 30% in
12
13 6 men in people aged 65-75 years [8]. Although knee OA is known to be more common in
14
15 7 older age groups, the increasing global prevalence of obesity is anticipated to elevate the
16
17 8 prevalence of knee OA in younger people [9]. Currently, knee OA in younger people is most
18
19 9 often secondary to congenital disorders or sporting injuries and other traumas to the knee
20
21
22
23 10 [10, 11].
24
25
26
27

28 12 Traditionally, knee OA has been defined as a pathological condition characterized by focal
29
30 13 areas of loss of articular cartilage within the synovial joints, associated with hypertrophy of
31
32 14 the bone (osteophytes and sub-chondral bone sclerosis) and thickening of the capsule [12].
33
34 15 The mechanisms of knee OA-related pain are, however, complex [13] particularly in chronic
35
36 16 pain conditions where pain experience is nowadays believed to be more a result of changes
37
38 17 in the nervous system than in tissue structures [14], which somehow reflects a paradigm
39
40 18 shift in the understanding of the pathology of pain related to knee OA. Because of the
41
42 19 plasticity of the nervous system, pain lowers the threshold level of the nociceptive receptor
43
44 20 system [15], making it more sensitive to stimuli during normal movements like walking and
45
46 21 bending – so-called mechanical or loading allodynia. These changes occur in the peripheral
47
48 22 receptor system located in the knee and in the receptor system in the spinal cord resulting in
49
50 23 changes in the nervous system, i.e. peripheral and central sensitization [16]. The rationale
51
52 24 for this theory is that the problem lies more in the nervous system than in the knee and may
53
54
55
56
57
58
59
60

1 partly explain why there are poor correlations between structural degenerative changes of
2 the knee, and pain, and functioning [17, 18].

3
4 The level of pain caused by these sensitization processes is also affected by psychological
5 factors such as anxiety and depression, which cause increased nociceptive input that
6 increases the pain experience [19, 20]. When pain becomes more persistent and does not
7 resolve, the person can develop negative attitudes and beliefs [20-22] that are closely linked
8 to catastrophizing and anxiety. This may result in further sensitization with long-term pain
9 [19, 23, 24]. Shifting our understanding of pain-related knee OA from exclusively involving
10 changes in tissue structures to involving changes in the nervous system is - we believe - an
11 important paradigm shift for not only a better understanding of what knee OA is, but also for
12 improved optimal treatment designs including exercise therapy which is a frequently used
13 modality in treating knee OA.

14
15 In a systematic review, it was concluded that there exists high-level evidence that land-
16 based therapeutic exercise provides short-term effects on pain relief, and that there is a
17 moderate quality evidence regarding improvement in physical functioning among patients
18 with knee OA [25]. Despite this, several questions remain unanswered, particularly regarding
19 dose, intensity, and duration of the exercise therapy applied [26]. These unanswered
20 questions may be one of the reasons why we see a large variation in treatment effects
21 observed across studies making it difficult to conclude what is the optimal dose when
22 delivering exercise therapy [25, 26]. The exercises vary from neuromuscular exercise [27],
23 knee joint stabilization exercises [28], strengthening exercises [29], and endurance exercises
24 [30]. These forms of exercise therapy do not necessarily take into consideration the theories

1 of local and central sensitization, thus opening up for new exercise therapies, where the goal
2 is modulation of pain decreasing local and central sensitizations. The knowledge that pain
3 and swelling inhibits motor output, decreases range of motion, and changes
4 coordination [31] and that a traditional strengthening exercise program can cause adverse
5 effects [32], questions the use of strengthening exercises. In their review [32], Liu et al.
6 concluded that out of 121 trials, 53 had no comments about adverse events, 25 reported no
7 adverse events, and 43 trials reported adverse events. The majority of the adverse events
8 from the strength training were muscle strain and joint pain and more adverse events were
9 reported when performing high intensity strength training. There was also a higher degree
10 of these complications in trials recruiting elderly participants with health conditions and
11 functional limitations. Liu et al. [32] also argue that adverse events may be underreported
12 due to the lack of consensus on their definition. Another factor for underreporting could be
13 a general attitude that increased pain due to strength training is expected and normal, and
14 that patients should endure that. In a recent systematic review of randomized trials on the
15 role of muscle strengthening exercise therapy in knee OA [33], the authors conclude that
16 strength training provides superior outcomes in knee extensor strength but not in terms of
17 pain and disability. In this context there is increasing evidence [34] that exercise therapy
18 should focus more on treating the causality of pain-related knee OA such as peripheral and
19 central sensitization [14] and pain-related bodily and psychological changes [19] from a
20 biopsychosocial perspective [35, 36] rather than an impairment like muscle strength. This
21 view is supported by research showing that pain-related fear is more disabling than pain
22 itself [37]. To break the vicious circle of long-term knee pain, we believe it is important to
23 see beyond the knee [14], beyond an impairment such as muscle strength [33], using a
24 biopsychosocial sensitization model of pain [36].

1
2
3 14
5 2 **Medical Exercise Therapy**

6
7 3 Medical Exercise Therapy (MET) was developed in Norway more that 50 years ago and is an
8
9 4 established treatment in the Nordic countries, other parts of Europe, and North America [36,
10
11 5 38, 39]. MET focuses on applying the optimal dose of exercise; i.e combining global aerobic
12
13 6 exercises with semiglobal and local joint exercises, where the goal is to apply 70 to 90
14
15 7 minutes of active dynamic exercise therapy [38, 40-48] . Using the principle of self-paced
16
17 8 exercises [49] the patient is to perform more than 1000 pain-free or close to pain-free
18
19 9 repetitions per MET-session [38, 40-48] . Even though the optimal dose goal of MET is high,
20
21 10 the treatment usually starts with a low dose lasting 15 to 20 minutes mirroring the ability of
22
23 11 the patient within a biopsychosocial context [35, 36], starting with an acceptable baseline
24
25 12 where the patient manages the exercise therapy [36, 38].
26
27
28
29

30 13

31
32 14 The theoretical basis for MET differs from most other forms of exercise therapy in that MET
33
34 15 focuses on decreasing the pain experience and the bodily and psychological reactions to the
35
36 16 pain experience [36] by applying an exercise time lasting from 15 to 90 minutes [36]. The
37
38 17 goal is to reach 70 to 90 minutes of graded exercise that, over the course of the intervention
39
40 18 period, results in a decrease in pain and improvement in functioning. Possible physiological
41
42 19 mechanisms for achieving this are an activation of the descending pain inhibiting system [50,
43
44 20 51], achieving spinal and cortical inhibition of nociceptive input and decreasing low
45
46 21 inflammatory processes [52-54], inflammatory processes which are believed to contribute to
47
48 22 sensitization [55, 56]. The goal of MET is hence to modulate the pain experience and
49
50 23 decrease sensitization like allodynia and hyperalgesia [34, 57], increase range of motion, and
51
52 24 improve functioning [46], resulting in improved muscle strength [46].
53
54
55
56
57
58
59
60

1 The practical application of MET protocols also differs from most other forms of exercise
2 therapies due to MET mixing global, semiglobal, and local exercises. Global exercises are
3 exercises that activate the whole body exercising the trunk as well as upper and lower
4 extremities, a semiglobal exercise activates muscles, joints and other structures in an
5 extremity and a local exercise activates one joint and the muscles acting on it. Sessions of
6 global exercises are performed several times during one treatment occasion, where the goal
7 is to substantially increase the heart rate activating the endocrine and pain modulating
8 systems of the body, i.e. the descending pain inhibiting system, achieving cortical and spinal
9 inhibition of nociceptive input. Semiglobal and local exercises are performed for the same
10 purpose, however, they are performed in sets of three where each set consists of 30
11 repetitions. A local exercise can also be performed continuously for 3 to 5 minutes as one
12 set, for example deloaded knee extension, see Figure 1.

13 **[Figure 1 about here].**

14 The principle of deloading also makes MET different from most other forms of exercise
15 therapies. To achieve deloading, the weight stack from different pulley apparatus is used to
16 deload a part of the body or the whole body, resulting in less joint forces in the knee joint,
17 making it easier to perform a high volume of repetitions pain-free or close to pain-free.
18 Deloaded squatting is performed using a deloading frame attached to a latissimus pulley
19 (lat.pulley), exercise number, two high dose MET, see Figure two. Deloaded step up and step
20 down exercises are performed using a handle attached to the lat.pulley, exercises number
21 four and six high dose MET, see Figure two. Compared to walking and running, stationary
22 cycling is also viewed as a form of deloading where the compressive forces in the knee are
23 lower compared to weight bearing activities, exercise one, five and nine high dose MET, see
24 Figure two.

1
2
3 1
4
5 2 The theoretical basis for the principle of the de-loading is that the weight from the pulley
6
7 3 deloads the weight of the lower leg with a decrease in the compressive forces between bony
8
9 4 and cartilaginous structures. The deloading also results in decreased pull and loading of
10
11 5 muscles, tendons, and other soft tissue, decreasing sensitization including
12
13 6 mechanical/loading allodynia, making it possible to exercise pain-free or close to pain-free.
14
15 7 The goals of local knee exercises are both biological and psychological. Biologically, the
16
17 8 exercises aim to increase the local circulation, stimulating mechanoreceptors activating the
18
19 9 muscles and collagen tissue in the knee, which could result in pain modulation and an anti-
20
21 10 inflammatory effect. Psychologically, the patient is instructed to exercise the part of the
22
23 11 body, in this case the knee, that is painful and a reason for anxiety and fear of movement.
24
25 12 The goal of the local exercise is therefore for the person to “regain the knee” as a part of the
26
27 13 body resulting in a decrease of negative psychological factors.
28
29
30
31

32
33 **[Figure 2 about here].**
34

35 15 MET has been evaluated in several clinical trials, and has been shown to be effective, both in
36
37 16 the short and long term, in patients with long-term low back pain with or without sciatica
38
39 17 [39], subacromial pain [46-48], and long-term anterior knee pain [40, 41]. In these latter
40
41 18 studies, an exercise dose lasting 70 to 90 minutes has been more favourable than an
42
43 19 exercise dose lasting 20 to 30 minutes. In a narrative review, Lorås et al., 2015 [36], included
44
45 20 four RCTs on the effectiveness of high-dose MET, concluding that high-dose MET was
46
47 21 positive and promising. However, to be able to draw any firm conclusions about the efficacy
48
49 22 of MET for patients with knee OA, rigorous trials are needed on the effect of MET in this
50
51 23 major patient group [58]. Effect trials of cost-effectiveness are also needed as they are
52
53 24 presently lacking in the scientific literature, and the present project has the potential to fill
54
55
56
57
58
59

1 this knowledge gap. It is also important to point out that no exercise protocol is suited to all
2 patients, and as knowledge of early predictors of poor treatment outcomes obtained from
3 longitudinal data is sparse, the development of patient-customized treatments is hindered
4 [59]. According to the Swedish Agency for Health Technology Assessment and Assessment of
5 Social Services (SBU) as well as a recent review [60], prediction studies are needed to be able
6 to better individualize the treatment and match the most promising treatment option to a
7 certain patient profile in order to maximize treatment outcomes and minimize costs.
8 Therefore, we plan to conduct an RCT post-hoc prediction study to gain insights into which
9 patient characteristics predict treatment outcome and which patients benefit more or less
10 from exercise treatments.

11
12 In this trial, the rationale for comparing high dose MET (70-90 minutes) versus low dose MET
13 (20-30 minutes) is that high dose MET should be more effective through an increased
14 activation of the pain modulation systems like the descending pain inhibiting system [51].

15 The evidence is that exercise-induced hypoalgesia is obtained through higher and more
16 intensive exercise doses of 70% of HRR activating the pain modulating systems and
17 decreasing the sensation of pain [61]. However, it has also been shown that an exercise
18 intensity of 50% of HRR is capable of producing an analgesic effect in healthy adults [62],
19 similar exercise intensities used in both high and low dose MET. This could have important
20 implications for the use of exercise in the management of pain, particularly in deconditioned
21 individuals (e.g., older adults with OA of the knee). In 2008 it was shown for the first time
22 that an endurance activity lasting two hours resulted in the production of endogenous
23 neuropeptides (endorphins), creating chemical reactions in brain areas involved in cognitive
24 function and pain modulation, primarily in the prefrontal cortices, insula, and the limbic

1 system [63]. The rationale is that high dose MET exercising for 70 to 90 minutes should
2 result in an increased production of endogenous neuropeptides in the spinal cord, the brain
3 stem, and in the brain, compared to a lower dose MET exercising 20-30 minutes. The
4 hypothesis is that this should result in less pain and improved functioning in favour of the
5 high dose MET therapy.

6 7 **AIM OF THE STUDY**

8 The aim of this project is to prospectively evaluate short- and long-term effects of high-dose
9 MET compared to low-dose MET in patients with X-ray verified knee OA regarding pain,
10 functioning, and cost-effectiveness. A further aim is to conduct a post-hoc analysis on early
11 prognostic factors that predict short- and long-term follow-up outcomes, by targeting
12 patients' early status and patient adherence to the intervention. The long-term goal is to
13 further develop and implement updated knowledge into knee OA rehabilitation to meet the
14 challenge of tomorrow's patients with knee OA pain.

- 15 1. What is the effect of high-dose MET compared to a low-dose exercise therapy (low-dose
16 MET) with respect to self-rated pain, functional limitations, health-related quality of life,
17 depression, and anxiety?
- 18 2. What is the effect of high-dose MET compared to low-dose MET on objective
19 performance measures such as physical functioning of a 20-metre walk, sit to stand, and
20 single knee bends, and pain threshold as determined by a pain-matcher instrument?
- 21 3. What is the cost-effectiveness of MET in patients with knee OA with respect to costs
22 against potential effects (incremental cost-effectiveness ratio, ICER), and cost per
23 quality-adjusted life year (QALY)?

1
2
3 1 4. Which patient characteristics (demographic or disease-related) predict long-term
4
5 2 treatment outcomes with a focus on pain, functional limitation, and health-related
6
7 3 quality of life? What important interaction effects between patient characteristics and
8
9 4 exercise dose may predict treatment outcomes?
10
11
12 5

6 MATERIAL AND METHODS

7 Study design

8 This is a phase three superiority trial of high dose MET versus low dose MET. The trial is
9
10 9 blinded regarding outcome assessment and analyses. It is a two-arm multicentre trial of a
11
12 10 twelve-week exercise intervention with a twelve-month follow-up. Measurements will be
13
14 11 taken at baseline and during the treatment at two weeks (six treatments), four weeks (12
15
16 12 treatments), six weeks (18 treatments), eight weeks (24 treatments), ten weeks (30
17
18 13 treatments), twelve weeks (36 treatments), which is end of treatment, and at follow-up at
19
20 14 26, and 52 weeks after end of treatment. **Primary endpoint is at end of treatment.**
21
22 15 Secondary endpoints are at the 26 and 52 weeks follow-up. The study will conform to
23
24 16 CONSORT guidelines for reporting parallel, randomised trials [64], see Figure 2.
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 [Figure 3 about here]
40

41 Participants

42 18 We are planning to include 200 patients with a diagnosis of symptomatic and radiographic
43
44 19 knee OA who will be recruited from primary and secondary health care settings in Luleå and
45
46 20 Västerвик in Sweden, and in Trondheim and Mosjøen in Norway, named the SWENOR knee
47
48 21 OA study.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 1 *Inclusion criteria:*

4
5 2 Subjects aged 45-85 years, living in the defined geographic areas (Västervik and Luleå
6
7 3 municipalities in Sweden, and Trondheim and Mosjøen in Norway), who have had a
8
9 4 diagnosis of symptomatic and radiographic verified osteoarthritis grade I-III according to
10
11 5 Kellgren and Lawrence [65, 66], with at least three months pain duration, and decreased
12
13 6 functioning. The patient is willing to participate in a twelve-week intervention period with
14
15 7 three sessions each week

16
17
18
19 8 *Exclusion criteria:*

20
21 9 Physiotherapy or other conservative therapy during the previous three months or a history
22
23 10 of major knee trauma such as knee fractures or ligament ruptures. Inflammatory joint
24
25 11 disease, hip symptoms more aggravating than the knee symptoms, scheduled to have knee
26
27 12 replacement surgery within six months, and co-morbidities not allowing exercise such as
28
29 13 cardiovascular, respiratory, systemic, or metabolic conditions limiting exercise tolerance.
30
31
32
33
34

35 15 **Procedure**

36
37 16 Before intervention starts, regular visits will be made to each intervention place by the first
38
39 17 author (TAT), informing and communicating with the local research team about the aims and
40
41 18 run of the study. Detailed description of the different stages of the study from recruitment,
42
43 19 treatment, and follow-up assessments after the end of the intervention period will be
44
45 20 instructed and discussed. Physiotherapists in charge of the objective clinical testing (two in
46
47 21 Västervik, one in Luleå, two in Trondheim and two in Mosjøen), otherwise not involved in
48
49 22 the treatment, will be educated theoretically and practically on how these tests should be
50
51 23 performed. The physiotherapists delivering the exercise intervention (two in Västervik, one
52
53 24 in Luleå, two in Trondheim and two in Mosjøen) will, in addition, have structured theoretical
54
55
56
57
58
59
60

1 and practical sessions on how to apply and grade the exercise therapies. A study nurse at
2 each intervention place is in charge of randomization, questionnaires, and the scheduling of
3 patients for treatments and assessments. Each of the four intervention centres has a local
4 administration officer.

5
6 A data security monitoring plan is conducted by the current investigator monitoring the
7 present pragmatic trial. Tom Arild Torstensen (TAT) will visit the four centres from the
8 planning phase of the trial, during the treatment phase, and during the follow up phase in
9 order to monitor that the protocol is followed. Adverse and SAEs are reported to the ethics
10 committee.

11
12 Recruitment will be achieved through referrals from medical doctors in primary and
13 secondary health care clinics. The local investigator at each study centre will contact medical
14 doctors (MDs) and send written information about the study. The first screening is
15 performed by a MD and a second screening is performed by one of the treating
16 physiotherapists. Both the MD and the physiotherapist guarantee the radiographic inclusion
17 criteria.

18
19 Patients will receive oral and written information about the study, and after signing an
20 informed consent form, they will be assessed for eligibility by physiotherapists at each
21 intervention centre. Participants initially fill out questionnaires for baseline data and
22 perform the physical performance tests. Each patient is then randomized, as described
23 below, to either high or low dose medical exercise therapy.

24

1
2
3 1 *Data collection and management.*

4
5 2 Data from the questionnaires will be depersonalised at each intervention centre by the local
6
7 3 research assistant. In order to transfer data from Norway to Sweden, a data transfer
8
9 4 agreement (DTA) between Norges Teknisk-Naturvitenskapelige Universitet
10
11 5 (NTNU)/Norwegian University of Science and Technology and Karolinska Institutet, (KI/NVS),
12
13 6 has been set up. The questionnaires from the Swedish centres are posted to Karolinska
14
15 7 Institutet where data is registered on digital sheets. In Norway, questionnaires from
16
17 8 Mosjøen are posted to Trondheim where all questionnaires from the two Norwegian centres
18
19 9 are registered on sheets and delivered to Karolinska Institutet according to DTA; Tom Arild
20
21 10 Torstensen, Björn Äng, and Wilhelmus Grooten are in charge of the data synthesis and
22
23 11 analysis
24
25
26
27
28
29

30 13 *Post-recruitment retention and compliance strategies*

31
32 14 Our experiences of MET as an experimental intervention (HØ and TAT) [38, 40-48] leads to
33
34 15 the following retention and compliance strategies to be applied in this study.

- 35
36
37
38 16 • An independent study nurse at each intervention centre will always be available to
39
40 17 answer questions when patients are filling out the questionnaires
41
42 18 • This is important to avoid any unnecessary misunderstandings regarding the content
43
44 19 of the questionnaire and to make sure that patients understand that all information
45
46 20 will be depersonalized.
47
48 21 • During the interventions, the treating physiotherapist is present the whole time in
49
50 22 the exercise room answering questions from patients and re-grading the exercises
51
52 23 according to changes in patients' exercise status and knee-OA symptoms.
53
54 24 Participants are not informed about the hypothesis of the study.
55
56
57
58
59
60

- 1
- 2
- 3 1 • At inclusion and at the end of the 12-week intervention period the patient is
- 4
- 5 2 informed by the local administration nurse about the six- and 12-month follow-ups.
- 6
- 7 3 • During the post-intervention follow-ups, the patient will be contacted three weeks
- 8
- 9 4 prior to the assessment and informed when to come to the intervention site for
- 10
- 11 5 the planned post treatment evaluation.
- 12
- 13
- 14

15 6 During the intervention period, KOOS and the eight different VAS scales are assessed

16

17 7 after every sixth treatment meaning after two-, four-, six-, eight-, ten-, and 12 weeks

18

19 8 giving a total of six assessments. The purpose of such repeated measurements is to

20

21 9 obtain a reasonable measurement accuracy of both functioning status and pain during

22

23 10 the twelve-week intervention period. The primary end-point will be on completion of

24

25 11 the intervention after 36 treatments, which will take an average of twelve weeks. This

26

27 12 is to obtain evaluation of effects on organized exercise therapy related with its direct

28

29 13 implementation, while further follow-ups evaluate its retention effects. At this point

30

31 14 primary and secondary outcomes are assessed.

32

33

34

35

36

37

38 16 **Randomization procedure**

39

40 17 In this individual randomized trial, a stratified allocation by age and intervention centre is

41

42 18 used, using a computerized program, where the goal is to get an equal number of patients

43

44 19 between the ages of 45 and 64 years and 65 and 85 years at each of the four intervention

45

46 20 centres. The randomization key is concealed at each intervention place and kept under lock

47

48 21 by a research assistant not involved with the assessment or interventions.

49

50

51

52

53

54

55

56

57

58

59

60

1 **Blinding procedures**

2 The physiotherapists conducting the physical performance tests are blinded to an allocation
3 group and the study participants are instructed by the treating physiotherapists not to reveal
4 details of their intervention during testing. The principal investigators (BÄ), the assistant
5 principal investigator (TAT), and the research assistants are also blinded to groups when
6 entering data to data-sheets, i.e. they do not know which patient has received high-dose or
7 low-dose MET. The group key will be opened after the analyses have been finalised and the
8 results have been written up in a manuscript (using intervention A and B until results have
9 been written).

10

11 **Interventions**

12 All participants receive an MET intervention, where they are treated in groups of four or five
13 in sessions lasting 20 to 90 minutes. During the sessions, they are supervised by an
14 experienced physiotherapist in an outpatient clinic. All participants are treated three times a
15 week for twelve weeks, giving a total of 36 treatments. Each patient in the group has an
16 individualized exercise program tailored to their specific clinical symptoms and functional
17 level. As the treatment proceeds, exercises are adapted according to changes in symptoms
18 and functioning. The pain experience when exercising should not exceed a three on a zero to
19 ten scale, where zero is no pain and ten is the worst imaginable pain [34]. Specially designed
20 exercise equipment consisting of different forms of pulleys, exercise benches, dumbbells,
21 and barbells is used to grade and dose the exercises to be pain free or close to pain free,
22 with the purpose of mitigating peripheral and central sensitization while exercising [36]. The
23 difference between groups regarding exercise dose is outlined below in Table 1.

24

Table 1: Differences between the high-dose and low-dose MET regarding number of exercises, sets, and repetitions. Difference in time, performing global exercises and total time duration for each treatment.

	Number of exercises	Number of sets	Number of repetitions	Time performing global exercise	Time duration of treatment
High dose MET	9	3	30	20 min+10 min +10 min	70-90 min
Low dose MET	5	2	10	10 min	20-30 min

The grading of the exercises, including baseline settings, is based on the initial clinical assessment by the treating physiotherapist. From the patients' past and present histories and physical clinical assessment, information is gained about the level of pain and possible sensitization (local versus central sensitization), range of motion, and tolerance for weight bearing within the available range of motion of the knee. This information is used for baseline setting of the exercises where the physiotherapist chooses a starting position, a range of motion, and a weight resistance believed to match the patient's ability to perform three sets of 30 repetitions (high dose MET) and two sets of ten repetitions (low dose MET), pain-free or close to pain-free. Then there is a test of each exercise where the physiotherapist asks the patient to do as many repetitions as the patient can manage. When the patient reaches ten repetitions the test is stopped and the patient has to evaluate if the weight/loading (L), starting position (SP), or range of motion (ROM) is appropriate to reach a total of 40 repetitions. Any of the above mentioned variables (L, SP, ROM), can be changed to reach 40 repetitions, making it possible to perform 30 repetitions in sets of three with a 30- to 60-second pause between each. The same test procedure is used for the low dose

1 group where the goal is a test of 15 repetitions making it possible to do two sets of 10
2 repetitions. At baseline setting, there is a continuous evaluation in the exercise room where
3 the physiotherapist and the patient is working towards optimal exercise dose for each
4 exercise, as is usually done in clinical practice [36]
5
6 It should also be possible for the patient to perform the exercise comfortably within the
7 preferred active range of active motion (AROM). For example, if a part of the AROM in the
8 knee joint is painful, the patient starts to exercise within the pain-free or close to pain-
9 free AROM. As the treatment proceeds, the AROM is adjusted, making the patient exercising
10 in a larger and more functional AROM. If it is not possible to grade the exercise pain-free or
11 close to pain-free, the patient is allowed to exercise with pain. When exercising with pain it
12 is important that the pain experience dose not cause any anxiety or fear. The pain has to be
13 experienced as meaningful for improvement [67]. If the exercise therapy results in an acute
14 increase in pain, the pain should have returned to baseline before the next treatment
15 session commences. If pain does not go back to the prior level, exercises are reassessed,
16 with the most comfortable exercise performed several times, preferably deloaded knee
17 extension and stationary. The group of four to five patients also contains patients with other
18 diagnoses, who are not participating in this study, making the delivery of the MET
19 intervention pragmatically similar to a real life situation. To be able to monitor the exercise
20 dose, the treating physiotherapists follow a structured progression plan of the exercises, and
21 fill in a treatment log for each patient at each treatment, see appendix number one –
22 progression plan for high dose MET, and appendix number two – progression plan for low
23 dose MET. The log contains information about the number of exercises, duration of each
24 global exercise, number of repetitions, and sets and weight resistance applied for semiglobal

1 and local exercises. Figure two shows the main exercises from the two different exercise
2 interventions compared in this planned randomized trial: high dose MET versus low dose
3 MET.

4 **[Figure 2 about here]**

5 To be able to reach a high number of repetitions despite on-going pain, the principle of de-
6 loading is applied, facilitating a high number of repetitions that are nearly or entirely pain
7 free, see figure 1. For the high-dose MET, the deloaded knee extension is performed twice
8 during a treatment, each time for a five-minute duration. This exercise and the cycling in the
9 middle of each treatment session is a form of restitution, making it easier to both perform
10 the deloaded closed chain exercises and endure the high dose MET. Later, as the patient
11 improves and can tolerate increased loading, the exercises are adapted to be more
12 functional, using closed chain exercises without deloading the body weight.

13
14 To further increase the exercise dose for the high dose MET group patients perform one
15 home exercise - the seated deloaded knee extension with a yellow tube theraband. The
16 exercise is similar to exercise number three, see Figure two. They perform this home
17 exercise once every day, where the dose is three lots of three minutes with a 30- to 60-
18 second pause between each set. The treating physiotherapists make sure that the patients
19 are compliant in doing their home exercises. Patients in the low dose MET receive no home
20 exercises.

21 **Baseline data**

22
23 The following data will be obtained by questionnaire; gender, age, height, weight, physical
24 activity and exercise levels, living arrangement, education level, employment status,

1 **Table 2. Study measures to be collected**

2

Baseline measures and outcomes	Description and instrument	Data source	Collection points
Patient's characteristics	Date of birth, gender, BMI (height, weight) social and living status, leisure activities, level of physical activity, smoking, medicine, sleep, co-morbidities, anxiety and depression, catastrophizing, life satisfaction, kinesiophobia	SAQ	t0
Primary outcome measure	Clinical Outcomes		
Pain	KOOS: subscale pain	SAQ	t0, t2, t4, t6, t8, t10, t12, t26, t52
Other symptoms	KOOS: subscale other symptoms	SAQ	t0, t2, t4, t6, t8, t10, t12, t26, t52
Function	KOOS: subscale physical functioning	SAQ	t0, t2, t4, t6, t8, t10, t12, t26, t52
Sport, recreation	KOOS: subscale sport and recreation	SAQ	t0, t2, t4, t6, t8, t10, t12, t26, t52
Secondary outcome measures	Clinical Outcomes		
	VAS (100mm scale): pain	SAQ	t0, t2, t4, t6, t8, t10, t12, t26, t52
	VAS (100mm scale): knee pain not loading	SAQ	t0, t2, t4, t6, t8, t10, t12, t26, t52
	VAS (100 mm scale): pain at weight bearing	SAQ	t0, t2, t4, t6, t8, t10, t12, t26, t52
	VAS (100 mm scale): knee pain at night	SAQ	t0, t2, t4, t6, t8, t10, t12, t26, t52
	Physical functioning		
	20 m walk test	PT	t0, t12
	Chair stand test	PT	t0, t12
	Unilateral knee bending	PT	t0, t12
	Pain threshold and tolerance		
	Pain Matcher	Pain matcher apparatus	t0, t12
	Quality of life		
	(EQ-5D-5L)	SAQ	t0, t12, t26, t52
	(SF-36)	SAQ	t0, t12, t26, t52
	Life satisfaction		
	Life Satisfaction Questionnaire (LISAT)	SAQ	t0, t12, t26, t52
	Psychological outcomes		
	Anxiety and depression (HAD),	SAQ	t0, t12, t26, t52
	Catastrophizing (Pain Catastrophizing Scale)	SAQ	t0, t12, t26, t52
	Kinesiophobia (TSK)	SAQ	t0, t12, t26, t52
	Beliefs and attitude towards exercise		
	Self-efficacy for exercise (SEE)	SAQ	t0, t12, t26, t52
	Outcome Expectancy for Exercise Scale (OEE)	SAQ	t0, t12, t26, t52

Data source: Self-administered questionnaire (SAQ), physical testing (PT). Collection points: t0=inclusion, t1-t12= measurement every second week during the 12 week intervention period, t1=2 weeks, t2= 4 weeks, t3= 6 weeks, t4= 8 weeks, t5= 10 weeks, t6= 12 weeks (end of inclusion), t26= 6 months follow up, t52= 12 months follow up. Questionnaires: The Knee Injury and Osteoarthritis Scale (KOOS), Life Satisfaction Questionnaire (LISAT), Hospital Anxiety and Depression Scale (HAD), Pain Catastrophizing Scale (PCS), Tampa Scale of Kinesiophobia (TSK), Self-efficacy for exercise (SEE) and Outcome Expectancy for Exercise Scale (OEE)

3

4

1 possible medication, co-morbidities, smoking habits, sleeping habits, pain and function of
2 the knee, catastrophizing thoughts, fear avoidance beliefs, level of anxiety and depression,
3 life satisfaction and quality of life, and beliefs about exercise. A schematic presentation of
4 the outcome measures recorded at baseline and at the follow-ups is presented in Table 2.
5 Each assessment, which involves filling out questionnaires, will take approximately one hour.
6 The objective testing of the knee and the testing with the PainMatcher apparatus takes
7 approximately 30 minutes and will occur the following day.

8

9 **Primary outcome measures**

10 In accordance with international consensus regarding the core set of outcome measures for
11 clinical trials in OA [68], self-rated functioning and pain scoring (The Knee Injury and
12 Osteoarthritis Outcome Score, KOOS) [69-72] is used as primary outcome measures. KOOS
13 consists of 5 subscales; Pain, other Symptoms, Functioning in daily living (ADL), Functioning
14 in sport and recreation (Sport/Rec), and knee-related Quality of life (QOL). Standardized
15 answer options are given (5 Likert boxes) and each question is assigned a score from 0 to 4.
16 A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is
17 calculated for each subscale. For the purpose of an RCT, KOOS subscale scores can be
18 aggregated and averaged as the primary outcome. We are planning to use KOOS at several
19 time-points; at baseline, and during the intervention period until the final follow-up at 52
20 weeks, see Table 2.

21

22 **Secondary outcome measures**

23 As a secondary outcome measure, there are eight different pain measurements using a 100
24 mm visual analogue scale (VAS) [73], with terminal descriptors of “no pain” and “worst pain”

1 asking about how painful the knee is, 1) today and 2) on average during the last week,
2 related to the following four different life situations; 1) how painful is your knee, 2) how
3 painful is your knee when loading your knee (e.g. walking or standing), 3) how painful is your
4 knee when not loading your knee (e.g. sitting, lying), 4) how painful is your knee at night
5 when you are sleeping (e.g. knee pain that disturbs your sleep).

6 Data on health related to quality of life are collected using the EQ 5-D questionnaire [74] and
7 the SF-36 questionnaire [75]. These questionnaires will also be used to perform a health
8 economic evaluation of the exercise interventions. Psychological factors such as anxiety and
9 depression, catastrophizing, and fear-avoidance beliefs are believed to both predict
10 outcome of an intervention [76] as well as influence the level of pain in patients with knee
11 OA experience [77]. In this study, anxiety and depression are rated using the Hospital
12 Anxiety and Depression Scale (HAD) [78], catastrophizing is rated using the Pain
13 Catastrophizing Scale (PCS) [79], and fear avoidance beliefs [80] are rated using the Tampa
14 Scale of Kinesiophobia (TSK) [81], see Table 2. Life satisfaction is assessed using the Life
15 Satisfaction (LISAT) questionnaire by Fugl-Meyer [82]. Beliefs and attitudes towards exercise
16 are rated using the Self-Efficacy for Exercise Scale (SEE) [83], and the patient's expectations
17 of performing physical activity are rated using the Outcome Expectations for Exercise Scale
18 (OEE) [84]. PainMatcher apparatus [85] (Cefar Medical AB, Lund, Sweden) is used to record
19 sensory level, pain level, and pain tolerance level. Pressing the thumb and first finger against
20 a button on each side of the hand held PainMatcher apparatus; an electrode under each
21 button activates an electrical current. As long as the pressure is kept against the buttons, the
22 electrical current will slowly increase where the first sensation of the current is a
23 measurement of sensory threshold. As the pressure is maintained, the electrical current
24 slowly increases, and the sensation will turn into a pain sensation (pain threshold). Keeping

1 the pressure on the buttons, the painful electrical current increases, and pain tolerance is
2 recorded, i.e. the measure of how much painful electrical current the patient can endure.
3 Performance tests include the 20-meter walk test [86], first at a self-selected pace and then
4 at maximum pace, 30-second maximum number of chair to standing test [87], and 30-
5 second maximum number of repeated unilateral knee bends [86, 88]. Other measurements,
6 logged by the supervising therapist, are recordings of compliance of the exercise treatments
7 during the twelve-week intervention also including a recording of exercise dose (weights,
8 sets, repetitions, and treatment time) at each treatment occasion. Over the whole project
9 period, from inclusion to end of the 52-week follow-up, any adverse effects are to be noted
10 and reported.

12 **Statistical analysis**

13 In the statistical analyses of both primary and secondary outcomes, the principle of intention
14 to treat will be used, comparing high-dose MET with low-dose MET. Within-group and inter-
15 group statistical testing will be carried out using general linear model where an alpha level of
16 0.05 will be used where appropriate. Significance of main or interaction effects will be
17 explored using follow-up post hoc tests. Effect size Cohen's *d* will aid clinical interpretation
18 of the magnitude of treatment effect, where effect-size values below 0.2 will be considered
19 small, 0.5 medium, and 0.8 large. The primary end-point is at the end of the twelve-week
20 intervention period and potential baseline differences will be considered by adding
21 additional baseline variables as covariates to the statistical models. Potential floor or ceiling
22 effects will be computed and considered in our analyses. Because participants of both
23 interventions of both intervention groups are treated together with other patients in MET
24 groups, the treatment credibility and outcome expectations (OEE) will be evaluated as a

1 potential co-variate or confounder for treatment effects.

2

3 Analysis of cost-effectiveness will be performed using the incremental cost-effectiveness
4 ratio (ICER), in order to provide a single measure for weighing costs against benefits of
5 health care interventions. Cost per quality-adjusted life year (QALYs [89]), using data from
6 EQ-5D and SF-36, will be added. In the predictive analyses, multivariable logistic regressions
7 (e.g. GEE) will be used to estimate the association between potential predictors and
8 outcomes. A purposeful selection procedure is planned resulting in a final model that
9 contains only significant independent variables, identified confounders and interactions. All
10 final models will be examined for goodness-of-fit and accuracy according to established
11 methods.

12

13 **Sample size**

14 The power calculation was based on proportions that can document a minimal clinical
15 important change (MCIC). The primary outcome the Osteoarthritis Outcome Score (KOOS) is
16 a numerical scale ranging from 0 (maksimal problem) to 100 (no problem). A change of ten
17 points is evaluated as a clinically interesting change [70]. The hypothesis is that 40% of the
18 patients receiving high-dose MET and 20% of the patients receiving low-dose MET will
19 obtain a ten-point improvement after end of treatment at the three-month follow-up. The
20 power calculation showed that 82 patients are needed in each arm to reach 80% between-
21 group power. With a hypothetical drop out of the study of 20% the total sample is
22 $82 \times 2 \times 1.2 = 197$ patients. We plan to include 200 patients giving each exercise intervention
23 group a total of 100 participants.

24

1 ETHICS AND DISSEMINATION

2 The guidelines from the Helsinki declaration will be followed and the protocol has been
3 reviewed by the Regional Ethics Review Board in Stockholm. Some relevant ethical
4 considerations related to this study are mentioned below:

6 *The infliction of pain*

7 An often overlooked ethical issue is the infliction of pain when instructing patients to
8 exercise [32]. Knee OA is commonly a painful condition and it is questionable if it is ethical to
9 push patients through the painful exercise regimens included in the approach that today is
10 recommended for treating knee OA. A worst-case scenario for this type of treatment is
11 pushing the patient into endurance behaviour that in itself may result in long-term pain [90].
12 However, in this study, the focus on grading the exercises pain free or close to pain free
13 resolves, to some extent, this problem.

14 *The problem of large exercise dosage*

15 Asking patients to exercise for 70 to 90 minutes three times a week for twelve weeks may be
16 ethically questionable. However, such doses of exercise therapy have been shown to be
17 effective in patients with depression [91] and there is an argument today that both exercise
18 dose and exercise intensity should be increased for patients suffering from heart disease or
19 a metabolic syndrome, respectively [92]. The high compliance with a relatively extensive
20 exercise programme is possible because patients with chronic (or progressed) conditions
21 commonly prioritize rehabilitation to maintain (or improve) good functioning. Thus, it is a
22 need to investigate if a similar high dose of exercise therapy is effective for patients with
23 knee OA. It is also of high relevance to study whether a less time-consuming exercise

1 programme, such as the low-dose MET in the present study, results in similar effects
2 including effects on costs.

3

4 **DISCUSSION**

5 We believe one important strength of this study is the use of self-paced exercises, grading
6 the exercises pain-free or close to pain-free [49]. Research has shown that when patients are
7 asked to self-select their exercise intensity, they choose an intensity that results in a positive
8 affective response making them more motivated to do the exercise. This seems to be the
9 case for both populations without pain [93] and patients suffering from a painful condition
10 [94]. The use of a self-paced approach, exercising pain-free or close to pain-free may – we
11 believe - decreases the probability of patients dropping out of the study due to adverse
12 effects such as uncomfortable painful experiences [49, 94], which minimizes possible nocebo
13 effects [20], and breaks the vicious circle of knee pain [36]

14

15 To decrease negative affective experiences from exercising, MET applies the principle of
16 deloading, where the application of different types of exercise equipment deloads some of
17 the body weight or the weight of the lower extremity. This is also the case for aquatic
18 exercise therapy where the buoyancy of the water decreases compressive forces on the
19 knee joint. However, aquatic exercises do not seem to be superior to land-based exercises
20 [95], making a call for further research into dose-response effects from exercise therapy.

21

22 In an extensive review by Pedersen and Saltin [96], it was concluded that there is evidence
23 for prescribing exercise as a therapy for 26 different chronic diseases. In addition, there is
24 increasing evidence that a higher dose of exercise is more effective than a lower dose in

1 patients with long-term subacromial pain [47] and long-term anterior knee pain [40],
2 patients suffering from depression [91], and patients suffering from a metabolic syndrome
3 [92]. A high dose of exercise has a greater effect on heart function [97] and a greater
4 positive impact on mood states and quality of life [98] in patients suffering from heart
5 failure.

6
7 In terms of knee OA, however, the evidence level of exercise dose is poor [25, 26, 35, 96, 99,
8 100]. In a recent systematic review [26] only five studies that compared high-intensity versus
9 low-intensity physical activity were included. Of these five studies, there is only one study
10 [30] that is in any way similar to this planned study. The study [30] compared high-intensity
11 versus low-intensity cycle ergometry in older adults with knee OA. Both groups cycled for 25
12 minutes three times a week for 10 weeks. The high dose high intensity group cycled with an
13 intensity of 70% of HRR and the low dose low intensity group with an intensity of 40% of
14 HRR. After the end of the intervention period both groups had improved significantly on all
15 outcome measures but there were no differences between groups. Juhl and colleagues [100]
16 argue that an optimal exercise program for knee OA should focus on improving quadriceps
17 strength and aerobic capacity, as well as improving performance in the lower extremities.
18 Exercise programmes should be supervised and carried out three times a week. They also
19 argue that there is a great need to further investigate the effects of differing exercise doses
20 and that the interventions in such studies are described in detail with regard to intensity,
21 length of program, total number of supervised sessions, duration of individual supervised
22 sessions, and number of sessions per week.

23

1 To our knowledge, this study is the first to investigate, in a controlled manner, if an exercise
2 dose lasting 70-90 minutes is superior in terms of improvements in functioning and pain to a
3 lower dose of exercise therapy lasting 20 to 30 minutes in patients with knee OA.
4

5 **CONTRIBUTORSHIP STATEMENT**

6 Torstensen TA, Grooten WJA, Østerås H, Heijne A,-Harms-Ringdahl K and Äng B, have all
7 actively participated in the planning and design of the study as well as the writing of this
8 manuscript describing the research protocol of the study. Principle investigator in Sweden is
9 Björn Äng and in Norway Havard Østerås. Tom Arild Torstensen is the assistant principle
10 investigator for the study.
11

12 **COLLABORATORS**

13 The authors would like to acknowledge the following colleagues:

14 *Monitoring the study:*

15 The following colleagues are monitoring the study at respective intervention centre; In

16 Västervik, Nisse Wallberg PT, in Luleå Mikael Sjöström PT, in Trondheim Håvard Østerås
17 M.Sc PT and in Mosjøen Morten A Romslo PT.

18 *Assessment and treatment of patients:*

19 in Mosjøen (Norway), Morten Andre Romslo PT (MSc) and Iselind Thoresen PT, in Trondheim
20 (Norway) Lasse Haugerud PT and Håvard Østerås M.Sc PT, in Luleå (Sweden) Mikael
21 Sjöström PT, and in Västervik (Sweden) Nisse Wallberg PT and Thomas Aupers PT.

22 *Objective functional testing:*

1 In Mosjøen (Norway) Stine Krogh Dagsvik PT and Marte Nystad Glad PT, in Trondheim
2 (Norway) Maria Sommervold PT and Lisa Lid PT, in Luleå (Sweden) Peter Wallström PT and in
3 Västerwik (Sweden) Erik Sjöstedt PT and Fanny Ek Nordén PT.

4 *Local study nurse handling questionnaires and in charge of the randomization procedure*

5 *locally and informing patients about follow up assessments:*

6 In Mosjøen (Norway) Elin Slänsby and Lena Aufles, in Trondheim (Norway) Beate Iversen, in
7 Luleå (Sweden) Katarina Söderholm, and in Västerwik (Sweden) Marita Johansson.

8

9 **COMPETING INTERESTS**

10 I have read and understood the BMJ Group policy on declaration of interests and declare the
11 following interests:

12 Name: Tom Arild Torstensen, Date: 2017-06-30

13 Declaration of interests: Teaches courses and seminars in medical exercise therapy

14 Name: Grooten WJA, Date: 2017-06-30

15 Declaration of interests: None

16 Name: Østerås H, Date: 2017-06-30

17 Declaration of interests: None

18 Name: Heijne A, Date: 2017-06-30

19 Declaration of interests: None

20 Name: Harms-Ringdahl K, Date: 2017-06-30

21 Declaration of interests: None

22 Name: Äng BO, Date: 2017-06-30

23 Declaration of interests: None

24

1
2
3 **1 FUNDING STATEMENT:**

4
5 2 This work is supported by the Swedish Rheumatology Association and Karolinska Institutet
6
7 3 funds, which cover a part of the economical resources. None of the funders have had any
8
9 4 influence in developing the protocol or any other part of the study, their role has been
10
11 5 strictly financial.
12
13
14 6

15
16 **7 FIGURE CAPTIONS**

17
18
19 **8 Figure 1:** The principle of deloading performing a local knee exercise.
20
21 9

22
23 **10 Figure 2:** The two different exercise interventions compared in this randomized trial, high
24
25 11 dose MET (HDMET) and low dose MET (LDMET).
26
27
28 12

29
30 **13 Figure 3.** Flow chart of the design and run of the study. HDMET= High-dose MET
31
32 14 and LDMET= Low-dose MET.
33
34
35 15
36
37 16
38
39
40 17
41
42 18
43
44 19
45
46 20
47
48 21
49
50 22
51
52 23
53
54 24
55
56 25

1 REFERENCES

1. Nguyen, U.S., et al., *Increasing prevalence of knee pain and symptomatic knee osteoarthritis: survey and cohort data*. Ann Intern Med, 2011. **155**(11): p. 725-32.
2. Johnson, V.L. and D.J. Hunter, *The epidemiology of osteoarthritis*. Best Pract Res Clin Rheumatol, 2014. **28**(1): p. 5-15.
3. Cross, M., et al., *The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study*. Ann Rheum Dis, 2014. **73**(7): p. 1323-30.
4. Dieppe, P.A. and L.S. Lohmander, *Pathogenesis and management of pain in osteoarthritis*. Lancet, 2005. **365**(9463): p. 965-73.
5. March, L.M. and C.J. Bachmeier, *Economics of osteoarthritis: a global perspective*. Baillieres Clin Rheumatol, 1997. **11**(4): p. 817-34.
6. Holt, H.L., et al., *Forecasting the burden of advanced knee osteoarthritis over a 10-year period in a cohort of 60-64 year-old US adults*. Osteoarthritis Cartilage, 2011. **19**(1): p. 44-50.
7. Murphy, L., et al., *Lifetime risk of symptomatic knee osteoarthritis*. Arthritis Rheum, 2008. **59**(9): p. 1207-13.
8. Laxafoss, E., et al., *Case definitions of knee osteoarthritis in 4,151 unselected subjects: relevance for epidemiological studies: the Copenhagen Osteoarthritis Study*. Skeletal Radiol, 2010. **39**(9): p. 859-66.
9. Silverwood, V., et al., *Current evidence on risk factors for knee osteoarthritis in older adults: a systematic review and meta-analysis*. Osteoarthritis Cartilage, 2015. **23**(4): p. 507-15.
10. Risberg, M.A., et al., *Changes in Knee Osteoarthritis, Symptoms, and Function After Anterior Cruciate Ligament Reconstruction: A 20-Year Prospective Follow-up Study*. Am J Sports Med, 2016. **44**(5): p. 1215-24.
11. Roemer, F.W., et al., *Increased risk for radiographic osteoarthritis features in young active athletes: a cross-sectional matched case-control study*. Osteoarthritis Cartilage, 2015. **23**(2): p. 239-43.
12. Pereira, D., et al., *The effect of osteoarthritis definition on prevalence and incidence estimates: a systematic review*. Osteoarthritis Cartilage, 2011. **19**(11): p. 1270-85.
13. Iannetti, G.D. and A. Mouraux, *From the neuromatrix to the pain matrix (and back)*. Exp Brain Res, 2010. **205**(1): p. 1-12.
14. Arendt-Nielsen, L., *Joint pain: more to it than just structural damage?* Pain, 2017. **158 Suppl 1**: p. S66-S73.
15. Gold, M.S. and G.F. Gebhart, *Nociceptor sensitization in pain pathogenesis*. Nat Med, 2010. **16**(11): p. 1248-57.
16. Fingleton, C., et al., *Pain sensitization in people with knee osteoarthritis: a systematic review and meta-analysis*. Osteoarthritis Cartilage, 2015. **23**(7): p. 1043-56.
17. Tornbjerg, S.M., et al., *Structural pathology is not related to patient-reported pain and function in patients undergoing meniscal surgery*. Br J Sports Med, 2017. **51**(6): p. 525-530.
18. Thorstensson, C.A., et al., *Natural course of knee osteoarthritis in middle-aged subjects with knee pain: 12-year follow-up using clinical and radiographic criteria*. Ann Rheum Dis, 2009. **68**(12): p. 1890-3.


19. Campbell, C.M., et al., *Sleep, Pain Catastrophizing, and Central Sensitization in Knee Osteoarthritis Patients With and Without Insomnia*. Arthritis Care Res (Hoboken), 2015. **67**(10): p. 1387-96.
20. Colloca, L. and F. Benedetti, *Nocebo hyperalgesia: how anxiety is turned into pain*. Curr Opin Anaesthesiol, 2007. **20**(5): p. 435-9.
21. Frisaldi, E., A. Piedimonte, and F. Benedetti, *Placebo and nocebo effects: a complex interplay between psychological factors and neurochemical networks*. Am J Clin Hypn, 2015. **57**(3): p. 267-84.
22. Benedetti, F., et al., *The biochemical and neuroendocrine bases of the hyperalgesic nocebo effect*. J Neurosci, 2006. **26**(46): p. 12014-22.
23. Cruz-Almeida, Y., et al., *Psychological profiles and pain characteristics of older adults with knee osteoarthritis*. Arthritis Care Res (Hoboken), 2013. **65**(11): p. 1786-94.
24. Herbert, M.S., et al., *Pain hypervigilance is associated with greater clinical pain severity and enhanced experimental pain sensitivity among adults with symptomatic knee osteoarthritis*. Ann Behav Med, 2014. **48**(1): p. 50-60.
25. Fransen, M., et al., *Exercise for osteoarthritis of the knee: a Cochrane systematic review*. Br J Sports Med, 2015. **49**(24): p. 1554-7.
26. Regnaud, J.P., et al., *High-intensity versus low-intensity physical activity or exercise in people with hip or knee osteoarthritis*. Cochrane Database Syst Rev, 2015(10): p. CD010203.
27. Ageberg, E. and E.M. Roos, *Neuromuscular exercise as treatment of degenerative knee disease*. Exerc Sport Sci Rev, 2015. **43**(1): p. 14-22.
28. Knoop, J., et al., *Knee joint stabilization therapy in patients with osteoarthritis of the knee: a randomized, controlled trial*. Osteoarthritis Cartilage, 2013. **21**(8): p. 1025-34.
29. Latham, N. and C.J. Liu, *Strength training in older adults: the benefits for osteoarthritis*. Clin Geriatr Med, 2010. **26**(3): p. 445-59.
30. Mangione, K.K., et al., *The effects of high-intensity and low-intensity cycle ergometry in older adults with knee osteoarthritis*. J Gerontol A Biol Sci Med Sci, 1999. **54**(4): p. M184-90.
31. Henriksen, M., et al., *Experimental knee pain reduces muscle strength*. J Pain, 2011. **12**(4): p. 460-7.
32. Liu, C.J. and N. Latham, *Adverse events reported in progressive resistance strength training trials in older adults: 2 sides of a coin*. Arch Phys Med Rehabil, 2010. **91**(9): p. 1471-3.
33. Bartholdy, C., et al., *The role of muscle strengthening in exercise therapy for knee osteoarthritis: A systematic review and meta-regression analysis of randomized trials*. Semin Arthritis Rheum, 2017. **47**(1): p. 9-21.
34. Henriksen, M., et al., *Association of exercise therapy and reduction of pain sensitivity in patients with knee osteoarthritis: a randomized controlled trial*. Arthritis Care Res (Hoboken), 2014. **66**(12): p. 1836-43.
35. Hurley, M.V., H.L. Mitchell, and N. Walsh, *In osteoarthritis, the psychosocial benefits of exercise are as important as physiological improvements*. Exerc Sport Sci Rev, 2003. **31**(3): p. 138-43.
36. Loras, H., et al., *Medical Exercise Therapy for Treating Musculoskeletal Pain: A Narrative Review of Results from Randomized Controlled Trials with a Theoretical Perspective*. Physiother Res Int, 2015. **20**(3): p. 182-90.

- 1 37. Crombez, G., et al., *Pain-related fear is more disabling than pain itself: evidence on*
2 *the role of pain-related fear in chronic back pain disability.* Pain, 1999. **80**(1-2): p.
3 329-39.
- 4 38. Torstensen, T.A., H.D. Meen, and M. Stiris, *The effect of medical exercise therapy on*
5 *a patient with chronic supraspinatus tendinitis. Diagnostic ultrasound--tissue*
6 *regeneration: a case study.* J Orthop Sports Phys Ther, 1994. **20**(6): p. 319-27.
- 7 39. Torstensen, T.A., et al., *Efficiency and costs of medical exercise therapy,*
8 *conventional physiotherapy, and self-exercise in patients with chronic low back*
9 *pain. A pragmatic, randomized, single-blinded, controlled trial with 1-year follow-*
10 *up.* Spine (Phila Pa 1976), 1998. **23**(23): p. 2616-24.
- 11 40. Osteras, B., H. Osteras, and T.A. Torstensen, *Long-term effects of medical exercise*
12 *therapy in patients with patellofemoral pain syndrome: results from a single-*
13 *blinded randomized controlled trial with 12 months follow-up.* Physiotherapy,
14 2013. **99**(4): p. 311-6.
- 15 41. Osteras, B., et al., *Dose-response effects of medical exercise therapy in patients with*
16 *patellofemoral pain syndrome: a randomised controlled clinical trial.*
17 Physiotherapy, 2013. **99**(2): p. 126-31.
- 18 42. Osteras, H., *A 12-week medical exercise therapy program leads to significant*
19 *improvement in knee function after degenerative meniscectomy: a randomized*
20 *controlled trial with one year follow-up.* J Bodyw Mov Ther, 2014. **18**(3): p. 374-
21 82.
- 22 43. Osteras, H., B. Osteras, and T.A. Torstensen, *Medical Exercise Therapy is Effective*
23 *After Arthroscopic Surgery of Degenerative Meniscus of the Knee: A Randomized*
24 *Controlled Trial.* J Clin Med Res, 2012. **4**(6): p. 378-84.
- 25 44. Osteras, H., B. Osteras, and T.A. Torstensen, *Medical exercise therapy, and not*
26 *arthroscopic surgery, resulted in decreased depression and anxiety in patients with*
27 *degenerative meniscus injury.* J Bodyw Mov Ther, 2012. **16**(4): p. 456-63.
- 28 45. Osteras, H., B. Osteras, and T.A. Torstensen, *Is postoperative exercise therapy*
29 *necessary in patients with degenerative meniscus? A randomized controlled trial*
30 *with one year follow-up.* Knee Surg Sports Traumatol Arthrosc, 2014. **22**(1): p.
31 200-6.
- 32 46. Osteras, H. and T.A. Torstensen, *The dose-response effect of medical exercise*
33 *therapy on impairment in patients with unilateral longstanding subacromial pain.*
34 Open Orthop J, 2010. **4**: p. 1-6.
- 35 47. Osteras, H., T.A. Torstensen, and B. Osteras, *High-dosage medical exercise therapy*
36 *in patients with long-term subacromial shoulder pain: a randomized controlled*
37 *trial.* Physiother Res Int, 2010. **15**(4): p. 232-42.
- 38 48. Osteras, H., et al., *A comparison of work absence periods and the associated costs*
39 *for two different modes of exercise therapies for patients with longstanding*
40 *subacromial pain.* J Med Econ, 2008. **11**(3): p. 371-81.
- 41 49. Williams, D.M., *Exercise, affect, and adherence: an integrated model and a case for*
42 *self-paced exercise.* J Sport Exerc Psychol, 2008. **30**(5): p. 471-96.
- 43 50. Koltyn, K.F., et al., *Mechanisms of exercise-induced hypoalgesia.* J Pain, 2014.
44 **15**(12): p. 1294-1304.
- 45 51. Fuentes, C.J., et al., *Effects of exercise therapy on endogenous pain-relieving*
46 *peptides in musculoskeletal pain: a systematic review.* Clin J Pain, 2011. **27**(4): p.
47 365-74.
- 48 52. Schnyder, S. and C. Handschin, *Skeletal muscle as an endocrine organ: PGC-1alpha,*
49 *myokines and exercise.* Bone, 2015. **80**: p. 115-125.

- 1
2
3 1 53. Benatti, F.B. and B.K. Pedersen, *Exercise as an anti-inflammatory therapy for*
4 2 *rheumatic diseases-myokine regulation*. Nat Rev Rheumatol, 2015. **11**(2): p. 86-
5 3 97.
6 4 54. Pedersen, B.K., *Muscle as a secretory organ*. Compr Physiol, 2013. **3**(3): p. 1337-
7 5 62.
8 6 55. Scanzello, C.R., *Role of low-grade inflammation in osteoarthritis*. Curr Opin
9 7 Rheumatol, 2017. **29**(1): p. 79-85.
10 8 56. Schaible, H.G., *Nociceptive neurons detect cytokines in arthritis*. Arthritis Res Ther,
11 9 2014. **16**(5): p. 470.
12 10 57. Morgan, J.A., F. Corrigan, and B.T. Baune, *Effects of physical exercise on central*
13 11 *nervous system functions: a review of brain region specific adaptations*. J Mol
14 12 Psychiatry, 2015. **3**(1): p. 3.
15 13 58. McAlindon, T.E., et al., *OARSI Clinical Trials Recommendations: Design, conduct,*
16 14 *and reporting of clinical trials for knee osteoarthritis*. Osteoarthritis Cartilage,
17 15 2015. **23**(5): p. 747-60.
18 16 59. Deyle, G.D., et al., *Knee OA: which patients are unlikely to benefit from manual PT*
19 17 *and exercise?* J Fam Pract, 2012. **61**(1): p. E1-8.
20 18 60. Laisne, F., C. Lecomte, and M. Corbiere, *Biopsychosocial predictors of prognosis in*
21 19 *musculoskeletal disorders: a systematic review of the literature (corrected and*
22 20 *republished) **. Disabil Rehabil, 2012. **34**(22): p. 1912-41.
23 21 61. Koltyn, K.F., *Exercise-induced hypoalgesia and intensity of exercise*. Sports Med,
24 22 2002. **32**(8): p. 477-87.
25 23 62. Naugle, K.M., et al., *Intensity thresholds for aerobic exercise-induced hypoalgesia*.
26 24 Med Sci Sports Exerc, 2014. **46**(4): p. 817-25.
27 25 63. Boecker, H., et al., *The runner's high: opioidergic mechanisms in the human brain*.
28 26 Cereb Cortex, 2008. **18**(11): p. 2523-31.
29 27 64. Schulz, K.F., et al., *CONSORT 2010 statement: updated guidelines for reporting*
30 28 *parallel group randomised trials*. Int J Surg, 2011. **9**(8): p. 672-7.
31 29 65. Kellgren, J.H. and J.S. Lawrence, *Radiological assessment of osteo-arthritis*. Ann
32 30 Rheum Dis, 1957. **16**(4): p. 494-502.
33 31 66. Schiphof, D., M. Boers, and S.M. Bierma-Zeinstra, *Differences in descriptions of*
34 32 *Kellgren and Lawrence grades of knee osteoarthritis*. Ann Rheum Dis, 2008. **67**(7):
35 33 p. 1034-6.
36 34 67. Benedetti, F., et al., *Pain as a reward: changing the meaning of pain from negative*
37 35 *to positive co-activates opioid and cannabinoid systems*. Pain, 2013. **154**(3): p.
38 36 361-7.
39 37 68. Bellamy, N., et al., *Recommendations for a core set of outcome measures for future*
40 38 *phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development*
41 39 *at OMERACT III*. J Rheumatol, 1997. **24**(4): p. 799-802.
42 40 69. Roos, E.M., *Effectiveness and practice variation of rehabilitation after joint*
43 41 *replacement*. Curr Opin Rheumatol, 2003. **15**(2): p. 160-2.
44 42 70. Roos, E.M. and L.S. Lohmander, *The Knee injury and Osteoarthritis Outcome Score*
45 43 *(KOOS): from joint injury to osteoarthritis*. Health Qual Life Outcomes, 2003. **1**: p.
46 44 64.
47 45 71. Roos, E.M., et al., *Knee injury and Osteoarthritis Outcome Score (KOOS)--validation*
48 46 *of a Swedish version*. Scand J Med Sci Sports, 1998. **8**(6): p. 439-48.
49 47 72. Roos, E.M., et al., *Knee Injury and Osteoarthritis Outcome Score (KOOS)--*
50 48 *development of a self-administered outcome measure*. J Orthop Sports Phys Ther,
51 49 1998. **28**(2): p. 88-96.

- 1 73. Lundeberg, T., et al., *Reliability and responsiveness of three different pain*
2 *assessments*. J Rehabil Med, 2001. **33**(6): p. 279-83.
- 3 74. Fransen, M. and J. Edmonds, *Reliability and validity of the EuroQol in patients with*
4 *osteoarthritis of the knee*. Rheumatology (Oxford), 1999. **38**(9): p. 807-13.
- 5 75. Sullivan, M., J. Karlsson, and J.E. Ware, Jr., *The Swedish SF-36 Health Survey--I.*
6 *Evaluation of data quality, scaling assumptions, reliability and construct validity*
7 *across general populations in Sweden*. Soc Sci Med, 1995. **41**(10): p. 1349-58.
- 8 76. Orenius, T., et al., *Anxiety and depression are independent predictors of quality of*
9 *life of patients with chronic musculoskeletal pain*. J Health Psychol, 2013. **18**(2): p.
10 167-75.
- 11 77. Urquhart, D.M., et al., *Are cognitive and behavioural factors associated with knee*
12 *pain? A systematic review*. Semin Arthritis Rheum, 2015. **44**(4): p. 445-55.
- 13 78. Bjelland, I., et al., *The validity of the Hospital Anxiety and Depression Scale. An*
14 *updated literature review*. J Psychosom Res, 2002. **52**(2): p. 69-77.
- 15 79. Osman, A., et al., *Factor structure, reliability, and validity of the Pain*
16 *Catastrophizing Scale*. J Behav Med, 1997. **20**(6): p. 589-605.
- 17 80. Holla, J.F., et al., *The avoidance model in knee and hip osteoarthritis: a systematic*
18 *review of the evidence*. J Behav Med, 2014. **37**(6): p. 1226-41.
- 19 81. Lundberg, M., et al., *Pain-related fear: a critical review of the related measures*.
20 Pain Res Treat, 2011. **2011**: p. 494196.
- 21 82. Fugl-Meyer, A.R., M. Eklund, and K.S. Fugl-Meyer, *Vocational rehabilitation in*
22 *northern Sweden. III. Aspects of life satisfaction*. Scand J Rehabil Med, 1991. **23**(2):
23 p. 83-7.
- 24 83. Resnick, B. and L.S. Jenkins, *Testing the reliability and validity of the Self-Efficacy*
25 *for Exercise scale*. Nurs Res, 2000. **49**(3): p. 154-9.
- 26 84. Resnick, B., et al., *Outcome expectations for exercise scale: utility and*
27 *psychometrics*. J Gerontol B Psychol Sci Soc Sci, 2000. **55**(6): p. S352-6.
- 28 85. Stener-Victorin, E., J. Kowalski, and T. Lundeberg, *A new highly reliable instrument*
29 *for the assessment of pre- and postoperative gynecological pain*. Anesth Analg,
30 2002. **95**(1): p. 151-7, table of contents.
- 31 86. Villadsen, A., et al., *Agreement and reliability of functional performance and muscle*
32 *power in patients with advanced osteoarthritis of the hip or knee*. Am J Phys Med
33 Rehabil, 2012. **91**(5): p. 401-10.
- 34 87. Dobson, F., et al., *Measurement properties of performance-based measures to*
35 *assess physical function in hip and knee osteoarthritis: a systematic review*.
36 Osteoarthritis Cartilage, 2012. **20**(12): p. 1548-62.
- 37 88. Bremander, A.B., L.L. Dahl, and E.M. Roos, *Validity and reliability of functional*
38 *performance tests in meniscectomized patients with or without knee osteoarthritis*.
39 Scand J Med Sci Sports, 2007. **17**(2): p. 120-7.
- 40 89. Prieto, L. and J.A. Sacristan, *Problems and solutions in calculating quality-adjusted*
41 *life years (QALYs)*. Health Qual Life Outcomes, 2003. **1**: p. 80.
- 42 90. Hasenbring, M.I., et al., *Fear and anxiety in the transition from acute to chronic*
43 *pain: there is evidence for endurance besides avoidance*. Pain Manag, 2014. **4**(5): p.
44 363-74.
- 45 91. Dunn, A.L., et al., *Exercise treatment for depression: efficacy and dose response*. Am
46 J Prev Med, 2005. **28**(1): p. 1-8.
- 47 92. Slentz, C.A., J.A. Houmard, and W.E. Kraus, *Exercise, abdominal obesity, skeletal*
48 *muscle, and metabolic risk: evidence for a dose response*. Obesity (Silver Spring),
49 2009. **17 Suppl 3**: p. S27-33.






- 1
2
3 1 93. Ekkekakis, P., *People have feelings! Exercise psychology in paradigmatic transition.*
4 2 Curr Opin Psychol, 2017. **16**: p. 84-88.
5 3 94. Dipnarine, K., et al., *Pain-free treadmill exercise for patients with intermittent*
6 4 *claudication: Are there gender differences?* Vascular, 2016. **24**(3): p. 304-14.
7 5 95. Bartels, E.M., et al., *Aquatic exercise for the treatment of knee and hip*
8 6 *osteoarthritis.* Cochrane Database Syst Rev, 2016. **3**: p. CD005523.
9 7 96. Pedersen, B.K. and B. Saltin, *Exercise as medicine - evidence for prescribing*
10 8 *exercise as therapy in 26 different chronic diseases.* Scand J Med Sci Sports, 2015.
11 9 **25 Suppl 3**: p. 1-72.
12 10 97. Wisloff, U., O. Ellingsen, and O.J. Kemi, *High-intensity interval training to maximize*
13 11 *cardiac benefits of exercise training?* Exerc Sport Sci Rev, 2009. **37**(3): p. 139-46.
14 12 98. Evangelista, L.S., et al., *Dose-Response Relationship Between Exercise Intensity,*
15 13 *Mood States, and Quality of Life in Patients With Heart Failure.* J Cardiovasc Nurs,
16 14 2017. **32**(6): p. 530-537.
17 15 99. Hurley, M.V., *Muscle dysfunction and effective rehabilitation of knee osteoarthritis:*
18 16 *what we know and what we need to find out.* Arthritis Rheum, 2003. **49**(3): p. 444-
19 17 52.
20 18 100. Juhl, C., et al., *Impact of exercise type and dose on pain and disability in knee*
21 19 *osteoarthritis: a systematic review and meta-regression analysis of randomized*
22 20 *controlled trials.* Arthritis Rheumatol, 2014. **66**(3): p. 622-36.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



171x136mm (300 x 300 DPI)

View only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

EXERCISE	HIGH DOSE MET (70-90 MIN)	DOSE	LOW DOSE MET (20-30 MIN)	DOSE
1		GLOBAL 20 min		GLOBAL 10 min
2		SEMI GLOBAL CLOSED CHAIN 3x30 reps		SEMI GLOBAL CLOSED CHAIN 2x10 reps
3		LOCAL OPEN CHAIN 5 min		SEMI GLOBAL CLOSED CHAIN 2x10 reps
4		SEMI GLOBAL CLOSED CHAIN 3x30 reps		SEMI GLOBAL CLOSED CHAIN 2x10 reps
5		GLOBAL 10 min		SEMI GLOBAL OPEN CHAIN 2x10 reps
6		SEMI GLOBAL CLOSED CHAIN 3x30 reps		
7		LOCAL OPEN CHAIN 5 min		
8		LOCAL OPEN CHAIN 3x30 reps		
9		GLOBAL 10 min		

210x297mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60















Figure 2. Flow chart of the design and run of the study. HDMET= High-dose MET and LDMET= Low-dose MET.

250x312mm (300 x 300 DPI)












1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

HIGH DOSE MET 80-90 MINUTES | NAME:

Treatment	1 date	2 date	3 date	4 date	5 date	6 date	7 date	8 date	9 date	10 date	11 date	12 date
	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time












BMJ Open: first published as 10.1136/bmjopen-2024-018471 on 5 May 2024. Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.

HIGH DOSE MET 80-90 MINUTES | NAME:

Treatment	13 date	14 date	15 date	16 date	17 date	18 date	19 date	20 date	21 date	22 date	23 date	24 date
	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time

BMJ Open: first published as 10.1136/bmjopen-2024-018471 on 5 May 2024. Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.






HIGH DOSE MET 80-90 MINUTES | NAME:

Treatment	25 date	26 date	27 date	28 date	29 date	30 date	31 date	32 date	33 date	34 date	35 date	36 date
	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time

BMJ Open: first published as 10.1136/bmjopen-2024-018471 on 5 May 2024. Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.

Low dose MET 30 minutes

Name: _____

Treatment	1	2	3	4	5	6	7	8	9	10	11	12
	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date
Exercises												
	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time
	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time
	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time
	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time
	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time










Exercise program MET 30 minutter

Name: _____

Treatment	13	14	15	16	17	18	19	20	21	22	23	24
Exercises	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date
	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time
	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time
	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time
	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time

Exercise program MET 30 minutter

Name: _____

Treatment	25	26	27	28	29	30	31	32	33	34	35	36
	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date
Exercises												
	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time
 	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time
 	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time
 	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time
 	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time

1136/bmjopen-2017-018471 on 5 May 2018. Downloaded from <http://bmjopen.bmj.com/> on April 29, 2024 by guest. Protected by copyright.



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	p1, line 8-10
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	p2,line 27
	2b	All items from the World Health Organization Trial Registration Data Set	N/A
Protocol version	3	Date and version identifier	p1, line 37
Funding	4	Sources and types of financial, material, and other support	p31,lines 2-5
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	p1,line:13-23, p29,line:5-10
	5b	Name and contact information for the trial sponsor	N/A
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	p31, lines 2-5
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	p14, lines 5-9,p15,lines 1-10

.1136/bmjopen-2017-018471 on 5 May 2018. Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Introduction

Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	<u>p3-p10,</u>
	6b	Explanation for choice of comparators	p10,lines 11-24 p11,linea1-4
Objectives	7	Specific objectives or hypotheses	<u>p11,lines 7-24</u>
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	p12,line 6-14
Methods: Participants, interventions, and outcomes			
Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	<u>p12,lines17-20</u>
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	<u>p13,lines1-12</u>
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	<u>p17-20, figure 1,p 8 and fig 2 ,p 9, appendixes 1 and 2</u>
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	<u>p19,lines 10-17,</u>
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	<u>P27,lines 5-13</u>
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	<u>N/A</u>

1				
2	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	p21-23, p 24, lines1-9
3				
4				
5				
6				
7	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	page 12, figure 3
8				
9				
10				
11	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	p25,lines 14-23
12				
13				
14	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	p14,lines 11-16
15				
16	Methods: Assignment of interventions (for controlled trials)			
17	Allocation:			
18				
19	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	p16,lines 16-21
20				
21				
22				
23				
24	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	p16,lines 16-21
25				
26				
27				
28	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	p13,line 24, p14, lines 1-3
29				
30				
31	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	p17,lines 1-9
32				
33				
34		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	p15, line 23 and p17, lines 3-4
35				
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				
47				

Methods: Data collection, management, and analysis

Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	<u>p15,lines 1-10</u>
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocol	<u>p15,lines1-10, and page 15,lines 13-15, and page 16, lines1-5</u>
Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	p15,lines 1-10

For peer review only

0.1136/bmjopen-2017-018241
Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Methods: Monitoring

Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	<u>p14,lines 5-9</u>
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	<u>N/A</u>
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	<u>p14,lines 8-9</u>
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	<u>N/A</u>

Ethics and dissemination

Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	<u>p2, lines 24-26, ' page 26,lines 1-4</u>
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	<u>p14,line 8-9</u>

Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	<u>p14,lines9-11</u>
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	<u>not applicable</u>
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	<u>p14,lines20-23</u>
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	<u>p29,line1-2</u>
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	<u>p15,lines 6-8</u>
Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	<u>not applicable</u>
Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	<u>p2, lines 25-26</u>
	31b	Authorship eligibility guidelines and any intended use of professional writers	<u>not applicable</u>
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	<u>not applicable</u>
Appendices			
Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	<u>not applicable, only i in Swedish and Norwegian language</u>
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	<u>not applicable</u>

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

“[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)” license.

For peer review only

BMJ Open

How does exercise dose affect patients with long-term osteoarthritis of the knee? A study protocol of a randomized controlled trial in Sweden and Norway – the SWENOR study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-018471.R2
Article Type:	Protocol
Date Submitted by the Author:	01-Feb-2018
Complete List of Authors:	Torstensen, Tom Arild; Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Physiotherapy Grooten, Wilhelmus; Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Physiotherapy ; Karolinska University Hospital, Allied Health Professionals Function, Functional area Occupational Therapy and Physiotherapy Østerås, Håvard; Norwegian University of Science and Technology, Department of Neuromedicine and Movement Science Heijne, Annette; Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Physiotherapy ; Karolinska University Hospital, Allied Health Professionals Function, Functional area Occupational Therapy and Physiotherapy Harms-Ringdahl, Karin; Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Physiotherapy ; Karolinska University Hospital, Allied Health Professionals Function, Functional area Occupational Therapy and Physiotherapy Äng, Björn; Dalarna University, School of Education, Health and Social Sciences; Karolinska Institutet, Department of Neurobiology, Care Sciences and Society, Division of Physiotherapy
Primary Subject Heading:	Rehabilitation medicine
Secondary Subject Heading:	Rheumatology, Sports and exercise medicine
Keywords:	Knee < ORTHOPAEDIC & TRAUMA SURGERY, Musculoskeletal disorders < ORTHOPAEDIC & TRAUMA SURGERY, PAIN MANAGEMENT, Clinical trials < THERAPEUTICS, REHABILITATION MEDICINE

SCHOLARONE™
Manuscripts

Words in text 5996
 Words in abstract 299
 Tables 2
 Figures 3
 Appendixes 2

How does exercise dose affect patients with long-term osteoarthritis of the knee? A study protocol of a randomized controlled trial in Sweden and Norway – the SWENOR study

Torstensen TA (1), Grooten WJA (1,2), Østerås H (3), Heijne A (1,2), Harms-Ringdahl K (1,2), Äng BO (1,4,5).

- 1) Department of Neurobiology, Care Sciences and Society, Division of Physiotherapy, Karolinska Institutet, Huddinge, Sweden
- 2) Allied Health Professionals Function, Functional area Occupational Therapy and Physiotherapy, Karolinska University Hospital, Stockholm, Sweden
- 3) Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway
- 4) School of Education, Health and Social Sciences, Dalarna University, Falun, Sweden
- 5) Center for Clinical Research Dalarna, Falun, Sweden

Corresponding author:

Tom Arild Torstensen

Department of Neurobiology, Care Sciences and Society, Division of Physiotherapy, Karolinska Institutet

Alfred Nobels Allé 23 23100

141 83 Huddinge, Sweden

Tel: +46 707344102

E-mail: tom.torstensen@ki.se

Version 3, review, 2018 -01-31

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Introduction: Osteoarthritis (OA) of the knee is characterized by knee pain, disability, and degenerative changes, and places a burden on societies all over the world.

Exercise therapy is an often-used modality, but there is little evidence of what type of exercise dose is the most effective, indicating a need for controlled studies of the effect of different dosages. Thus, the aim of this study described in this protocol is to evaluate the effects of high-dose versus low-dose medical exercise therapy (MET) in patients with knee OA.

Methods and analysis: This is a multicentre prospective randomized two-arm trial with blinded assessment and data analysis. We are planning to include 200 patients aged 45-85 years with a diagnosis of symptomatic (pain and decreased functioning) and X-ray verified diagnosis of knee OA. Those eligible for participation will be randomly allocated to either high-dose (n=100) or low-dose (n=100) MET. All patients receive three supervised treatments each week for twelve weeks, giving a total of 36 MET sessions. The high-dose group exercises for 80-90 min compared to 20-30 min in the low-dose group. The high-dose group not only exercises for a longer time, but also receives a greater number of exercises with more repetitions and sets. Background and outcome variables are recorded at inclusion, and outcome measures are collected after every sixth treatment, at end of treatment, and at six- and twelve-month follow-ups. Primary outcome is self-rated knee functioning and pain using the Knee Injury and Osteoarthritis Outcome Score (KOOS). The primary endpoint is at the end of treatment after three months, and secondary endpoints are at six and twelve months after end of treatment.

Ethics and dissemination: This project has been approved by the Regional Research Ethics Committees in Stockholm, Sweden, and in Norway. Our results will be submitted to peer-reviewed journals and presented at national and international conferences.

Trial Registration number: (ClinicalTrials.gov NCT02024126)

Strengths and limitations of this study

- To the best of our knowledge, this is the first multicentre study, with a bio-psycho-social view of pain, prospectively, comparing the effectiveness of two defined doses of pain-free or close to pain-free exercise therapies in patients with symptomatic knee osteoarthritis.
- The proposed project includes a relatively large sample where outcomes are evaluated both during the twelve-week intervention period, at the end of treatment, and at six and twelve months, respectively.
- The overall project uses both subjective and objective data, and includes analyses of cost- effectiveness and early predictors for a follow-up clinical outcome.
- Even though the different components of the exercise programmes are well described, one limitation could be possible confounders related to the exercise dose given.

MAIN TEXT

BACKGROUND

Osteoarthritis (OA) is the most common form of arthritis and is a major worldwide health problem causing illness and disability [1, 2]. The burden to society caused by knee OA is substantial [3]. The knee joint is most frequently affected, which commonly results in chronic joint pain, knee stiffness, decreased functioning, reduced quality of life, and sick leave [4]. The associated costs of osteoarthritis are estimated to range between 1-2.5% of the gross national product as calculated in six industrialized countries (Sweden, Australia, Canada, France, UK, and US) [5]

1
2
3 1 Traditionally, knee OA has been defined as a pathological condition characterized by focal
4
5 2 areas of loss of articular cartilage within the synovial joints, associated with hypertrophy of
6
7 3 the bone (osteophytes and sub-chondral bone sclerosis) and thickening of the capsule [6].
8
9
10 4 The mechanisms of knee OA-related pain are, however, complex [7] particularly in chronic
11
12 5 pain conditions where pain experience is nowadays believed to be more a result of changes
13
14 6 in the nervous system than in tissue structures [8], i.e. peripheral and central sensitization
15
16 7 [9]. This may partly explain why there are poor correlations between structural
17
18 8 degenerative changes of the knee, and pain, and functioning [10, 11].
19
20
21 9

22
23 10 In a systematic review, it was concluded that there exists high-level evidence that land-
24
25 11 based therapeutic exercise provides short-term effects on pain relief, and that there is a
26
27 12 moderate quality evidence regarding improvement in physical functioning among patients
28
29 13 with knee OA [12]. Despite this, several questions remain unanswered, particularly regarding
30
31 14 dose, intensity, and duration of the exercise therapy applied [13]. These unanswered
32
33 15 questions may be one of the reasons why we see a large variation in treatment effects
34
35 16 observed across studies making it difficult to conclude what is the optimal dose when
36
37 17 delivering exercise therapy [12, 13]. The exercises vary from neuromuscular exercise [14],
38
39 18 knee joint stabilization exercises [15], strengthening exercises [16], and endurance exercises
40
41 19 [17]. These forms of exercise therapy do not necessarily take into consideration the theories
42
43 20 of local and central sensitization, thus opening up for exercise therapies where the goal is
44
45 21 modulation of pain decreasing local and central sensitizations. The knowledge that pain and
46
47 22 swelling inhibits motor output, decreases range of motion, and changes coordination [18]
48
49 23 and that a strengthening exercise program can cause adverse effects [19], questions the use
50
51 24 of strengthening exercises. In their review [19], Liu et al. concluded that out of 121 trials, 53
52
53
54
55
56
57
58
59
60

1 had no comments about adverse events, 25 reported no adverse events, and 43 trials
2 reported adverse events. The majority of the adverse events from the strength training were
3 muscle strain and joint pain, while more adverse events were reported when performing
4 high intensity strength training. In this context there is increasing evidence [20] that exercise
5 therapy should focus more on treating pain-related knee OA such as peripheral and central
6 sensitization [8] and pain-related bodily and psychological changes [21] from a
7 biopsychosocial perspective [22, 23] rather than an impairment like muscle strength. This
8 view is supported by research showing that pain-related fear is more disabling than pain
9 itself [24]. To break the vicious circle of long-term knee pain, we believe it is important to
10 see beyond the knee [8], beyond an impairment such as muscle strength [25], using a
11 biopsychosocial sensitization model of pain [23].

13 **Medical Exercise Therapy**

14 Medical Exercise Therapy (MET) focuses on applying the optimal dose of exercise; i.e
15 combining global aerobic exercises with semiglobal and local joint exercises, where the goal
16 is to apply 70 to 90 minutes of active dynamic exercise therapy [26-35] . Using the principle
17 of self-paced exercises [36] the patient is to perform more than a 1000 pain-free or close to
18 pain-free repetitions per MET-session [26-35] . Even though the optimal dose goal of MET is
19 high, the treatment usually starts with a low dose lasting 15 to 20 minutes mirroring the
20 ability of the patient within a biopsychosocial context [22, 23], starting with an acceptable
21 baseline where the patient manages the exercise therapy [23, 26].

22
23 A global exercise is an exercise that activate the whole body exercising the trunk aswell as
24 upper and lower extremities, a semiglobal exercise activates muscles, joints and other

1 structures in an extremity and a local exercise activates one joint and the muscles acting on
2 it. Sessions of global exercises are performed several times during one treatment occasion,
3 where the goal is to substantially increase the heart rate activating the endocrine and pain
4 modulating systems of the body, i.e. the descending pain inhibiting system, achieving
5 cortical and spinal inhibition of nociceptive input. Semiglobal and local exercises are
6 performed for the same purpose, however, they are performed in sets of three where each
7 set consists of 30 repetitions. A local exercise can also be performed continuously for 3 to 5
8 minutes as one set, for example deloaded knee extension, see figure 1.

9 **[Figure 1 about here].**

10 To achieve a high volume of repetitions pain-free or close to pain-free the principle of
11 deloading is applied where the weight stack from different pulley apparatus is used to
12 deload a part of the body or the whole body, resulting in less joint forces in the knee joint,
13 see Figure 1.

14
15 The theoretical basis for the principle of the de-loading is that the weight from the pulley
16 deloads the weight of the lower leg with a decrease in the compressive forces between bony
17 and cartilaginous structures. The deloading also results in decreased pull and loading of
18 muscles, tendons, and other soft tissue, decreasing sensitization including
19 mechanical/loading allodynia, making it possible to exercise pain-free or close to pain-free.

20
21 MET has been evaluated in several clinical trials, and has been shown to be effective, both in
22 the short and long term, in patients with long-term low back pain with or without sciatica
23 [37], subacromial pain [33-35], and long-term anterior knee pain [27, 28]. In these latter
24 studies, an exercise dose lasting 70 to 90 minutes has been more favourable than an

1
2
3 1 exercise dose lasting 20 to 30 minutes. In a narrative review, Lorås et al., 2015 [23], included
4
5 2 four RCTs on the effectiveness of high-dose MET, concluding that high-dose MET was
6
7 3 positive and promising. However, to be able to draw any firm conclusions about the efficacy
8
9 4 in patients with knee OA, rigorous trials are needed on the effect of MET in this major
10
11 5 patient group [38]. Effect trials of cost-effectiveness are also needed as they are presently
12
13 6 lacking in the scientific literature, and the present project has the potential to fill this
14
15 7 knowledge gap. It is also important to point out that no exercise protocol is suited to all
16
17 8 patients, and as knowledge of early predictors of poor treatment outcomes obtained from
18
19 9 longitudinal data is sparse, the development of patient-customized treatments is hindered
20
21 10 [39]. According to the Swedish Agency for Health Technology Assessment and Assessment of
22
23 11 Social Services (SBU) as well as a recent review [40], prediction studies are needed to be able
24
25 12 to better individualize the treatment and match the most promising treatment option to a
26
27 13 certain patient profile in order to maximize treatment outcomes and minimize costs.
28
29 14 Therefore, we plan to conduct an RCT post-hoc prediction study to gain insights into which
30
31 15 patient characteristics predict treatment outcome and which patients benefit more or less
32
33 16 from exercise treatments.

34
35 17 In this trial, the rationale for comparing high dose MET (70-90 minutes) versus low dose MET
36
37 18 (20-30 minutes) is that high dose MET should be more effective through an increased
38
39 19 activation of the pain modulation systems like the descending pain inhibiting system [41].
40
41 20 The evidence is that exercise-induced hypoalgesia is obtained through higher and more
42
43 21 intensive exercise doses of 70% of HRR activating the pain modulating systems and
44
45 22 decreasing the sensation of pain [42]. However, it has also been shown that an exercise
46
47 23 intensity of 50% of HRR is capable of producing an analgesic effect in healthy adults [43],
48
49 24 similar exercise intensities used in both high and low dose MET. This could have important
50
51
52
53
54
55
56
57
58
59
60

1 implications for the use of exercise in the management of pain, particularly in deconditioned
2 individuals (e.g., older adults with OA of the knee). In 2008 it was shown for the first time
3 that an endurance activity lasting two hours resulted in the production of endogenous
4 neuropeptides (endorphins), creating chemical reactions in brain areas involved in cognitive
5 function and pain modulation, primarily in the prefrontal cortices, insula, and the limbic
6 system [44]. The rationale is that high dose MET exercising for 70 to 90 minutes may result
7 in an increased production of endogenous neuropeptides in the spinal cord, the brain stem,
8 and in the brain, compared to a lower dose MET exercising 20-30 minutes. The hypothesis is
9 that this should result in less pain and improved functioning in favour of the high dose MET
10 therapy.

11 **AIM OF THE STUDY**

12 The aim of this project is to prospectively evaluate short- and long-term effects of high-dose
13 MET compared to low-dose MET in patients with X-ray verified knee OA regarding pain,
14 functioning, and cost-effectiveness. A further aim is to conduct a post-hoc analysis on early
15 prognostic factors that predict short- and long-term follow-up outcomes, by targeting
16 patients' early status and patient adherence to the intervention. The long-term goal is to
17 further develop and implement updated knowledge into knee OA rehabilitation to meet the
18 challenge of tomorrow's patients with knee OA pain.

19 This study seeks to answer the following research questions:

- 20 1. What is the effect of high-dose MET compared to a low-dose exercise therapy (low-dose
21 MET) with respect to self-rated pain, functional limitations, health-related quality of life,
22 depression, and anxiety?
23

- 1
2
3 1 2. What is the effect of high-dose MET compared to low-dose MET on objective
4
5 2 performance measures such as physical functioning of a 20-metre walk, sit to stand, and
6
7 3 single knee bends, and pain threshold as determined by a pain-matcher instrument?
8
9
10 4 3. What is the cost-effectiveness of MET in patients with knee OA with respect to costs
11
12 5 against potential effects (incremental cost-effectiveness ratio, ICER), and cost per
13
14 6 quality-adjusted life year (QALY)?
15
16 7 4. Which patient characteristics (demographic or disease-related) predict long-term
17
18 8 treatment outcomes with a focus on pain, functional limitation, and health-related
19
20 9 quality of life? What important interaction effects between patient characteristics and
21
22 10 exercise dose may predict treatment outcomes?
23
24
25
26
27

28 **MATERIAL AND METHODS**

29 **Study design**

30
31
32 14 This is a phase three superiority trial of high dose MET versus low dose MET. The trial is
33
34 15 blinded regarding outcome assessment and analyses. It is a two-arm multicentre trial of a
35
36 16 twelve-week exercise intervention with a twelve-month follow-up. Measurements will be
37
38 17 taken at baseline and during the treatment at two weeks (six treatments), four weeks (12
39
40 18 treatments), six weeks (18 treatments), eight weeks (24 treatments), ten weeks (30
41
42 19 treatments), twelve weeks (36 treatments), which is end of treatment, and at follow-up at
43
44 20 26, and 52 weeks after end of treatment. Primary endpoint is at end of the treatment.
45
46 21 Secondary endpoints are at the 26 and 52 weeks follow-up. The study will conform to
47
48 22 CONSORT guidelines for reporting parallel, randomised trials [45], see Figure 2.
49
50
51
52

53 **[Figure 2 about here]**
54
55
56
57
58
59
60

1

2 **Participants**

3 We are planning to include 200 patients with a diagnosis of symptomatic and radiographic
4 knee OA who will be recruited from primary and secondary health care settings in Luleå and
5 Västerвик in Sweden, and in Trondheim and Mosjøen in Norway, named the SWENOR knee
6 OA study.

7 *Inclusion criteria:*

8 Subjects aged 45-85 years, living in the defined geographic areas (Västerвик and Luleå
9 municipalities in Sweden, and Trondheim and Mosjøen in Norway), who have had a
10 diagnosis of symptomatic and radiographic verified osteoarthritis grade I-III according to
11 Kellgren and Lawrence [46, 47], with at least three months pain duration, and decreased
12 functioning. The patient is willing to participate in a twelve-week intervention period with
13 three sessions each week

14 *Exclusion criteria:*

15 Physiotherapy or other conservative therapy during the previous three months or a history
16 of major knee trauma such as knee fractures or ligament ruptures. Inflammatory joint
17 disease, hip symptoms more aggravating than the knee symptoms, scheduled to have knee
18 replacement surgery within six months, and co-morbidities not allowing exercise such as
19 cardiovascular, respiratory, systemic, or metabolic conditions limiting exercise tolerance.

20

21 **Procedure**

22 Before intervention starts, regular visits will be made to each intervention place by the first
23 author (TAT), informing and communicating with the local research team about the aims and
24 run of the study. Detailed description of the different stages of the study from recruitment,

1 treatment, and follow-up assessments after the end of the intervention period will be
2 instructed and discussed. Physiotherapists in charge of the objective clinical testing (two in
3 Västerвик, one in Luleå, two in Trondheim and two in Mosjøen), otherwise not involved in
4 the treatment, will be educated theoretically and practically on how these tests should be
5 performed. The physiotherapists delivering the exercise intervention (two in Västerвик, one
6 in Luleå, two in Trondheim and two in Mosjøen) will, in addition, have structured theoretical
7 and practical sessions on how to apply and grade the exercise therapies. A study nurse at
8 each intervention place is in charge of randomization, questionnaires, and the scheduling of
9 patients for treatments and assessments. Each of the four intervention centres has a local
10 administration officer.

11
12 A data security monitoring plan is conducted by the current investigator monitoring the
13 present pragmatic trial. Tom Arild Torstensen (TAT) will visit the four centres from the
14 planning phase of the trial, during the treatment phase, and during the follow up phase in
15 order to monitor that the protocol is followed. Adverse and SAEs are reported to the ethics
16 committee.

17
18 Recruitment will be achieved through referrals from medical doctors in primary and
19 secondary health care clinics. The local investigator at each study centre will contact medical
20 doctors (MDs) and send written information about the study. The first screening is
21 performed by a MD and a second screening is performed by one of the treating
22 physiotherapists. Both the MD and the physiotherapist guarantee the radiographic inclusion
23 criteria.

24

1 Patients will receive oral and written information about the study, and after signing an
2 informed consent form obtained by the local administration officer, they will be assessed for
3 eligibility by physiotherapists at each intervention centre. Participants initially fill out
4 questionnaires for baseline data and perform the physical performance tests. Each patient is
5 then randomized, as described below, to either high or low dose medical exercise therapy.

6

7 *Data collection and management.*

8 Data from the questionnaires will be depersonalised at each intervention centre by the local
9 research assistant. In order to transfer data from Norway to Sweden, a data transfer
10 agreement (DTA) between Norges Teknisk-Naturvitenskapelige Universitet
11 (NTNU)/Norwegian University of Science and Technology and Karolinska Institutet, (KI/NVS),
12 has been set up. The questionnaires from the Swedish centres are posted to Karolinska
13 Institutet where data is registered on digital sheets. In Norway, questionnaires from
14 Mosjøen are posted to Trondheim where all questionnaires from the two Norwegian centres
15 are registered on sheets and delivered to Karolinska Institutet according to DTA; Tom Arild
16 Torstensen, Björn Äng, and Wilhelmus Grooten are in charge of the data synthesis and
17 analysis

18

19 *Post-recruitment retention and compliance strategies*

20 Our experiences of MET as an experimental intervention (HØ and TAT) [26-35] leads to the
21 following retention and compliance strategies to be applied in this study.

- 22 • An independent study nurse at each intervention centre will always be available to
23 answer questions when patients are filling out the questionnaires

- 1
- 2
- 3 1 • This is important to avoid any unnecessary misunderstandings regarding the content
- 4
- 5 2 of the questionnaire and to make sure that patients understand that all information
- 6
- 7 3 will be depersonalized.
- 8
- 9
- 10 4 • During the interventions, the treating physiotherapist is present the whole time in
- 11
- 12 5 the exercise room answering questions from patients and re-grading the exercises
- 13
- 14 6 according to changes in patients' exercise status and knee-OA symptoms.
- 15
- 16 7 Participants are not informed about the hypothesis of the study.
- 17
- 18
- 19 8 • At inclusion and at the end of the 12-week intervention period the patient is
- 20
- 21 9 informed by the local administration nurse about the six- and 12-month follow-ups.
- 22
- 23
- 24 10 • During the post-intervention follow-ups, the patient will be contacted three weeks
- 25
- 26 11 prior to the assessment and informed when to come to the intervention site for
- 27
- 28 12 the planned post treatment evaluation.
- 29
- 30

31 During the intervention period, KOOS and the eight different VAS scales are assessed

32

33 14 after every sixth treatment meaning after two-, four-, six-, eight-, ten-, and 12 weeks

34

35 15 giving a total of six assessments. The purpose of such repeated measurements is to

36

37

38 16 obtain a reasonable measurement accuracy of both functioning status and pain during

39

40 17 the twelve-week intervention period. The primary end-point will be on completion of

41

42 18 the intervention after 36 treatments, which will take an average of twelve weeks. This

43

44

45 19 is to obtain evaluation of effects on organized exercise therapy related with its direct

46

47 20 implementation, while further follow-ups evaluate its retention effects. At this point

48

49 21 primary and secondary outcomes are assessed.

50

51

52 22

53

54 23

55

56

57

58

59

60

1 **Randomization procedure**

2 In this individual randomized trial, a stratified allocation by age and intervention centre is
3 used, using a computerized program, where the goal is to get an equal number of patients
4 between the ages of 45 and 64 years and 65 and 85 years at each of the four intervention
5 centres. The randomization key is concealed at each intervention place and kept under lock
6 by a research assistant not involved with the assessment or interventions.

8 **Blinding procedures**

9 The physiotherapists conducting the physical performance tests are blinded to an allocation
10 group and the study participants are instructed by the treating physiotherapists not to reveal
11 details of their intervention during testing. The principal investigators (BÄ), the assistant
12 principal investigator (TAT), and the research assistants are also blinded to groups when
13 entering data to data-sheets, i.e. they do not know which patient has received high-dose or
14 low-dose MET. The group key will be opened after the analyses have been finalised and the
15 results have been written up in a manuscript (using intervention A and B until results have
16 been written).

18 **Interventions**

19 All participants receive an MET intervention, where they are treated in groups of four or five
20 in sessions lasting 20 to 90 minutes. During the sessions, they are supervised by an
21 experienced physiotherapist in an outpatient clinic. All participants are treated three times a
22 week for twelve weeks, giving a total of 36 treatments. Each patient in the group has an
23 individualized exercise program tailored to their specific clinical symptoms and functional
24 level. As the treatment proceeds, exercises are adapted according to changes in symptoms

1 and functioning. The pain experience when exercising should not exceed a three on a zero to
 2 ten scale, where zero is no pain and ten is the worst imaginable pain [34]. Specially designed
 3 exercise equipment consisting of different forms of pulleys, exercise benches, dumbbells,
 4 and barbells is used to grade and dose the exercises to be pain free or close to pain free,
 5 with the purpose of mitigating peripheral and central sensitization while exercising [23]. The
 6 difference between groups regarding exercise dose is outlined below in Table 1.

7
 8 **Table 1:** Differences between the high-dose and low-dose MET regarding number of
 9 exercises, sets, and repetitions. Difference in time, performing global exercises and total time
 10 duration for each treatment.

	Number of exercises	Number of sets	Number of repetitions	Time performing global exercise	Time duration of treatment
High dose MET	9	3	30	20 min+10 min +10 min	70-90 min
Low dose MET	5	2	10	10 min	20-30 min

11
 12 The grading of the exercises, including baseline settings, is based on the initial clinical
 13 assessment by the treating physiotherapist. From the patients' past and present histories
 14 and physical clinical assessment, information is gained about the level of pain and possible
 15 sensitization (local versus central sensitization), range of motion, and tolerance for weight
 16 bearing within the available range of motion of the knee. This information is used for
 17 baseline setting of the exercises where the physiotherapist chooses a starting position, a
 18 range of motion, and a weight resistance believed to match the patient's ability to perform
 19 three sets of 30 repetitions (high dose MET) and two sets of ten repetitions (low dose MET),

1 pain-free or close to pain-free. Then there is a test of each exercise where the
2 physiotherapist asks the patient to do as many repetitions as the patient can manage. When
3 the patient reaches ten repetitions the test is stopped and the patient has to evaluate if the
4 weight/loading (L), starting position (SP), or range of motion (ROM) is appropriate to reach a
5 total of 40 repetitions. Any of the above mentioned variables (L, SP, ROM), can be changed
6 to reach 40 repetitions, making it possible to perform 30 repetitions in sets of three with a
7 30- to 60-second pause between each. The same test procedure is used for the low dose
8 group where the goal is a test of 15 repetitions making it possible to do two sets of 10
9 repetitions. At baseline setting, there is a continuous evaluation in the exercise room where
10 the physiotherapist and the patient is working towards optimal exercise dose for each
11 exercise, as is usually done in clinical practice [23]

12
13 It should also be possible for the patient to perform the exercise comfortably within the
14 preferred active range of active motion (AROM). For example, if a part of the AROM in the
15 knee joint is painful, the patient starts to exercise within the pain-free or close to pain-
16 free AROM. As the treatment proceeds, the AROM is adjusted, making the patient exercising
17 in a larger and more functional AROM. If it is not possible to grade the exercise pain-free or
18 close to pain-free, the patient is allowed to exercise with pain. When exercising with pain it
19 is important that the pain experience dose not cause any anxiety or fear. The pain has to be
20 experienced as meaningful for improvement [48]. If the exercise therapy results in an acute
21 increase in pain, the pain should have returned to baseline before the next treatment
22 session commences. If pain does not go back to the prior level, exercises are reassessed,
23 with the most comfortable exercise performed several times, preferably deloaded knee
24 extension and stationary. The group of four to five patients also contains patients with other

1 diagnoses, who are not participating in this study, making the delivery of the MET
2 intervention pragmatically similar to a real life situation. To be able to monitor the exercise
3 dose, the treating physiotherapists follow a structured progression plan of the exercises, and
4 fill in a treatment log for each patient at each treatment, see appendix number 1 –
5 progression plan for high dose MET, and appendix number 2 – progression plan for low dose
6 MET. The log contains information about the number of exercises, duration of each global
7 exercise, number of repetitions, and sets and weight resistance applied for semiglobal and
8 local exercises. Consent to publish the photographs in the appendices has been obtained
9 from the person pictured. Figure 3 shows the main exercises from the two different exercise
10 interventions compared in this planned randomized trial: high dose MET versus low dose
11 MET. **[Figure 3 about here]**

12 To be able to reach a high number of repetitions despite on-going pain, the principle of de-
13 loading is applied, facilitating a high number of repetitions that are nearly or entirely pain
14 free, see figure 1. For the high-dose MET, the deloaded knee extension is performed twice
15 during a treatment, each time for a five-minute duration. This exercise and the cycling in the
16 middle of each treatment session is a form of restitution, making it easier to both perform
17 the deloaded closed chain exercises and endure the high dose MET. Later, as the patient
18 improves and can tolerate increased loading, the exercises are adapted to be more
19 functional, using closed chain exercises without deloading the body weight.

20
21 To further increase the exercise dose for the high dose MET group patients perform one
22 home exercise - the seated deloaded knee extension with a yellow tube theraband. The
23 exercise is similar to exercise number three, see Figure 1. They perform this home exercise
24 once every day, where the dose is three lots of three minutes with a 30- to 60-second pause

1 between each set. The treating physiotherapists make sure that the patients are compliant
2 in doing their home exercises. Patients in the low dose MET receive no home exercises.

4 **Baseline data**

5 The following data will be obtained by questionnaire; gender, age, height, weight, physical
6 activity and exercise levels, living arrangement, education level, employment status,
7 possible medication, co-morbidities, smoking habits, sleeping habits, pain and function of
8 the knee, catastrophizing thoughts, fear avoidance beliefs, level of anxiety and depression,
9 life satisfaction and quality of life, and beliefs about exercise. A schematic presentation of
10 the outcome measures recorded at baseline and at the follow-ups is presented in Table 2.
11 Each assessment, which involves filling out questionnaires, will take approximately one hour.
12 The objective testing of the knee and the testing with the PainMatcher apparatus takes
13 approximately 30 minutes and will occur the following day.

15 **Primary outcome measures**

16 In accordance with international consensus regarding the core set of outcome measures for
17 clinical trials in OA [49], self-rated functioning and pain scoring (The Knee Injury and
18 Osteoarthritis Outcome Score, KOOS) [50-53] is used as primary outcome measures. KOOS
19 consists of 5 subscales; Pain, other Symptoms, Functioning in daily living (ADL), Functioning
20 in sport and recreation (Sport/Rec), and knee-related Quality of life (QOL). Standardized
21 answer options are given (5 Likert boxes) and each question is assigned a score from 0 to 4.
22 A normalized score (100 indicating no symptoms and 0 indicating extreme symptoms) is
23 calculated for each subscale. For the purpose of an RCT, KOOS subscale scores can be
24 aggregated and averaged as the primary outcome. We are planning to use KOOS at

1 **Table 2. Study measures to be collected**

2

Baseline measures and outcomes	Description and instrument	Data source	Collection points
Patient's characteristics	Date of birth, gender, BMI (height, weight) social and living status, leisure activities, level of physical activity, smoking, medicine, sleep, co-morbidities, anxiety and depression, catastrophizing, life satisfaction, kinesiophobia	SAQ	t0
Primary outcome measure	Clinical Outcomes		
Pain	KOOS: subscale pain	SAQ	t0, t2, t4, t6, t8, t10, t12, t26, t52
Other symptoms	KOOS: subscale other symptoms	SAQ	t0, t2, t4, t6, t8, t10, t12, t26, t52
Function	KOOS: subscale physical functioning	SAQ	t0, t2, t4, t6, t8, t10, t12, t26, t52
Sport, recreation	KOOS: subscale sport and recreation	SAQ	t0, t2, t4, t6, t8, t10, t12, t26, t52
Secondary outcome measures	Clinical Outcomes		
	VAS (100mm scale): pain	SAQ	t0, t2, t4, t6, t8, t10, t12, t26, t52
	VAS (100mm scale): knee pain not loading	SAQ	t0, t2, t4, t6, t8, t10, t12, t26, t52
	VAS (100 mm scale): pain at weight bearing	SAQ	t0, t2, t4, t6, t8, t10, t12, t26, t52
	VAS (100 mm scale): knee pain at night	SAQ	t0, t2, t4, t6, t8, t10, t12, t26, t52
	Physical functioning		
	20 m walk test	PT	t0, t12
	Chair stand test	PT	t0, t12
	Unilateral knee bending	PT	t0, t12
	Pain threshold and tolerance		
	Pain Matcher	Pain matcher apparatus	t0, t12
	Quality of life		
	(EQ-5D-5L)	SAQ	t0, t12, t26, t52
	(SF-36)	SAQ	t0, t12, t26, t52
	Life satisfaction		
	Life Satisfaction Questionnaire (LISAT)	SAQ	t0, t12, t26, t52
	Psychological outcomes		
	Anxiety and depression (HAD),	SAQ	t0, t12, t26, t52
	Catastrophizing (Pain Catastrophizing Scale)	SAQ	t0, t12, t26, t52
	Kinesiophobia (TSK)	SAQ	t0, t12, t26, t52
	Beliefs and attitude towards exercise		
	Self-efficacy for exercise (SEE)	SAQ	t0, t12, t26, t52
	Outcome Expectancy for Exercise Scale (OEE)	SAQ	t0, t12, t26, t52

Data source: Self-administered questionnaire (SAQ), physical testing (PT). Collection points: t0=inclusion, t1-t12= measurement every second week during the 12 week intervention period, t1=2 weeks, t2= 4 weeks, t3= 6 weeks, t4= 8 weeks, t5= 10 weeks, t6= 12 weeks (end of inclusion), t26= 6 months follow up, t52= 12 months follow up. Questionnaires: The Knee Injury and Osteoarthritis Scale (KOOS), Life Satisfaction Questionnaire (LISAT), Hospital Anxiety and Depression Scale (HAD), Pain Catastrophizing Scale (PCS), Tampa Scale of Kinesiophobia (TSK), Self-efficacy for exercise (SEE) and Outcome Expectancy for Exercise Scale (OEE)

3

4

1 several time-points; at baseline, and during the intervention period until the final follow-up
2 at 52 weeks, see Table 2.

3

4 **Secondary outcome measures**

5 As a secondary outcome measure, there are eight different pain measurements using a 100
6 mm visual analogue scale (VAS) [54], with terminal descriptors of “no pain” and “worst pain”
7 asking about how painful the knee is, 1) today and 2) on average during the last week,
8 related to the following four different life situations; 1) how painful is your knee, 2) how
9 painful is your knee when loading your knee (e.g. walking or standing), 3) how painful is your
10 knee when not loading your knee (e.g. sitting, lying), 4) how painful is your knee at night
11 when you are sleeping (e.g. knee pain that disturbs your sleep). Data on health related to
12 quality of life are collected using the EQ 5-D questionnaire [55] and the SF-36
13 questionnaire [56]. These questionnaires will also be used to perform a health economic
14 evaluation of the exercise interventions. Psychological factors such as anxiety and
15 depression, catastrophizing, and fear-avoidance beliefs are believed to both predict
16 outcome of an intervention [57] as well as influence the level of pain in patients with knee
17 OA experience [58]. In this study, anxiety and depression are rated using the Hospital
18 Anxiety and Depression Scale (HAD) [59], catastrophizing is rated using the Pain
19 Catastrophizing Scale (PCS) [60], and fear avoidance beliefs [61] are rated using the Tampa
20 Scale of Kinesiophobia (TSK) [62], see Table 2. Life satisfaction is assessed using the Life
21 Satisfaction (LISAT) questionnaire by Fugl-Meyer [63]. Beliefs and attitudes towards exercise
22 are rated using the Self-Efficacy for Exercise Scale (SEE) [64], and the patient’s expectations
23 of performing physical activity are rated using the Outcome Expectations for Exercise Scale
24 (OEE) [65]. PainMatcher apparatus [66] (Cefar Medical AB, Lund, Sweden) is used to record

1 sensory level, pain level, and pain tolerance level. Pressing the thumb and first finger against
2 a button on each side of the hand held PainMatcher apparatus; an electrode under each
3 button activates an electrical current. As long as the pressure is kept against the buttons, the
4 electrical current will slowly increase where the first sensation of the current is a
5 measurement of sensory threshold. As the pressure is maintained, the electrical current
6 slowly increases, and the sensation will turn into a pain sensation (pain threshold). Keeping
7 the pressure on the buttons, the painful electrical current increases, and pain tolerance is
8 recorded, i.e. the measure of how much painful electrical current the patient can endure.
9 Performance tests include the 20-meter walk test [67], first at a self-selected pace and then
10 at maximum pace, 30-second maximum number of chair to standing test [68], and 30-
11 second maximum number of repeated unilateral knee bends [67, 69]. Other measurements,
12 logged by the supervising therapist, are recordings of compliance of the exercise treatments
13 during the twelve-week intervention also including a recording of exercise dose (weights,
14 sets, repetitions, and treatment time) at each treatment occasion. Over the whole project
15 period, from inclusion to end of the 52-week follow-up, any adverse effects are to be noted
16 and reported.

18 **Statistical analysis**

19 In the statistical analyses of both primary and secondary outcomes, the principle of intention
20 to treat will be used, comparing high-dose MET with low-dose MET. Within-group and inter-
21 group statistical testing will be carried out using general linear model where an alpha level of
22 0.05 will be used where appropriate. Significance of main or interaction effects will be
23 explored using follow-up post hoc tests. Effect size Cohen's *d* will aid clinical interpretation
24 of the magnitude of treatment effect, where effect-size values below 0.2 will be considered

1 small, 0.5 medium, and 0.8 large. The primary end-point is at the end of the twelve-week
2 intervention period and potential baseline differences will be considered by adding
3 additional baseline variables as covariates to the statistical models. Potential floor or ceiling
4 effects will be computed and considered in our analyses. Because participants of both
5 interventions of both intervention groups are treated together with other patients in MET
6 groups, the treatment credibility and outcome expectations (OEE) will be evaluated as a
7 potential co-variate or confounder for treatment effects.

8
9 Analysis of cost-effectiveness will be performed using the incremental cost-effectiveness
10 ratio (ICER), in order to provide a single measure for weighing costs against benefits of
11 health care interventions. Cost per quality-adjusted life year (QALYs [70]), using data from
12 EQ-5D and SF-36, will be added. In the predictive analyses, multivariable logistic regressions
13 (e.g. GEE) will be used to estimate the association between potential predictors and
14 outcomes. A purposeful selection procedure is planned resulting in a final model that
15 contains only significant independent variables, identified confounders and interactions. All
16 final models will be examined for goodness-of-fit and accuracy according to established
17 methods.

18 19 **Sample size**

20 The power calculation was based on proportions that can document a minimal clinical
21 important change (MCIC). The primary outcome the Osteoarthritis Outcome Score (KOOS) is
22 a numerical scale ranging from 0 (maksimal problem) to 100 (no problem). A change of ten
23 points is evaluated as a clinically interesting change [51]. The hypothesis is that 40% of the
24 patients receiving high-dose MET and 20% of the patients receiving low-dose MET will

1 obtain a ten-point improvement after end of treatment at the three-month follow-up. The
2 power calculation showed that 82 patients are needed in each arm to reach 80% between-
3 group power. With a hypothetical drop out of the study of 20% the total sample is
4 $82 \times 2 \times 1.2 = 197$ patients. We plan to include 200 patients giving each exercise intervention
5 group a total of 100 participants.

6

7 **ETHICS AND DISSEMINATION**

8 The guidelines from the Helsinki declaration will be followed and the protocol has been
9 approved by the Regional Ethics Review Board in Stockholm. Some relevant ethical
10 considerations related to this study are mentioned below:

11

12 *The infliction of pain*

13 An often overlooked ethical issue is the infliction of pain when instructing patients to
14 exercise [19]. Knee OA is commonly a painful condition and it is questionable if it is ethical to
15 push patients through the painful exercise regimens included in the approach that today is
16 recommended for treating knee OA. A worst-case scenario for this type of treatment is
17 pushing the patient into endurance behaviour that in itself may result in long-term pain [71].
18 However, in this study, the focus on grading the exercises pain free or close to pain free
19 resolves, to some extent, this problem.

20 *The problem of large exercise dosage*

21 Asking patients to exercise for 70 to 90 minutes three times a week for twelve weeks may be
22 ethically questionable. However, such doses of exercise therapy have been shown to be
23 effective in patients with depression [72] and there is an argument today that both exercise
24 dose and exercise intensity should be increased for patients suffering from heart disease or

1 a metabolic syndrome, respectively [73]. The high compliance with a relatively extensive
2 exercise programme is possible because patients with chronic (or progressed) conditions
3 commonly prioritize rehabilitation to maintain (or improve) good functioning. Thus, it is a
4 need to investigate if a similar high dose of exercise therapy is effective for patients with
5 knee OA. It is also of high relevance to study whether a less time-consuming exercise
6 programme, such as the low-dose MET in the present study, results in similar effects
7 including effects on costs.

8

9 **DISCUSSION**

10 We believe one important strength of this study is the use of self-paced exercises, grading
11 the exercises pain-free or close to pain-free [36]. Research has shown that when patients are
12 asked to self-select their exercise intensity, they choose an intensity that results in a positive
13 affective response making them more motivated to do the exercise. This seems to be the
14 case for both populations without pain [74] and patients suffering from a painful condition
15 [75]. The use of a self-paced approach, exercising pain-free or close to pain-free may – we
16 believe - decrease the probability of patients dropping out of the study due to adverse
17 effects such as uncomfortable painful experiences [36, 75], which minimizes possible nocebo
18 effects [76], and breaks the vicious circle of knee pain [23]

19

20 To decrease negative affective experiences from exercising, MET applies the principle of
21 deloading, where the application of different types of exercise equipment deloads some of
22 the body weight or the weight of the lower extremity. This is also the case for aquatic
23 exercise therapy where the buoyancy of the water decreases compressive forces on the
24 knee joint. However, aquatic exercises do not seem to be superior to land-based exercises

1 [77], making a call for further research into dose-response effects from exercise therapy.

2

3 In an extensive review by Pedersen and Saltin [78], it was concluded that there is evidence
4 for prescribing exercise as a therapy for 26 different chronic diseases. In addition, there is
5 increasing evidence that a higher dose of exercise is more effective than a lower dose in
6 patients with long-term subacromial pain [34] and long-term anterior knee pain [27],
7 patients suffering from depression [72], and patients suffering from a metabolic syndrome
8 [73]. A high dose of exercise has a greater effect on heart function [79] and a greater
9 positive impact on mood states and quality of life [80] in patients suffering from heart
10 failure.

11

12 In terms of knee OA, however, the evidence level of exercise dose is poor [12, 13, 22, 78, 81,
13 82]. In a recent systematic review [13] only five studies that compared high-intensity versus
14 low-intensity physical activity were included. Of these five studies, there is only one study
15 [17] that is in any way similar to this planned study. The study [17] compared high-intensity
16 versus low-intensity cycle ergometry in older adults with knee OA. Both groups cycled for 25
17 minutes three times a week for 10 weeks. The high dose high intensity group cycled with an
18 intensity of 70% of HRR and the low dose low intensity group with an intensity of 40% of
19 HRR. After the end of the intervention period both groups had improved significantly on all
20 outcome measures but there were no differences between groups. Juhl and colleagues [82]
21 argue that an optimal exercise program for knee OA should focus on improving quadriceps
22 strength and aerobic capacity, as well as improving performance in the lower extremities.
23 Exercise programmes should be supervised and carried out three times a week. They also
24 argue that there is a great need to further investigate the effects of differing exercise doses

1 and that the interventions in such studies are described in detail with regard to intensity,
2 length of program, total number of supervised sessions, duration of individual supervised
3 sessions, and number of sessions per week.
4

5 To our knowledge, this study is the first to investigate, in a controlled manner, if an exercise
6 dose lasting 70-90 minutes is superior in terms of improvements in functioning and pain to a
7 lower dose of exercise therapy lasting 20 to 30 minutes in patients with knee OA.
8

9 **CONTRIBUTORSHIP STATEMENT**

10 Torstensen TA, Grooten WJA, Østerås H, Heijne A,-Harms-Ringdahl K and Äng B, have all
11 actively participated in the planning and design of the study as well as the writing of this
12 manuscript describing the research protocol of the study. Principle investigator in Sweden is
13 Björn Äng and in Norway Havarð Østerås. Tom Arild Torstensen is the assistant principle
14 investigator for the study.
15

16 **COLLABORATORS**

17 The authors would like to acknowledge the following colleagues:

18 *Monitoring the study:*

19 The following colleagues are monitoring the study at respective intervention centre; In

20 Västervik, Nisse Wallberg PT, in Luleå Mikael Sjöström PT, in Trondheim Håvard Østerås

21 M.Sc PT and in Mosjøen Morten A Romslo PT.

22 *Assessment and treatment of patients:*

1 in Mosjøen (Norway), Morten Andre Romslo PT (MSc) and Iselind Thoresen PT, in Trondheim
2 (Norway) Lasse Haugerud PT and Håvard Østerås M.Sc PT, in Luleå (Sweden) Mikael
3 Sjöström PT, and in Västervik (Sweden) Nisse Wallberg PT and Thomas Aupers PT.

4 *Objective functional testing:*

5 In Mosjøen (Norway) Stine Krogh Dagsvik PT and Marte Nystad Glad PT, in Trondheim
6 (Norway) Maria Sommervold PT and Lisa Lid PT, in Luleå (Sweden) Peter Wallström PT and in
7 Västervik (Sweden) Erik Sjöstedt PT and Fanny Ek Nordén PT.

8 *Local study nurse handling questionnaires and in charge of the randomization procedure*

9 *locally and informing patients about follow up assessments:*

10 In Mosjøen (Norway) Elin Slänsby and Lena Aufles, in Trondheim (Norway) Beate Iversen, in
11 Luleå (Sweden) Katarina Söderholm, and in Västervik (Sweden) Marita Johansson.

12

13 **COMPETING INTERESTS**

14 I have read and understood the BMJ Group policy on declaration of interests and declare the
15 following interests:

16 Name: Tom Arild Torstensen, Date: 2017-06-30

17 Declaration of interests: Teaches courses and seminars in medical exercise therapy

18 Name: Grooten WJA, Date: 2017-06-30

19 Declaration of interests: None

20 Name: Østerås H, Date: 2017-06-30

21 Declaration of interests: None

22 Name: Heijne A, Date: 2017-06-30

23 Declaration of interests: None

24 Name: Harms-Ringdahl K, Date: 2017-06-30

1
2
3 1 Declaration of interests: None

4
5 2 Name: Äng BO, Date: 2017-06-30

6
7 3 Declaration of interests: None

8
9 4

10
11
12 5 **FUNDING STATEMENT:**

13
14 6 This work is supported by the Swedish Rheumatology Association and Karolinska Institutet
15
16 7 funds, which cover a part of the economical resources. None of the funders have had any
17
18 8 influence in developing the protocol or any other part of the study, their role has been
19
20 9 strictly financial.
21
22

23 10

24
25 11 **FIGURE CAPTIONS**

26
27
28 12 **Figure 1:** The principle of deloading performing a local knee exercise.

29
30 13

31
32 14 **Figure 2:** The two different exercise interventions compared in this randomized trial, high
33
34 15 dose MET (HDMET) and low dose MET (LDMET).
35
36

37 16

38
39 17 **Figure 3.** Flow chart of the design and run of the study. HDMET= High-dose MET
40
41 18 and LDMET= Low-dose MET.
42
43

44 19

45
46 20

47
48
49 21

50
51 22

52
53 23

54
55 24

56
57 25

1 REFERENCES


1. Nguyen, U.S., et al., *Increasing prevalence of knee pain and symptomatic knee osteoarthritis: survey and cohort data*. *Ann Intern Med*, 2011. **155**(11): p. 725-32.
2. Johnson, V.L. and D.J. Hunter, *The epidemiology of osteoarthritis*. *Best Pract Res Clin Rheumatol*, 2014. **28**(1): p. 5-15.
3. Cross, M., et al., *The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study*. *Ann Rheum Dis*, 2014. **73**(7): p. 1323-30.
4. Dieppe, P.A. and L.S. Lohmander, *Pathogenesis and management of pain in osteoarthritis*. *Lancet*, 2005. **365**(9463): p. 965-73.
5. March, L.M. and C.J. Bachmeier, *Economics of osteoarthritis: a global perspective*. *Baillieres Clin Rheumatol*, 1997. **11**(4): p. 817-34.
6. Pereira, D., et al., *The effect of osteoarthritis definition on prevalence and incidence estimates: a systematic review*. *Osteoarthritis Cartilage*, 2011. **19**(11): p. 1270-85.
7. Iannetti, G.D. and A. Mouraux, *From the neuromatrix to the pain matrix (and back)*. *Exp Brain Res*, 2010. **205**(1): p. 1-12.
8. Arendt-Nielsen, L., *Joint pain: more to it than just structural damage?* *Pain*, 2017. **158 Suppl 1**: p. S66-S73.
9. Fingleton, C., et al., *Pain sensitization in people with knee osteoarthritis: a systematic review and meta-analysis*. *Osteoarthritis Cartilage*, 2015. **23**(7): p. 1043-56.
10. Tornbjerg, S.M., et al., *Structural pathology is not related to patient-reported pain and function in patients undergoing meniscal surgery*. *Br J Sports Med*, 2017. **51**(6): p. 525-530.
11. Thorstensson, C.A., et al., *Natural course of knee osteoarthritis in middle-aged subjects with knee pain: 12-year follow-up using clinical and radiographic criteria*. *Ann Rheum Dis*, 2009. **68**(12): p. 1890-3.
12. Fransen, M., et al., *Exercise for osteoarthritis of the knee: a Cochrane systematic review*. *Br J Sports Med*, 2015. **49**(24): p. 1554-7.
13. Regnaud, J.P., et al., *High-intensity versus low-intensity physical activity or exercise in people with hip or knee osteoarthritis*. *Cochrane Database Syst Rev*, 2015(10): p. CD010203.
14. Ageberg, E. and E.M. Roos, *Neuromuscular exercise as treatment of degenerative knee disease*. *Exerc Sport Sci Rev*, 2015. **43**(1): p. 14-22.
15. Knoop, J., et al., *Knee joint stabilization therapy in patients with osteoarthritis of the knee: a randomized, controlled trial*. *Osteoarthritis Cartilage*, 2013. **21**(8): p. 1025-34.
16. Latham, N. and C.J. Liu, *Strength training in older adults: the benefits for osteoarthritis*. *Clin Geriatr Med*, 2010. **26**(3): p. 445-59.
17. Mangione, K.K., et al., *The effects of high-intensity and low-intensity cycle ergometry in older adults with knee osteoarthritis*. *J Gerontol A Biol Sci Med Sci*, 1999. **54**(4): p. M184-90.
18. Henriksen, M., et al., *Experimental knee pain reduces muscle strength*. *J Pain*, 2011. **12**(4): p. 460-7.
19. Liu, C.J. and N. Latham, *Adverse events reported in progressive resistance strength training trials in older adults: 2 sides of a coin*. *Arch Phys Med Rehabil*, 2010. **91**(9): p. 1471-3.

- 1
2
3 1 20. Henriksen, M., et al., *Association of exercise therapy and reduction of pain sensitivity in patients with knee osteoarthritis: a randomized controlled trial*. Arthritis Care Res (Hoboken), 2014. **66**(12): p. 1836-43.
- 4 2
5 3
6 4 21. Campbell, C.M., et al., *Sleep, Pain Catastrophizing, and Central Sensitization in Knee Osteoarthritis Patients With and Without Insomnia*. Arthritis Care Res (Hoboken), 2015. **67**(10): p. 1387-96.
- 7 5
8 6
9 7 22. Hurley, M.V., H.L. Mitchell, and N. Walsh, *In osteoarthritis, the psychosocial benefits of exercise are as important as physiological improvements*. Exerc Sport Sci Rev, 2003. **31**(3): p. 138-43.
- 10 8
11 9
12 10 23. Loras, H., et al., *Medical Exercise Therapy for Treating Musculoskeletal Pain: A Narrative Review of Results from Randomized Controlled Trials with a Theoretical Perspective*. Physiother Res Int, 2015. **20**(3): p. 182-90.
- 13 11
14 12
15 12 24. Crombez, G., et al., *Pain-related fear is more disabling than pain itself: evidence on the role of pain-related fear in chronic back pain disability*. Pain, 1999. **80**(1-2): p. 329-39.
- 16 13
17 14
18 15
19 16 25. Bartholdy, C., et al., *The role of muscle strengthening in exercise therapy for knee osteoarthritis: A systematic review and meta-regression analysis of randomized trials*. Semin Arthritis Rheum, 2017. **47**(1): p. 9-21.
- 20 17
21 18
22 19 26. Torstensen, T.A., H.D. Meen, and M. Stiris, *The effect of medical exercise therapy on a patient with chronic supraspinatus tendinitis. Diagnostic ultrasound--tissue regeneration: a case study*. J Orthop Sports Phys Ther, 1994. **20**(6): p. 319-27.
- 23 20
24 21
25 21 27. Osteras, B., H. Osteras, and T.A. Torstensen, *Long-term effects of medical exercise therapy in patients with patellofemoral pain syndrome: results from a single-blinded randomized controlled trial with 12 months follow-up*. Physiotherapy, 2013. **99**(4): p. 311-6.
- 26 22
27 23
28 24
29 25
30 26 28. Osteras, B., et al., *Dose-response effects of medical exercise therapy in patients with patellofemoral pain syndrome: a randomised controlled clinical trial*. Physiotherapy, 2013. **99**(2): p. 126-31.
- 31 27
32 28
33 29 29. Osteras, H., *A 12-week medical exercise therapy program leads to significant improvement in knee function after degenerative meniscectomy: a randomized controlled trial with one year follow-up*. J Bodyw Mov Ther, 2014. **18**(3): p. 374-82.
- 34 30
35 31
36 32
37 33 30. Osteras, H., B. Osteras, and T.A. Torstensen, *Medical Exercise Therapy is Effective After Arthroscopic Surgery of Degenerative Meniscus of the Knee: A Randomized Controlled Trial*. J Clin Med Res, 2012. **4**(6): p. 378-84.
- 38 33
39 34
40 35
41 36 31. Osteras, H., B. Osteras, and T.A. Torstensen, *Medical exercise therapy, and not arthroscopic surgery, resulted in decreased depression and anxiety in patients with degenerative meniscus injury*. J Bodyw Mov Ther, 2012. **16**(4): p. 456-63.
- 42 37
43 38
44 39 32. Osteras, H., B. Osteras, and T.A. Torstensen, *Is postoperative exercise therapy necessary in patients with degenerative meniscus? A randomized controlled trial with one year follow-up*. Knee Surg Sports Traumatol Arthrosc, 2014. **22**(1): p. 200-6.
- 45 39
46 40
47 41
48 42
49 43 33. Osteras, H. and T.A. Torstensen, *The dose-response effect of medical exercise therapy on impairment in patients with unilateral longstanding subacromial pain*. Open Orthop J, 2010. **4**: p. 1-6.
- 50 44
51 45
52 46 34. Osteras, H., T.A. Torstensen, and B. Osteras, *High-dosage medical exercise therapy in patients with long-term subacromial shoulder pain: a randomized controlled trial*. Physiother Res Int, 2010. **15**(4): p. 232-42.
- 53 47
54 48
55
56
57
58
59
60

- 1
2
3 1 35. Osteras, H., et al., *A comparison of work absence periods and the associated costs*
4 2 *for two different modes of exercise therapies for patients with longstanding*
5 3 *subacromial pain.* J Med Econ, 2008. **11**(3): p. 371-81.
- 6 4 36. Williams, D.M., *Exercise, affect, and adherence: an integrated model and a case for*
7 5 *self-paced exercise.* J Sport Exerc Psychol, 2008. **30**(5): p. 471-96.
- 8 6 37. Torstensen, T.A., et al., *Efficiency and costs of medical exercise therapy,*
9 7 *conventional physiotherapy, and self-exercise in patients with chronic low back*
10 8 *pain. A pragmatic, randomized, single-blinded, controlled trial with 1-year follow-*
11 9 *up.* Spine (Phila Pa 1976), 1998. **23**(23): p. 2616-24.
- 12 10 38. McAlindon, T.E., et al., *OARSI Clinical Trials Recommendations: Design, conduct,*
13 11 *and reporting of clinical trials for knee osteoarthritis.* Osteoarthritis Cartilage,
14 12 2015. **23**(5): p. 747-60.
- 15 13 39. Deyle, G.D., et al., *Knee OA: which patients are unlikely to benefit from manual PT*
16 14 *and exercise?* J Fam Pract, 2012. **61**(1): p. E1-8.
- 17 15 40. Laisne, F., C. Lecomte, and M. Corbiere, *Biopsychosocial predictors of prognosis in*
18 16 *musculoskeletal disorders: a systematic review of the literature (corrected and*
19 17 *republished) **. Disabil Rehabil, 2012. **34**(22): p. 1912-41.
- 20 18 41. Fuentes, C.J., et al., *Effects of exercise therapy on endogenous pain-relieving*
21 19 *peptides in musculoskeletal pain: a systematic review.* Clin J Pain, 2011. **27**(4): p.
22 20 365-74.
- 23 21 42. Koltyn, K.F., *Exercise-induced hypoalgesia and intensity of exercise.* Sports Med,
24 22 2002. **32**(8): p. 477-87.
- 25 23 43. Naugle, K.M., et al., *Intensity thresholds for aerobic exercise-induced hypoalgesia.*
26 24 *Med Sci Sports Exerc,* 2014. **46**(4): p. 817-25.
- 27 25 44. Boecker, H., et al., *The runner's high: opioidergic mechanisms in the human brain.*
28 26 *Cereb Cortex,* 2008. **18**(11): p. 2523-31.
- 29 27 45. Schulz, K.F., et al., *CONSORT 2010 statement: updated guidelines for reporting*
30 28 *parallel group randomised trials.* Int J Surg, 2011. **9**(8): p. 672-7.
- 31 29 46. Kellgren, J.H. and J.S. Lawrence, *Radiological assessment of osteo-arthrosis.* Ann
32 30 *Rheum Dis,* 1957. **16**(4): p. 494-502.
- 33 31 47. Schiphof, D., M. Boers, and S.M. Bierma-Zeinstra, *Differences in descriptions of*
34 32 *Kellgren and Lawrence grades of knee osteoarthritis.* Ann Rheum Dis, 2008. **67**(7):
35 33 p. 1034-6.
- 36 34 48. Benedetti, F., et al., *Pain as a reward: changing the meaning of pain from negative*
37 35 *to positive co-activates opioid and cannabinoid systems.* Pain, 2013. **154**(3): p.
38 36 361-7.
- 39 37 49. Bellamy, N., et al., *Recommendations for a core set of outcome measures for future*
40 38 *phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development*
41 39 *at OMERACT III.* J Rheumatol, 1997. **24**(4): p. 799-802.
- 42 40 50. Roos, E.M., *Effectiveness and practice variation of rehabilitation after joint*
43 41 *replacement.* Curr Opin Rheumatol, 2003. **15**(2): p. 160-2.
- 44 42 51. Roos, E.M. and L.S. Lohmander, *The Knee injury and Osteoarthritis Outcome Score*
45 43 *(KOOS): from joint injury to osteoarthritis.* Health Qual Life Outcomes, 2003. **1**: p.
46 44 64.
- 47 45 52. Roos, E.M., et al., *Knee injury and Osteoarthritis Outcome Score (KOOS)--validation*
48 46 *of a Swedish version.* Scand J Med Sci Sports, 1998. **8**(6): p. 439-48.
- 49 47 53. Roos, E.M., et al., *Knee Injury and Osteoarthritis Outcome Score (KOOS)--*
50 48 *development of a self-administered outcome measure.* J Orthop Sports Phys Ther,
51 49 1998. **28**(2): p. 88-96.

- 1
2
3 1 54. Lundeberg, T., et al., *Reliability and responsiveness of three different pain*
4 2 *assessments*. J Rehabil Med, 2001. **33**(6): p. 279-83.
- 5 3 55. Fransen, M. and J. Edmonds, *Reliability and validity of the EuroQol in patients with*
6 4 *osteoarthritis of the knee*. Rheumatology (Oxford), 1999. **38**(9): p. 807-13.
- 7 5 56. Sullivan, M., J. Karlsson, and J.E. Ware, Jr., *The Swedish SF-36 Health Survey--I.*
8 6 *Evaluation of data quality, scaling assumptions, reliability and construct validity*
9 7 *across general populations in Sweden*. Soc Sci Med, 1995. **41**(10): p. 1349-58.
- 10 8 57. Orenius, T., et al., *Anxiety and depression are independent predictors of quality of*
11 9 *life of patients with chronic musculoskeletal pain*. J Health Psychol, 2013. **18**(2): p.
12 10 167-75.
- 13 11 58. Urquhart, D.M., et al., *Are cognitive and behavioural factors associated with knee*
14 12 *pain? A systematic review*. Semin Arthritis Rheum, 2015. **44**(4): p. 445-55.
- 15 13 59. Bjelland, I., et al., *The validity of the Hospital Anxiety and Depression Scale. An*
16 14 *updated literature review*. J Psychosom Res, 2002. **52**(2): p. 69-77.
- 17 15 60. Osman, A., et al., *Factor structure, reliability, and validity of the Pain*
18 16 *Catastrophizing Scale*. J Behav Med, 1997. **20**(6): p. 589-605.
- 19 17 61. Holla, J.F., et al., *The avoidance model in knee and hip osteoarthritis: a systematic*
20 18 *review of the evidence*. J Behav Med, 2014. **37**(6): p. 1226-41.
- 21 19 62. Lundberg, M., et al., *Pain-related fear: a critical review of the related measures*.
22 20 *Pain Res Treat*, 2011. **2011**: p. 494196.
- 23 21 63. Fugl-Meyer, A.R., M. Eklund, and K.S. Fugl-Meyer, *Vocational rehabilitation in*
24 22 *northern Sweden. III. Aspects of life satisfaction*. Scand J Rehabil Med, 1991. **23**(2):
25 23 p. 83-7.
- 26 24 64. Resnick, B. and L.S. Jenkins, *Testing the reliability and validity of the Self-Efficacy*
27 25 *for Exercise scale*. Nurs Res, 2000. **49**(3): p. 154-9.
- 28 26 65. Resnick, B., et al., *Outcome expectations for exercise scale: utility and*
29 27 *psychometrics*. J Gerontol B Psychol Sci Soc Sci, 2000. **55**(6): p. S352-6.
- 30 28 66. Stener-Victorin, E., J. Kowalski, and T. Lundeberg, *A new highly reliable instrument*
31 29 *for the assessment of pre- and postoperative gynecological pain*. Anesth Analg,
32 30 2002. **95**(1): p. 151-7, table of contents.
- 33 31 67. Villadsen, A., et al., *Agreement and reliability of functional performance and muscle*
34 32 *power in patients with advanced osteoarthritis of the hip or knee*. Am J Phys Med
35 33 *Rehabil*, 2012. **91**(5): p. 401-10.
- 36 34 68. Dobson, F., et al., *Measurement properties of performance-based measures to*
37 35 *assess physical function in hip and knee osteoarthritis: a systematic review*.
38 36 *Osteoarthritis Cartilage*, 2012. **20**(12): p. 1548-62.
- 39 37 69. Bremander, A.B., L.L. Dahl, and E.M. Roos, *Validity and reliability of functional*
40 38 *performance tests in meniscectomized patients with or without knee osteoarthritis*.
41 39 *Scand J Med Sci Sports*, 2007. **17**(2): p. 120-7.
- 42 40 70. Prieto, L. and J.A. Sacristan, *Problems and solutions in calculating quality-adjusted*
43 41 *life years (QALYs)*. Health Qual Life Outcomes, 2003. **1**: p. 80.
- 44 42 71. Hasenbring, M.I., et al., *Fear and anxiety in the transition from acute to chronic*
45 43 *pain: there is evidence for endurance besides avoidance*. Pain Manag, 2014. **4**(5): p.
46 44 363-74.
- 47 45 72. Dunn, A.L., et al., *Exercise treatment for depression: efficacy and dose response*. Am
48 46 *J Prev Med*, 2005. **28**(1): p. 1-8.
- 49 47 73. Slentz, C.A., J.A. Houmard, and W.E. Kraus, *Exercise, abdominal obesity, skeletal*
50 48 *muscle, and metabolic risk: evidence for a dose response*. Obesity (Silver Spring),
51 49 2009. **17 Suppl 3**: p. S27-33.

- 1
2
3 1 74. Ekkekakis, P., *People have feelings! Exercise psychology in paradigmatic transition.*
4 2 Curr Opin Psychol, 2017. **16**: p. 84-88.
5 3 75. Dipnarine, K., et al., *Pain-free treadmill exercise for patients with intermittent*
6 4 *claudication: Are there gender differences?* Vascular, 2016. **24**(3): p. 304-14.
7 5 76. Colloca, L. and F. Benedetti, *Nocebo hyperalgesia: how anxiety is turned into pain.*
8 6 Curr Opin Anaesthesiol, 2007. **20**(5): p. 435-9.
9 7 77. Bartels, E.M., et al., *Aquatic exercise for the treatment of knee and hip*
10 8 *osteoarthritis.* Cochrane Database Syst Rev, 2016. **3**: p. CD005523.
11 9 78. Pedersen, B.K. and B. Saltin, *Exercise as medicine - evidence for prescribing*
12 10 *exercise as therapy in 26 different chronic diseases.* Scand J Med Sci Sports, 2015.
13 11 **25 Suppl 3**: p. 1-72.
14 12 79. Wisloff, U., O. Ellingsen, and O.J. Kemi, *High-intensity interval training to maximize*
15 13 *cardiac benefits of exercise training?* Exerc Sport Sci Rev, 2009. **37**(3): p. 139-46.
16 14 80. Evangelista, L.S., et al., *Dose-Response Relationship Between Exercise Intensity,*
17 15 *Mood States, and Quality of Life in Patients With Heart Failure.* J Cardiovasc Nurs,
18 16 2017. **32**(6): p. 530-537.
19 17 81. Hurley, M.V., *Muscle dysfunction and effective rehabilitation of knee osteoarthritis:*
20 18 *what we know and what we need to find out.* Arthritis Rheum, 2003. **49**(3): p. 444-
21 19 52.
22 20 82. Juhl, C., et al., *Impact of exercise type and dose on pain and disability in knee*
23 21 *osteoarthritis: a systematic review and meta-regression analysis of randomized*
24 22 *controlled trials.* Arthritis Rheumatol, 2014. **66**(3): p. 622-36.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



171x136mm (300 x 300 DPI)

View only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2. Flow chart of the design and run of the study. HDMET= High-dose MET and LDMET=

Low-dose MET.

250x312mm (300 x 300 DPI)












EXERCISE	HIGH DOSE MET (70-90 MIN)	DOSE	LOW DOSE MET (20-30 MIN)	DOSE
1		GLOBAL 20 min		GLOBAL 10 min
2		SEMI GLOBAL CLOSED CHAIN 3x30 reps		SEMI GLOBAL CLOSED CHAIN 2x10 reps
3		LOCAL OPEN CHAIN 5 min		SEMI GLOBAL CLOSED CHAIN 2x10 reps
4		SEMI GLOBAL CLOSED CHAIN 3x30 reps		SEMI GLOBAL CLOSED CHAIN 2x10 reps
5		GLOBAL 10 min		SEMI GLOBAL OPEN CHAIN 2x10 reps
6		SEMI GLOBAL CLOSED CHAIN 3x30 reps		
7		LOCAL OPEN CHAIN 5 min		
8		LOCAL OPEN CHAIN 3x30 reps		
9		GLOBAL 10 min		

210x297mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60












1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

HIGH DOSE MET 80-90 MINUTES | NAME:

Treatment	1 date	2 date	3 date	4 date	5 date	6 date	7 date	8 date	9 date	10 date	11 date	12 date
	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time

BMJ Open: first published as 10.1136/bmjopen-2024-018471 on 5 May 2024. Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.












HIGH DOSE MET 80-90 MINUTES | NAME:

Treatment	13 date	14 date	15 date	16 date	17 date	18 date	19 date	20 date	21 date	22 date	23 date	24 date
	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time

BMJ Open: first published as 10.1136/bmjopen-2024-018471 on 5 May 2024. Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60






HIGH DOSE MET 80-90 MINUTES | NAME:

Treatment	25 date	26 date	27 date	28 date	29 date	30 date	31 date	32 date	33 date	34 date	35 date	36 date
	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time	Weight/Sets/Reps/Time
	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time	Borg scale/Time

BMJ Open: first published as 10.1136/bmjopen-2024-018471 on 5 May 2024. Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.

Low dose MET 30 minutes

Name: _____

Treatment	1	2	3	4	5	6	7	8	9	10	11	12
	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date
Exercises												
	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time
	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time
	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time
	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time
	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time	Weight Sets Reps Time






Exercise program MET 30 minutter

Name: _____

Treatment	13	14	15	16	17	18	19	20	21	22	23	24
	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date
Exercises												
	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time
	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time
	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time
	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time

Exercise program MET 30 minutter

Name: _____

Treatment	25	26	27	28	29	30	31	32	33	34	35	36
	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date	Date
Exercises												
	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time	Borg scale Time
	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Serie Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time
	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time
	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time
	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time	Weight Set Rep Time

1136/bmjopen-2017-018471 on 5 May 2018. Downloaded from <http://bmjopen.bmj.com/> on April 29, 2024 by guest. Protected by copyright.



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	Item No	Description	Addressed on page number
Administrative information			
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	p1, line 8-10
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	p2,line 27
	2b	All items from the World Health Organization Trial Registration Data Set	N/A
Protocol version	3	Date and version identifier	p1, line 37
Funding	4	Sources and types of financial, material, and other support	p31,lines 2-5
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors	p1,line:13-23, p29,line:5-10
	5b	Name and contact information for the trial sponsor	N/A
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	p31, lines 2-5
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	p14, lines 5-9,p15,lines 1-10

.1136/bmjopen-2017-018471 on 5 May 2018. Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Introduction

Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	<u>p3-p10,</u>
	6b	Explanation for choice of comparators	p10,lines 11-24 p11,linea1-4
Objectives	7	Specific objectives or hypotheses	<u>p11,lines 7-24</u>
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	p12,line 6-14
Methods: Participants, interventions, and outcomes			
Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	<u>p12,lines17-20</u>
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	<u>p13,lines1-12</u>
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	<u>p17-20, figure 1,p 8 and fig 2 ,p 9, appendixes 1 and 2</u>
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	<u>p19,lines 10-17,</u>
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	<u>P27,lines 5-13</u>
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	<u>N/A</u>

1				
2	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	<u>p21-23, p 24, lines1-9</u>
3				
4				
5				
6				
7	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	<u>page 12, figure 3</u>
8				
9				
10				
11	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	<u>p25,lines 14-23</u>
12				
13				
14	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	<u>p14,lines 11-16</u>
15				
16	Methods: Assignment of interventions (for controlled trials)			
17	Allocation:			
18				
19	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	<u>p16,lines 16-21</u>
20				
21				
22				
23				
24	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	<u>p16,lines 16-21</u>
25				
26				
27				
28	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	<u>p13,line 24, p14, lines 1-3</u>
29				
30				
31	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	<u>p17,lines 1-9</u>
32				
33				
34		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	<u>p15, line 23 and p17, lines 3-4</u>
35				
36				
37				
38				
39				
40				
41				
42				
43				
44				
45				
46				
47				

Methods: Data collection, management, and analysis

Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	<u>p15,lines 1-10</u>
	18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocol	<u>p15,lines1-10, and page 15,lines 13-15, and page 16, lines1-5</u>
Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	p15,lines 1-10

For peer review only

0.1136/bmjopen-2017-018244
Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Methods: Monitoring

Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	<u>p14,lines 5-9</u>
	21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	<u>N/A</u>
Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	<u>p14,lines 8-9</u>
Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	<u>N/A</u>

Ethics and dissemination

Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	<u>p2, lines 24-26, ' page 26,lines 1-4</u>
Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	<u>p14,line 8-9</u>

Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	<u>p14,lines9-11</u>
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	<u>not applicable</u>
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	<u>p14,lines20-23</u>
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	<u>p29,line1-2</u>
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	<u>p15,lines 6-8</u>
Ancillary and post-trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	<u>not applicable</u>
Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	<u>p2, lines 25-26</u>
	31b	Authorship eligibility guidelines and any intended use of professional writers	<u>not applicable</u>
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	<u>not applicable</u>
Appendices			
Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	<u>not applicable, only i in Swedish and Norwegian language</u>
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	<u>not applicable</u>

*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

“[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)” license.

For peer review only